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PRESS CONFERENCE BY PRESIDENT DELORS AND MRS LENOIR (24 MAY 1994) 
PRESS RELEASE - ETHICS AND BIOTECHNOLOGY 
Biotechnology is a  MAJOR CHALLENGE FOR SOCIETY.  The debate is fueJJed  by 
excessive fears on the one hand and  unrealistic expectations on  the other. 
Apan from  its economic significance (almost 9% of the labour force  and gross added 
value in  the European Union),  BIOTECHNOLOGY- as a tool for manipulating  living 
organisms ·  presents  a major socio-cultural challenge to Europe. 
In  medicine, biotechnology is  revolutionizing our approach to disease (genetic testing) 
and  its  treatment  (gene therapy).  In  agriculture,  transgenesis (transgenic animals and 
plants) could  weJI  revolutionize the way  we grow crops and breed livestock.  And the 
application  of biotechnology  to  the  fight  against  pollution  (using  micro-organisms to 
dissipate oil  slicks, for instance) opens up  exciting new prospects for the environment. 
This is why the recommendations of  the WIDTE PAPER on growth, competitiveness and 
employment give pride of place to the development of biotechnology.  which is so rich 
in  potential. 
The  Commission  is  fully  involved  in  the  biotechnology  debate.  A  GROUP  OF 
ADVISERS ON THE ETinCS OF BIOTECHNOLOGY was formed on  20 November 
I 991.  Because it  achieved so  much  during its first two-year term,  the  Commission 
decided to  expand its role and increase its resources, in the light inter alia of the  White 
Paper's recommendations.  On 25 February 1994 new appointments were made and the 
Group now has nine rather than the original six members.  Mrs Noelle Lenoir, a member 
of the French Constitutional Court and President of UNESCO's International Bioethics 
Commitee,  has been appointed chairperson. 
The Group has a high profile.  It has plans to step up its contacts with the general public 
and international organizations.  Today's press conference should be seen as  a first step 
in  this direction. 
Because of its terms of reference, the Group has a unique place in the European Union. 
It is closely involved, in a consultative capacity, in the elaboration of  relevant Community 
policy but is completely independent.  And it is able, at its own initiative, to examine any 
topic touching on biotechnology. 
The  Group's  activities  are  consistent  with  the  new approach  to  European  integration 
introduced by the MAASTRICHT TREATY.  It is particularly alive to  the concerns of 
Parliament  and  the  PEOPLE OF EUROPE.  Its work  is based  on  the  principles of 
freedom and responsibility  set out in  the European Convention for the Protection  of 
Human Rights and Fundamental Freedoms,  which has been recognized as a source of 
Community law by  the Maastricht Treaty. 
Europe cannot be  built on  purely  utilitarian  foundations.  Integration  presupposes an 
ongoing social  dialogue  based on ethical and human values which are common to our 
cultures.  The Group's task is to integrate these values into its reflections so that it can 
advise the Commission on initiatives to be taken in this key area PRESS CONFERENCE BY PRESIDENT DELoRS 
AND MRS LENOIR 
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eud162 4 vm 289  dpa-euro US 
EU/ 
Ethik der Biomechnologie: EU-Berater legen Bilanz vor = 
Btilssd (dpa) -In der Frage der ethischen Auswirkungen der 
Biotechnologie hat die Beratergruppe der Europaischen Kommission 
eine erne Bilanz vorgdegt. Wie die Vorsirzende des unabh.angigen 
neunkopfigen Ethik-Komirees, Noelle Lenoir, am Diensr.ag in Briissel 
sagte, gaben die Mitglieder Meinungen zur V  erwendung des die  · 
Milchproduktion srimulierenden Hormons BST, zu aus menschlichem Blur 
gewonnenen Produkt:en und zur  Fnge.  der Parente in der Biotechologie 
ab. 
Die Gruppe hielr die V erwendung von BST unter besrimmten 
Voraussetzu.ngen fiir annehmbar. Bedingungen sei, dafi die Behandlung 
der •Turbokiihe" sofon eingestdlt werden miisse, wenn es zu 
· Entziindunge.n bei den Tieren komme. Das Niveau von Sbmazellen pro 
Milliliter in der exzeugten Milch diirfe nicht hoh.er sein als in der 
mit traditionellen Methoden gewonnenen Milch. Die mit BST produziene 
lvfilch sollte naCh Ansicht der Experte.n £iir den V  erbraucher 
gekennzcichnet sein. 
Blutprod.ukte soil  ten laut dem Komitee nicht als normale Ware 
angesehen werden, und niemand solle zusattlich.e Gewinne aus den 
7  Produkten machen. Bei der Patentierung von "lebendiger Materie" 
siehL die Gruppe keine grundsarilichen ethischen Problem.e. Patente 
von T echniken der menschenlichen Genmanipulat:i.on sollten aber 
verboten werden, wenn Sie nicht klar fiir therapeutische Zwecke 
bestimmt seien.  · 
Wie EU-Kommissionsprasident Jacques Delors am Dienstag sagte, hat 
die Europaische Kommission die Empfehlungeo. angc:nommen. Die neun 
Expen:en beschaftigen sich gegenwircig mit: den Problemen 
u;msgenetischer Tiere und der Gentherapie. Die Gruppe wurde 1991 
gebildet. Die Zahl ihrer Mitglieder wurde Anfang des J  ahres von sechs 
auf neun erhohr. 
Sie besteht stehr auBer Genetikexpenen aus Theologen, Profesoren 
fur Ethik und Philosophie sowie Juristen. Ihre Aufagabe ist es, sich 
mit den "Sorgen der europaischen Bii.rgc:r und mit den Risiken der 
Ei.nfiihrung der neuen Techniken auseinanderzuserzen. Die Mitglieder 
sollen Ethik, Fonschritt und Fragen der Sicherheit gegeneinander 
abwigen. Delors verwies am Dienmg noch einmal auf die grofie 
wirtschaftliche Bedeutung des Sektors. Zehn Prozent der europiischen 
Industrieproduktion seien von den Auswirkungen betroffen.. 
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Bioethics group to examine prenatal tests, gene therapy 
BRUSSELS,  May 24 (Reuter) - A group advising the European 
Commission on ethical questions related to biotechnology will 
examine issues including test-tube babies and genetically 
engineered animals, the·group's new chairwoman said on Monday. 
Noelle Lenoir, a member of the French Constitutional 
Council, said the group would also debate gene therapy - an 
experimental technique that involves inserting healthy genes 
into a body's cells to replace defective ones to cure diseases. 
The nine-member group, which includes professors and 
scientists from  across the EU, was created by the Commission in 
1991  and is just beginning a second two-year term. 
Lenoir said one of its priorities would be "prenatal 
diagnosis'', including ethical questions related to the creation 
of embryos in a laboratory to implant into a woman's womb -- for 
example, whether parents should be allowed to select embryos by 
sex. 
Some European countries permit such a selection to prevent 
the transmission of inherited diseases such as haemophilia, 
which is passed on only to males, she said. 
Lenoir said the issue of genetically engineered, or 
''transgenic'', animals involved the basic "relationship between 
man and animal"'. 
She noted that the genetic make-up of  pigs was being altered 
to help human beings -- for example, to create organs that can 
be transplanted into humans. 
''Do we envisage the animal species in a completely 
utilitarian way or do we have another vision?'', she said. 
Lenoir said the group wanted to study gene therapy because 
the EU's European Medicines Agency would have to decide whether 
to authorise biotechnology products related to the procedure. 
Commission President Jacques Delors said he had proposed the 
group be created as a way to get advice on sometimes uninformed 
and emotional debates about biotechnology.  · 
''We who are in the middle of  all the lobbies need to see 
things clearly,'' he said. 
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La Commission s'inquiete de l'ethique dans les niles biotechnologies 
BRUXELLES 24/05 (BELGA) = La Commission europ6enne, inquiete de 
des problemes ethiques inherents au developpement foudroyant de Ia 
biotechnologie, a renforce les effectifs du groupe de conseillers 
Service du Porte-Parole pour J'ethique en matiere de biotechnologie, qui est passe de 6 a  9 
membres.  Leur programme de travail touchera a  l'avenir des questions 
aussi sensibles que Ia therapie genique, le diagnostic prenatal et 
les animaux transgeniques, a indique mardi a  Bruxelles Ia presidente 
du groupe, Mme Noelle Lenoir, par ailleurs presidente du Comite 
International de Bioethique de I  'UNESCO. 
Le nouveau groupe de conseillers, issus des secteurs 
scientifique, juridique, philosophique, theologique et politique, se 
reunira pour Ia premiere fois officiellement le 16 juin prochain a 
Bruxelles. Parmi eux figure notamment le Pr Gilbert Hottois, 
professeur de philosophie du Centre de Recherches Interdisciplinaires 
de I  'Universite libre de Bruxelles (ULB) 
"La science va plus vite que I  'homme et les problemes 
(bioethiques) renvoient a  des questions de societe a  l'egard 
desquelles il faut avoir une attitude d'honnetete", a notamment 
souligne la presidente du groupe, qui dressait devant Ia presse le 
bilan de deux ans et demi d 'activites. 
"Nous ne sommes pas un tribunal de Ia morale ou de !'inquisition, 
mais nous sommes Ia pour faire le point", a-t-elle ajoute. 
Les conseillers devraient notamment approfondir Ia reflexion sur 
les problemes de diffusion de Ia therapie genique, une nouvelle 
technologie fort couteuse consistant a  corriger une alteration 
genetique (comme le cancer) par voie d'injection, a souligne Mme 
Lenoir.  · 
Par ailleurs, le diagnostic prenatal et preimplantatoire, qui 
permet de selectionner, en cas de fecondation in vitro, les embryons 
selon leur sexe est juge defendable pour raisons medicates, notamment 
dans le cas de families d 'hemophiles, une maladie qui se transmet par 
les femmes et ne touche que les hommes, a souligne Mme Lenoir. 
Les conseillers en bioethique de Ia Commission devraient aussi 
etudie les problemes poses par les animaux transgeniques, dont 
l'identite genetique a ete modifiee, notamment pour servir de cobaye 
ou pour ameliorer Ia qualite de Ia viande. Mme Lenoir a notamment 
cite le cas de pores awiquels ont injecte des genes humains pour en 
pre  lever ensuite les foies et s 'en servir comme greffon pour des 
transplantations sur des etres humains. 
L'idee de Ia creation d'un tel groupe est nee a  Ia suite de 
}'explosion de Ia centrale nucleaire de Tchemobyl. Une discussion 
vraiment scientifique sur les consequences de Ia catastrophe s 'est 
averee impossible, chacun se contentant d'expliquer que ses produits 
etaient "sOrs", a explique le president de Ia Commission europeenne, 
Jacques Delors. D 'oil Ia mise sur pied de ce groupe en novembre 1991. 
Depuis lors, le groupe a notamment preconise une limitation de 
I  'emploi de Ia somatotropine bovine (BST), une hormone galactogene 
(accroissant Ia production de lait), au profit de Ia sante du 
c6nsommateur et du bien-etre des animaux. II s'  est aussi exprime en 
faveur de l'interdiction de brevetabilite du corps ou d'elements du 
corps humain. 
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Scion Jacques Delors,  Ia Commission a repris daris les trois cas 
prccites le point de vue exprime par Ies experts. 
"Tout Ie monde parle de biotechnologie, mais on vend beaucoup de 
contreverites a  cet egard", a encore souligne M. Delors, justifiant 
ninsi  Ia neccssite, pour Ia Conunission, d 'un avis autorise lui 
pcnnettant de mieux informer le public et le monde politique  . 
.. L'  opinion publique do it etre bien consciente des risques reels 
de Ia bioteclmologie. C'est de cette maniere que l'on pourra eviter 
un rejet infonde" des nouvelles possibilites qu' offre Ia science, 
a-t-il encore dit/. L  VE (CET) 
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COMISION EUROPEA ABRE DEBAlE SOBRE ETICA Y BIOlECNOLOGIA EN 
UE 
Bruselas, 24 may (EFE).- El presidente de Ia Comisi6n Europea, 
Jacques Delors expres6 hoy, martes, Ia preocupaci6n etica que 
tienen las instituciones europeas por Ia aplicaci6n de Ia 
biotecnologia dentro de Ia Uni6n Europea (UE) y el desafio socio-
cultural que representa para sus ciudadanos. 
El grupo de consejeros de Ia Comisi6n para Ia etica de Ia 
biotecnologia, presidido por Ia francesa Noelle Lenoir, .dio a 
conocer hoy los resultados provisionales de su anaJ.isis sobre las 
implicaciones eticas del uso de sustancias y t6cnicas sobre seres 
vivos para mejorar Ia producci6n agricola o pesquera, o Ia terapia 
medica en humanos ... 
Este comite de expertos de canicter consultivo se form6 en 
noviembre de 1991, a instancias del mismo Delors, tras el 
accidente nuclear de Chemobil, y a el pertenecen personalidades 
independientes del mundo de Ia ciencia, el derecbo y Ia teologia, 
entre otros ~pos,  de toda Ia UE.  . 
En una intervenci6n ante la prensa, Jacques Delors insisti6 en 
que el desarrollo de Ia biotecnologia oftece un potencial 
considerable, que va mas alia de su peso econ6mico en Ia UE, dolide 
rcpresenta el 9 por ciento de Ia mano de obm y del valor aiiadido 
bnrto.  · 
El desarrollo de este sector y sus implicaciones 6ticas 
tambien aparece en el Libro Blanco sobre Ia competitividad, el  · i 
crecimiento y el empleo, en el que ·Delors submya que cs necesario 
aclarar las cuestianes morales unidas a ciertas aplicaciones de Ia 
biotecnologia, en especial las relacionadas con Ia investigaci6n 
biomedica. 
Lenoir, que preside tambi6n el Comit6 de Bio6tica de Ia 
UNESCO, sef1al6 que este grupo "es independiente y desde luego no 
somos ni un tribunal de Ia inquisici6n .ni uno moral. Nos limitamos 
Service du Po~Parole  ~· Page 5 
a infonnar a Ia  Comision de lo que hay, y sabemos que no tenemos 
ninguna legitimidad politica". 
Entre sus primeras conclusiones, el grupo de expertos se 
inclina, "en un plano etico", por Ia utilizacion de la hormona 
BST, siempre que se respeten Ia seguridad y Ia sanidad de los 
consumidores, el bienestar de los animales y se preserve Ia 
biodiversidad. 
La BST, o somatotropina bovina, es una proteina hormonal 
hipofisiaria que estimula el crecimiento 6seo y el anabolismo 
proteico, y tambien aumenta Ia producci6n de leche en los bovinos 
entre un diez y un veinte por ciento. 
Tambien han sometido a analisis Ia directiva sobre los 
.productos farmaceuticos derivados de Ia sangre y del plasma 
sanguineo ( 1988), que suscit6 vivas criticas en Francia tras los 
casos de transfusiones de sangre contaminada por el virus que 
causa el sindrome de inmunodeficiencia adquirida (SIDA). 
La presidenta del Comite sefial6 que en el futuro iruitediato 
estudianin cuestiones relacionadas con Ia terapia genica, los 
diagn6sticos prenatales y de preimplantaci6n de embriones, asi 
como los animales transgenicos. 
A los trabajos de est~ grupo han contribuido el jurista 
Marcelino Oreja, antes de su nombramiento como comisario europeo 
de Transportes, y el presidente del Comite Director de Ia Bioetica 
(CDBI) del Consejo de Europa, Octavi Quintana Trias. EFE 
emm/jms/man 
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ue: bioetica, per delors centro· dibattito su scelta societa' 
(ansa)- bruxelles, 24 mag- circondato da gruppi di 
pressione, illegislatore europeo ha pisogno di un aiuto estemo 
indipendente per ''vederci chiaro'' soprattutto quando si tratta 
di dare una valutazione etica aile attivita' che scaturiscono 
dalla biotecnologia, ossia dall'applicazione dell' ingegneria 
genetica all  'industria. 
cosi', il presidente della commissione europea jacques delors 
ha presentato oggi a bruxelles il  gruppo di consiglieri 
indipendenti che da due anni contribuisce con i suoi 
suggerimenti a sciogliere dubbi e a rispondere aile 
preoccupazioni etiche delle istituzioni europee. sono filosofi, 
giuristi, scienziati, medici, teologi, ai quali e' chiesto di 
individuare i problemi etici sollevati dalla biotecnologia, 
valutare gli aspetti etici dell  'attivita' comunitaria e studiare 
l'impatto potcnziale che queste ·attivita' possono avere sul1a 
societa' e sugli individui. 
un ruolo che secondo ·delors va ra.ffOIZBto ·in qUamO ritiene 
che Ia bioetica sia, nell'  europa dei ~odici, "al cuore del 
-------------------------------------------4&.  <'  .... -.:,..  ...  ~99 'Dn  ....... n ...... n1,. dibattito sulla scelta di  societa'' '. per il presidente della 
conunissione bisogna ''  lottare contra le false notizie'' e 
''an  dare oltre Ia dimensione economica della biotecnologia'' che 
rappresenta ormai il nove per cento del prodotto interno lordo 
dell 'unione. (segue). 
len 
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(ansa)- bruxelles, 24 mag- il gruppo di consiglieri, che ha 
un potere consultivo, si e' gia' pronunciato su problemi 
delicati: dai brevetti, per dare protezione giuridica aile 
invenzioni biotecnologiche, ai principii etici da rispettare per 
i prodotti derivati dal sangue o dal plasma umano e per un 
eventuale utilizzo della somatotropina bovina, l'onnone frutto 
della biotecnologia che e' an  cora vietato nei dodici e che 
provoca  l'aumento fmo al 20 per cento della produzione di 
latte nelle vacche. 
problematiche altrettanto delicate sono attualmente all'  esame 
del gruppo di consiglieri. il gruppo sta ad esempio valutando 
quali principii etici vadano rispettati nella diagnosi prenatale, 
compreso l'impianto del feto nell'embrione, per evitare 
discriminazioni sui sesso del nascituro o sui diritto alia vita 
dei portatori di handicap. o ancora., quali sono i limiti 
invalicabili della terapia genetica, quando intervenendo sui 
geni per combattere una malattia si rischia di trasmettere Ia 
mutazione genetica alle altre generazioni. 
il gruppo che ha un potere consultivo e' rinnovato ogni due 
anni. per I'  italia e' presente attualmente stefano rodota', 
professore ordinaria di diritto civile dell  'universita' di roma 
e membro del comitato etico del consiglio nazionale delle 
ricerche. (ansa). 
len 
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(EU) UEIETHIQUE: LE PRESIDENT DELORS ET MME LENOIR ONT PRESENTE LE PREMIER 
BILAN ET LES NOUVEAUX OBJECTIFS DU "GROUPE DE CONSEILLERS POUR L'ETHIQUE 
DE LA  BIOTECHNOLOGIE" 
Bruxel/es, 2410511994 (Agence Europe) ... Le president de Ia Commission europeenne Jacques Delors 
et le nouveau president du "groupe de conseillers pour l'ethique de Ia biotechnologie" ont presente ce 
mardi a  Ia presse un premier bilan de l'activite de ce groupe ainsi que ses nouveaux objectifs. M.Delors 
a souligne les orientations generales et les raisons qui  .. ont amene Ia Commission a  creer cet organisme; 
Mme Lenoir a foumi des indications sur les travaux en cours ou envisages. 
Le groupe examine· des questions qui sont au coeur de Ia destinee humaine et prendront de 
plus en plus d'importance a  l'avenir, a declare M.Delors. Ni Ia Commission, nile Parlement europeen, 
ni le Conseil ne peuvent trouver dans leurs connaissances les elements suffisants pour trancher certains 
problemes  fondamentaux;  et pourtant,  ils  soot obliges a prendre des  decisions.  C'est pourquoi  ils 
demandent  l'avis  de  personnes  particulierement  competentes  et  totalement  independantes,  qui  ne 
re~ivent aucune instruction; Ia Commission finance leurs travaux, et c'est tout. Chaque jour, ceux qui 
ont Ia responsabilite de decider se trouvent confrontes a  des problemes ethigues resultant des nouvelles 
sciences g,yLpeuvent modifier lJ..matiere vivante: pour ('alimentation, l'environnement, Ia lutte contre 
les grandes maladies, etc. Ce qui preoccupe particulierement M.Delors face a ces  grands problemes, 
c'est que "n'impone qui peut raconter n'impone quoi". QY.PILgoiit dY_sensationnel o.u  au service d'un 
~;  il  est absolument indispensable que les decideurs disposent d'elements qui leur permettent de 
decider et d'informer objectivement l'opinion publique, en dehors des pressions des lobbies et d'une 
cenaine presse. 
Mme·Umc;ir a insiste sur le caractere libre tt ind~dant  des·travaux du groupe, qui~ 
entreprendre l'etiade trun problem~  aussi bien.de sOil initiative qu'ila clemande de Ia Commission.  ti~ · 
premier bilan  •  pOSsible apres le premier mandat de deux ans. Le gro&ipe a exprime trois avis  qui oirt 
ete  entieremeot  sujyjs par Ia Commission.  Par le premier,  il  a  estime qu'il  n'etait Pas  cmponun 
d'introduire sur le marche Ia BST (hormene qui developpe Ia production de lait chez les vaches); ~ 
le second, il a justifie entierement Ia directive communautaire sur les produits ctenves du sang; par~ 
troisieme. jl a souterjb fermement le proiet11e directive commvnautaire sur les brevets pow les pmduits 
issus de Ia  biotec;hnologie, en estimmt q~  le vide juridique est Ia pirc solutipn. Ces  trois avis '!i! 
implique l'exameo de questions fondamentales telles que les relations ~  l'homme avec les autres ~ 
vivants;  en  meme temps.  le groupe  a  tenu compte des aspects  economiques.  de  Ia  concurrence 
intemationale en  ~aliere de biotecbnologie (surtout de Ia part des Etats-Unis et du Japon) et en general 
de l'equilibre a  respecter entre les risques et les avantages. 
I..e  groupe  va  franchir i  present une nouvelle  etaoe.  Grice aux  moyens accrus  dont il 
disposera, il pourra notamment 
...  s'ouvrir vers l'exterieur, dans le sens que ses interlocuteurs ne seront plus seulement les instances 
de Ia Commission mais aussi le Parlement eW'Opeen, le Comite economique et social, les associations 
(  dont certaines representant les malades poussent en faveur d'une exploitation rapide des c:onnaissances 
nouvelles, d'autres representant les ecologistes poussent dans le sens oppose); 
- aborder aussi des •suiets d'anticipation• comme Ia medecine genetique. les •individus a risque•, 
les plants transgemques, etc. 
La Commission a domande au groupe d'6tudier Ia question du •diagnostic prenatal•  (qui 
permettrait aussi  Ia manipulation de l'embryon). Le groupe examine en  outre deux autres sujets: Ia 
therapie genetique (modifications de l'etre vivan~ pour eliminer les maladies hereditaires); les animaux 
transgeniques. Eo outre, il maintieot a  son ordre du jour Ia question des brevets sur les produits issus 
de Ia biotechnologie, qui, i  son avis. reste d'actualite aussi longtemps que Ia Communaute n'a pas pris 
de decision Oc projct est toujoun devmt le CoDICil. apres de tres vi& debats au scia du Parlcmeat curopCea). 
Le  groupe est actuellement preside par Mme Lenoir. membre du Conseil c:onstitutionnel 
fran~s. et comprend huit membres: dr Anne Me Laren (GB); dr Margaretta Mikkelsen (DK); prof. 
Luis Jorge Peixeto Archer (P); prof.Gilbert Hottois (B); prof.Dietmar Mieth (AI), M.Octavi Quintana 
Trias (Es); prof. Stefano Rodoti (It); prof.Egbert Scbroten (PB). 
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8  - Biotechnology and its 
diffusion 
5.5.  As  a  result  of  intensive  scientific 
research  and  major  discoveries  over  the 
past four decades in molecular biology, bio-
technology has emerged as one of the most 
promising and crucial technologies for  sus-
tainable  development  in  the  next  century. 
Modem  biotechnology  constitutes  a 
growing  range  of techniques,  procedures 
and  processes,  such  as  cell  fusion,  r-ONA 
technology, biocatalysis, that can substitute 
and  complement  classical  biotechnologies 
of selective breeding and fermentation. This 
confluence of classical and modem techno-
logies  enables  the  creation  of new  products 
and  highly  competitive  processes  in  a  large 
number  of industrial  and  agricultural  acti-
vities  as  well  as  in  the  health  sector.  This 
would  provide  the  impulse  to  radically 
transform  the  competitiveness  and growth 
potential  for  a  number  of activities  and 
open  up  new  possibilities  in  other sectors 
such  as  diagnostics,  bioremediation  and 
production of process equipment (biohard-
ware)~  In  terms  of the  quality  of life,  we 
should  not  underrate the  important poten-
tial  of  biotechnology  for  improving  the 
environment by correcting pollution and for 
improving  health  by  preventing  or  reme-
dying  illnes~ or other physical problems. 
The  Community  has  taken  a  number  of 
initiatives. on  the one hand, to promote the 
competitiveness  of bio-industries  and,  on 
the  other hand. to  ensure the safe applica-
tion  of  biotechnology.  It  implies  mainly 
funding  of research  and development and 
the putting into place of a regulatory frame-
work. 
5.6.  Potential of biotechnology and 
similarities with information 
technologies 
Reinforcing the  potential of biotechnology 
are  a  number  of features  which  biotech-
nology shares with electronics and informa-
tion  technologies:  it  is  science-based,  the 
scientific  input  being the  most  crucial  ele-
ment of the technology trajectory; the gap 
between developments in  basic science and 
their  research  and  development  applica-
tions and even further downstream is small 
and diminishing; a very major and growing 
115 stimulus can be expected for process equip-
ment,  instrument  and  engineering  sectors; 
and  finally  the  impacts  of  the  processes, 
techniques and  hardware represented  by  bio-
technology  are  across  a  number  of sectors. 
The Community is highly competitive in these 
sectors which  cover chemicals,  pharmaceu-
ticals  health  care,  agriculture  and  agricul-
tural 'processing, bulk and specialized  pla~t 
protection  products  as  well  ~s decontami-
nation  waste treatment and dtsposal. These 
sectors'  where  biotechnology  has  a  direct 
impact  currently  account  for  9%  of  th_e 
Community's  gross  value-added  (approxi-
mately  ECU  450  billion)  and  8%  of  its 
employment  (approximately  9  m_illion). 
Beyond this,  perhaps only modem btotech-
nology  has  the  potential to  provi~e sign~fi­
cant  and  viable  thrusts,  compattble  wtth 
CAP reform  and  not  dependent on  opera-
ting  subsidies,  to  new  energy/fuel  and 
industrial  outlets  for  agricultural  raw 
materials.  The  important  role  of  biotech-
nology  in  these  sectors  is  likely  to  be  to 
maintain  employment  by  stimulating  its 
productivity  as  well  as  to  create  highly 
skilled labour demand. 
The  following  are  two  valid  indicators  of 
the  potential of biotechnology: the  pace of 
international  innovative  activity  and  the 
evidence  of growth  in  output  and  value-
added in  products derived through biotech-
nology.  Measuring  innovative  activity  by 
patents  filed  for  relevant  products  in  the 
USA, the Community and Japan show that 
patents filed  have increased from  I 100 per 
anrium  in  the  early  1980s  to  3 350  per 
annum  in  1990.  In  1980  the  Community 
was in a leading  position~ by  1990 the USA 
was filing 50% more patents than the Com-
munity. European Patent Office (EPO) stat-
istics  reveal  a  similar  evolution:  between 
1980  and  1991  biotechnology  patents  filed 
with  the  EPO  increased  by  a factor of 10, 
the  most  being  filed  by  US-based  com-
panies. 
Current  global  indicators  of  the  growth 
prospects of the biotechnology industry are 
the  following:  in  the  USA  the  industry 
based on modem biotechnology had a tum-
over  of over  USD  8  billion  in  1992,  a 
growth  rate  of  ~8% .  with  employme~t 
growing at  13%.  It as estimated on the basas 
of the  observed  rates  of diffusion  of bio-
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technology  that  the  US  biotechnology 
industry's revenues will grow  at an  average 
rate of 40% to  reach  USD  52  billion by the 
year  2000.  The  current  industry  size  in 
Japan  is  officially  put  at  USD  3.8  billion 
and is estimated by the Ministry of Interna-
tional Trade and Industry to reach  USD 35 
billion  by  the  end  of the  century.  In  the 
Community, despite the emergence of a sig-
nificant  number of firms  and a substantial 
growth  in  markets,  primarily  of bio-phar-
maceuticals,  to  over  USD  3 billion,  at  the 
current  rate of growth,  the  value  of output 
and  employment  is  about the same  as that 
in  Japan.  It  is  therefore  clear  that  by. the 
year  2000  with  an  estimated  world  market 
of ECU  100  billion  for  the  biotechnology 
industry,  the  Community  growth  rate  will 
have  to  be substantially higher than at  pre-
sent  to  ensure  that  the  Community  will 
become a major producer of such products, 
thereby  reaping  the  output  and  employ-
ment  advantages  while  at  the  same  time 
remaining  a  key  player  in  the  related 
research area. 
5.7.  Factors favouring growth, 
competitiveness and 
employment in the Community 
The  sectors  with  the  greatest  potential  for 
the  applications  of  biotechnology  are 
amongst the most vigorous and competitive 
sectors  in  the  Community  with  a  long 
record  of  sustained  growth,  productivity 
increase, and highly  competitive trade per-
formance. 
The  Community  firms  in  these  sectors 
(chemicals,  pharmaceuticals,  agricultural 
processing)  are  leading  firms  at  a  global 
level  with  important  capabilities  in  the 
domain of innovation. 
Among other factors  favouring  investment 
in biotechnology in the Community are the 
strong science  base  and  infrastructure,  ~he 
availability  of skilled  labour, and the  hagh 
quality of process engineering and produc-
tion facilities. 
5.8. Unfavourable factors 
The key factors that may jeo~ardize a sig!'if-
icant  expansion  of  biOtechnological 
applications in  the Community are the fol-
lowing: (i)  In a domain  where the technology tra-
jectory is crucially  dependent on  basic 
science, the public research and develop-
ment expenditure in the Community lags 
behind.  For  the  1993  financial  year 
publicly  financed  US  biotechnology 
research  and  development  expendi-
tures are set  to  exceed  USD 4 billion: 
in  Japan  in  1991  they  exceeded  USD 
900  million  whereas  the  Community's 
and  Member  States'  expenditures 
totalled around  USD 600  million. The 
fourth  research  and  development 
framework  programme's  proposes 
ECU  650  million  in  biotechnology 
over  five  years.  Member  States  have 
also  programmes  devoted  to  R&D  in 
biotechnology. 
(ii)  Privately financed  research and develop-
ment  on  biotechnology  in  the  Com-
munity  has  not  compensated  for  the 
shortfall  in  public funding;  on the con-
trary,  available  indicators  identify  a 
delocalization  - an  investment  out-
flow,  largely  net,  from  Communit~ 
companies  mainly  towards  the  USA 
and  Japan  of  USD  2.2  billion  since 
1984.  In  the  most  vigorous  sector  of 
biotechnology,  biopharmaceuticals,  in 
1990  67%  of  patents  were  held  by 
US-based companies and only  15% by 
Community-based  companies.  There 
exists the risk that the Community will 
be a leading future market for biophar-
maceuticals  but  not  a  leading  future 
producer. There is an evident feedback 
between  technology  diffusion  and  pri-
vate investment. 
(iii)  Regulation  concerning  the  safety  of 
applications of the  new  biotechnology 
is  necessary  to  ensure  harmonization, 
safety,  and  public  acceptance.  How-
ever, the current horizontal approach is 
unfavourably  perceived  by  scientists 
and industry as introducing constraints 
on  basic and applied  research  and its 
diffusion  and  hence  having  unfavour-
able effects on EC competitiveness. 
(iv)  Technology  hostility  and social  inertia 
in  respect of biotechnology have  been 
more  pronounced  in  the  Community 
in general than in the USA or Japan. It 
has  become  clear  that  these  issues 
should be examined in greater detail in 
order  to  properly  address  these  con- J 
cerns. Supporting actions such as those 
under the  Biotech  programme and the 
creation of a group of advisers to  look 
at ethical issues have been undertaken. 
5.9.  Conclusions and 
recommendations 
The  potential of ·biotechnology to dramati-
cally  impact on  competitiveness  is  greatest 
in certain sectors of the Community chemi-
cals,  pharmaceuticals,  process  equipments 
and appliances, agriculture and agricultural 
processing. These sectors contribute impor-
tantly to value-added and employment. The 
observed  international growth  in  output of 
between 30 and 40% in the most vigorous of 
the  biotechnology  dependent  sectors  and 
the  associated  labour-intensive service acti-
vities  (e.g.  research,  health  care)  has  the 
capacity  to  pro\'ide  a \'aluable  stimulus  to 
employment growth. 
The means to achie\·e a fuller realization of 
the  Community's  inherent  strength  in  bio-
technology  are  to  be  found  in  overcoming 
existing constraints by creating appropriate 
channels for biotechnology policy develop-
ment  and  coordination  and  by  acting  on 
the following recommendations. 
(a)  Given the importance of regulations for 
a  stable  and  predictable  environment 
for  industry  and  given  that  they 
influence  localization  factors  such  as 
field  trials  and  scientific  experimenta-
tion, the Community should be open to 
review  its  regulatory  framework  with  a 
view to ensuring that advances in scien-
tific  knowledge  are  constantly  taken 
into  account  and  that  regulatory  over-
sight  is  based  on  potential  risks.  A 
greater recourse,  where  appropriate, to 
mutual  recognition,  is  warranted  to 
stimulate  research  activities  across 
Member  States.  Furthermore,  if  the 
Community  is  to  avoid  becoming 
simply a market rather than a producer 
of biotechnology-derived products then 
it  is  vital  that  Community  regulations 
are harmonized with international prac-
tice. The development of standards will 
supplement regulatory efforts. 
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use of the possibilities which exist in  the 
present  regulatory  framework  on  flexi-
bility and simplification of procedures as 
well  as  for  technical  adaptation.  To 
sustain  a  high  level  of environmental 
protection  and  to  underpin  public  ac-
ceptance, it  is important to reinforce and 
pool  the  scientific  support  for  regu-
lations.  An  advisory  scientific  body  at 
Community level  for biotechnology dif-
fusion  drawing on  the  scientific exper-
tise  within  and  at  the  disposal  of the 
existin2  committees  at  national  and 
Comm  ....  unity  level.  An advisory body al 
Community  level  - scientific  com· 
mittee  for  biotechnology  diffusion  -
could play a crucial  role  in  intensifying 
scientific  collaboration  and  in  pro-
viding  the  needed  support  for  a  har-
monized  approach  of the  development 
of risk  assessments  underlying  product 
approval.  This  body  could  also  advise 
on the  development  of a further  Com-
munity strategy for biotechnology. 
(c)  Since  the  Community  is  not  matching 
efforts elsewhere in  research and devel-
opment  expenditure,  it  needs  to  com-
pensate for  this through focusing on  the 
most  ,·igorous  biotechnology  research 
and  de,elopment  domains  and  increased 
coordination  between  the  Communit' 
and  t\·1ember  States  in  order  to  a\'oid 
duplication.  encourage  collaborati,·e 
research  and  improve  efficiency  of 
expenditure  on  research  and  develop-
ment. 
(d)  The  small  and  medium-sized 
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research-oriented  firms  play  an  impor-
tant role in  biotechnology diffusion and 
the growth of this sector would substan-
tially benefit from  the creation of a net-
work  of existing  and  new  biotechnolog)· 
science parks in  the Community linking 
together academic institutions, research 
laboratories  and  SM Es.  This  would 
create  the  possibilities  for,  on  the  one 
hand, greater educational investment in 
molecular  biology  and  biohardware, 
and,  on  the  other  hand,  the  involve-
ment of venture capital and other finan-
cial  institutions.  The  Structural  Funds 
could also play an important role. 
(e)  Member  States  should  provide 
additional incentives  to  improve  further 
the  investment climate for  biotechnology 
and to  facilitate  the  transfer of applied 
research  and  development  to  the 
market place. These might include fiscal 
incentives respecting the existing Com-
munity  guidelines  that  have  a  bearing 
on  biotechnology  innovation  and 
investment. 
(f)  The  commercialization  of  biotech-
nology will  in certain areas require spe-
cific actions aimed  at  further enhancing 
public  understanding  of  the  technology. 
Member  States  should  encourage 
interest groups to  make objective infor-
mation  available  and  to  encourage dia 
Iogue. 
(g)  It  is  necessary  to  clarify  further  value 
laden  issues  in  relation  to  some  applica-
tions  of biotechnology.  In  view  of this, 
the  Commission  will  reinforce the  role 
of the  Group  of Advisers  on  Ethical 
Implications  of  Biotechnology  and 
other groups  which  examine  in  partic-
ular ethical questions related to biomed-
ical research. BlaETHICS AND THE EUROPEAN UNioN 
3.b.  Communication "The Biotechnology and the White 
Paper"  (June 1994) BIOTECHNOLOGY AND THE WHITE PAPER 
ON GROWTH, COMPETITIVENESS AND EMPLOYMENT 
PREPARING  THE  NEXT  STAGE 
COmmunication  from the Commission to the Council,  the European 
Parliament  and  the Economic  and social committee CONTENTS 
INTRODUCTION 
REGULATORY  FRAMEWORK 
STRENGTHENING  OF  SCIENTIFIC  ADVICE 
RESEARCH  AND  DEVELOPMENT 
BIOTECHNOLOGY  AND  SMES 
THE  INVESTMENT  CLIMATE 
PUBLIC  UNDERSTANDING 
ETHICS 
CONCLUSIONS 
ANNEX  STATE  OF  PLAY  OF  THE  BIOTECHNOLOGICAL 
REGULATORY  FRAMEWORK 
1 
2 
7 
7 
8 
10 
10 
11  . 
13 
15 INTRODUCTION 
An  innova~ive ~ool 
The  White  Paper  on  Growth,  Competitiveness  and  Employment  acknowledged 
modern  biotechnology  as  one  of  the  fields  offering  the  greatest 
potential  for  innovation  and  growth.  Its  application  could  be  of 
particular  benefit  in  areas  such  as  healthcare,  industrial  chemicals, 
food  and  feeds,  agriculture  and  environmental  clean-up  services. 
Moreover,  the  further  development  of  biotechnology  will  require 
increasing  investment  in  supplies,  services  and  hardware.  This  would 
have  a  correspondingly positive effect on the employment  situation. 
A  Ca.muni~y role 
The  European  Community  has  been  becoming  increasingly  involved  in 
biotechnology since the mid-1970s.  By  funding  research  and developing  a 
regulatory  framework,  it  has  sought  to  promote  the  competitiveness  of 
bio-industries,  whilst  also  ensuring  the  safety  of  man  and  the 
environment. 
The  Commission  recognised,  in its  1991  initiative,  that  biotechnology 
is  a  key  technology  for  the  future  competitive  development  of  the 
Community.  As  such,  it will  determine  the  extent  to  which  Community 
industries  remain  world  leaders  in  the  development  of  innovatory 
products.  Although  the  main  responsibility  for  competitiveness  rests 
with  the  firms  themselves,  the  Commission  also  took  the  view  that 
public authorities  could  help to stimulate competitiveness  by  adopting 
a  consistent  and  supportive  approach  in  relevant  areas.  This  would 
entail  the  provision  of  financial  support  for  basic  and  applied 
research  and  related  infrastructure;  the  drawing  up  of  a  coherent 
regulatory  framework,  based  on  a  number  of  defined  principles 
(including protection of  intellectual property);  a  renewed  emphasia  on 
education  and  training;  the  st~ulation of  technology  tranafer;  and 
the  facilitation  of  public  understanding  and  consumer  choice.  A 
package of priority measures  was  subsequently approved. 
A  nev btlpetus 
The  White  Paper  confirmed  the  outstanding  promise  of  biotechnology  in 
terms of growth,  competitiveness  and employment. 
Taking  account  of  the content  and  state of  implementation  of the  1991 
package,  it gave  new  impetus  to achieving  a  fuller  realisation of  the 
Community's  inherent  strength  in  biotechnology  and  to  overcoming 
existing  constraints.  Reinforcing  conditions  at  both  the  R~D  and 
marketing  stages  of  biotechnology  would  increase  ita  potential  for 
employment  creation.  By  taking  a  number  of  specific  steps,  Europe's 
competitiveness in this field will be  further enhanced. 
The  present  communication  represents  the  commission's  raaponae  to tbe 
White  Paper's  recommendations,  and  ita  structure has  bean  designed  so 
aa  to follow  the order  in  which  these  recommendations  were  listed.  It 
is  baaed  on  the  premise  that  the  White  Paper's  goals  in  relation  to 
biotechnology  can  be  achieved  only  through  close  cooperation  between 
operators,  users,  COmmunity  Institutions,  Member  State authorities  and 
interest  groups.  The  Commission  r~cognises  the  important  interest  of 
the  European  Parliament  in developments  in biotechnology  and  is ready 
to  establish  the  necessary  dialogue  on  biotechnological  issues,  in 
particular with the  Parliament.  It will  also  seek,  as  in tbe past,  to 
organise round-table discussions. 
1 REGULATORY FRAMEWORK 
Int:.roduct:.ion 
Biotechnology  involves  the  use  of  modern  genetic  engineering,  which 
will  affect  many  different  products  and  processes.  The  Conununity' a 
regulatory  framework  for  biotechnology was  designed,  in the late 1980s, 
in  order  to  provide  the  necessary  legislation  to  ensure  adequate 
protection  of  health  and  the  environment,  while  at  the  same  time 
creating the internal market  for biotechnological products.  It is based 
on  a  number  of principles,  adopted  in  19911),  which  still retain their 
validity  (see Annex  1  for details). 
The  Community  is  putting  into  place  both  "horizontal"  and  product 
legislation  containing  a  specific  environmental  risk  assessment  of 
products containing or consisting of GMOs.  (An  overview of the state of 
play regarding current legislative activities is attached at Annex  1.) 
This  framework  has  been  built  upon  the  knowledge  available  at  that 
time,  when  there  was  still  considerable  uncertainty  as  to  safety  and 
the  risks  involved  in  the  application  of  modern  biotechnology.  The 
Community  adopted  legislation aiming at a  broadly preventative approach 
as regards the use of modern  biotechnology. 
The  White  Paper  concluded  that  the  Community  should  be  open  to 
reviewing  its  biotechnology  regulatory  framework,  in  order  that  the 
full potential of modern biotechnology for  jobs,  investment  and growth 
can be realised. 
Following this  commitment,  the Commission,  in consultation with  Member 
State  authorities,  undertook  such  a  review.  Its  objective  was  to 
ensure  that  the  safety  requirements  and  administrative  procedures  are 
appropriate  to  the  risks  for  human  health  and  the  environment  and 
reflect  acquired  experience,  advances  in  scientific  knowledge  and 
established  international  practices.  It  also  took  account  of  the 
existing regulatory frameworks  on modern  biotechnology used by ·ita main 
competitors,  in particular the United States. 
'rhe vay ahead 
In  carrying  ~ut the  review,  the  Commission  paid  special  attention to 
the wider  range of  knowledge  and  experience  currently available,  which 
has  increased  understanding  of  the  riaks  associated  with  genetic 
modifications  and  increased  confidence  among  acientists  in the  aafaty 
of genetic engineering. 
Much  use  has  now  been  made  of the  technology  in research  laboratories 
and  industrial  facilities  worldwide.  From  this  knowledge  and 
experience,  it  may  be  concluded  that  the  riaks  involved  in  the 
contained  use  of  GMMs  are  aubatantially  lass  than  were  once  foreseen. 
For  example,  the  potential  for  horizontal  gene  transfer  resulting  in 
novel  and  harmful  pro~rtiea being  acquired  by  microorganiama  baa  not 
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2 been  shown  to  present  hazards  to  human  health  and  the  environment. 
There  is  a  growing  confidence  that  the  GMMs  used  in  research  and  in 
industrial  production  can  be  more  precisely  categorised,  so  that  they 
are  unable  to  survive  except  in  the  epecial  environment  of  the 
exper~nt or process  in which  they are used.  Experience  baa  shown that 
the  majority  of  genetic  modifications  in  contained  facilities  can  be 
done safely by  applying good  laboratory practice. 
Worldwide,  there have  now  been many  deliberate releases of GMOs,  mainly 
with  a  number  of  well-known  crop  plants.  This  has  led  to  an  improved 
understanding  of  the  behaviour  of  these  plants  and  their  safety  in 
respect  of  human  health  and  the  environment.  So  far,  such  releases 
have  not  given  cause  for  concern,  and  evidence  is  accumulating  to the 
effect that genetically modified planta do not differ from  non-modified 
plants other than  in the specific character conferred by  the introduced 
gene. 
As  part  of  its  broader  reflections,  the  Commission  acknowledged  that 
the  biotechnological  regulatory  framework  is  a  factor  impacting  on 
industrial  competitiveness,  which  confirms  the  need  for  balanced  and 
proportionate  regulatory  requirements  commensurate  with  the  identified 
risks. 
It also noted the results of surveys  indicating the important role that 
the  regulatory  framework  has  to play  in building  public  confidence  inc· 
biotechnology.  This  shows  the  need  for  a  predictable  and  adaptable 
regulatory system. 
Taking these elements into account,  the Commission  confirms its earlier 
view  that,  in  the  future,  the  whole  network  of  interrelated 
biotechnological  regulations  needs  to  ensure  that  oversight  is  always 
appropriate  in  relation to the  risks  involved,  the  building  of  public 
confidence  and  to  the  competitive  development  of  the  industries 
involved,  while  guaranteeing  the  protection  of  human  health  and  the 
environment.  on  this basis,  the  Commission  is of  the  opinion that the 
following  two-track  approach  for  the  future  development  of  the 
biotechnological regulatory  framework  should be applied: 
the  exploitation  of  existing  possibilities  for  revising 
measures/procedures/  degree  of  oversight  I requirements,  through  use 
of  the  "light"  procedure  of  adaptation  to  technical  progreaa 
(regulatory Committee procedure).  (internal amendment) 
the bringing forward of amendments to existing legislation in order 
to  incorporate  changes  which  cannot  be  achieved  by  technical 
adaptation  while  leaving  the  basic  structure  of  the  framework 
intact  (external  amendment) 
*  * 
* 
The  COmmission  examined  the  application  of  the  two-track  approach  in 
greater. detail  for  apacific  parts  of  the  regulatory  framework, 
considering  each  such  part  on  its  particular  merits.  It  came  to  the 
conclusions outlined below. 
3 Directive  90/219/EEC  on  the  contained  use  of  genetically-modified 
.U.croorganisms 
The  review  indicated that extensive use  was  made  during  the  late 1970s 
and  the  1980s  of  genetically-modified  microorganisms  in  laboratories 
and  industrial  fermenters,  from  which  substantial  experience  was 
gained.  This  experience,  together with  the  recommendations  made  by  the 
OECD,  forms  the scientific basis of the Directive. 
The  commission  identified,  on  the basis of the substantially increased 
understanding of the risks associated with the use of  GMMs  in contained 
circumstances,  as mentioned  above,  the following objectives for  further 
action: 
i)  streamlining  and  easing  of  the  administrative/notification/ 
consent requirements where this does  not  compromise safety; 
ii)  ensuring  that  the  classification  of  the  genetically  modified 
micro-organisms  and  of  the  activities  in  which  they  are  used 
are appropriate to the risks involved; 
iii)  ensuring  that  the  conditions  of  use  are  appropriate  to  the 
risks involved;  · 
iv)  extension of the flexibility of the Directive so it can be more 
easily  adapted  to  technical  progress  by  regulatory  Committee 
procedures. 
In line with these objectives,  this will  mean  that it will  continue to 
make  full  use  of the  inherent flexibility of the Directive  (regulatory 
Committee procedure),  i.e. by: 
preparing a  Decision redefining the risk categories of  GMMs  through 
the revision of Annex  II; 
revising  the  guidelines  for  classification  as  established  under 
Article  4.2  of  the  Directive  as  a  result  of  the  discussion 
undertaken for  amending the criteria of Annex  II  (see above); 
further  exploiting  the  possibilities  to  adapt  safety  assessment 
parameters,  containment  measures  and  required  information  for 
technical progress. 
The  increased  knowledge  and  experience  mentioned  above  also  gives  a 
clearer indication of the present administrative  (notification)  consent 
requirements  necessary  to  ensure  safety  for  the  different  risk 
categories of GMMs. 
Taking  into  account  the  most  up  to  data  information,  it  may  be 
concluded  that  the  existing  administrative  arrangements  may  be 
lightened  for  activities  presenting  low  risk to  human  health  and  the 
environment,  without  jeopardising existing safety standards.  This would 
also  allow  a  greater  focusing  of  attention  on  higher  risk 
4 possibilities.  However,  as  the  Directive -does  not  provide  for  such 
adaptations,  a  number  of  specific  amendments  must  be  introduced,  as 
follows: 
replacing  the  consent  requirements  by  record-keeping,  or 
notification  for  information  purposes,  for  certain  low-risk 
activities; 
replacing the explicit consent  requirements  by  implicit consent  for 
certain higher-risk activities; 
reduction  of  time  periods  involved  in  implicit/explicit  consent 
procedures; 
adapting  the  present  risk  classification  system  for  GMMs,  in 
accordance with  new  safety considerations. 
removal  of  the  differentiation  between  activities  in  research 
laboratories and  production plants. 
The  Commission will propose the possibility of adapting the definitions 
contained within the  scope  of  the Directive via  a  Committee  procedure, 
as  is,  for  example,  at present  foreseen  in the  case  of  pharmaceutical 
legislation. 
The  Commission  will  conduct  the  necessary  broad  consultations  with 
operators,  users,  Member  State authorities and interest groups in order 
to  propose  amendments  before  the  European  Council  to be  held  in  Essen 
by the end of  1994. 
Direceive  90/220/BBC  on  the deliberate release  o~ genetically .adified 
orqaai ..  s  eo  the environmene 
The  Commission  bas  made  a  number  of  technical  adaptations  to  the 
Directive to reflect the evidence acquired  from  the wide  number  of  GMO 
releases  in the  plant area,  which  were  shown  not  to pose  any  specific 
risks.  These  measures  seek to  improve  uniform  application,  streamline 
and simplify the procedures and reduce the obligations on the notifiers 
while  maintaining  the  appropriate  protection  of  health  and·  the 
environment.  These activities are the following  : 
A  Commission  Decision  revising  the  notification  information 
requirements  of  Annex  II  of  the  Directive,  reducing  them 
significantly for releases of plants  (95' of releases)  (April 94). 
A commission Decision revising the Summary  Notification Information 
format  reducing the information required for plants  (April 94). 
A  Coalmission  Decision  establishing  criteria  for  introdu-cing 
simplified  procedures  under  Article  6.5  (Oct.  93)  for  genetically 
modified plants. 
Preparation  of  a  Commission  Decision  introducing  specific 
simplified  procedures  for  releases  of  plants  (to  be  adopted  by 
June/July 94). 
The commission  concluded,  on the basis of the progress made  in adapting 
aspects of the Directive,  that it is flexible enough to satisfy current 
needs  for  adaptation  to  technical  progress  and  simplification  of 
procedures.  In  the  short  term,  it  will  fully  exploit  the  existing 
possibilities in this area. 
5 Biotechnology is a  fast-moving  and  continually evolving technology,  and 
the  commission  recognises  that there  are  aspects  of the  Directive that 
might  be  improved.  It  is  not,  however,  possible  at  present  to  detail 
the  precise  nature  of  these  improvements,  as  further  experience  is 
necessary  in order  to determine the right  balance  between  the  need  for 
safety,  public  reassurance  and  the  minimum  restraint  on  industry  and 
research work. 
Hence,  on the basis of  future  experience and  scientific knowledge,  the 
Commission will  carry out  a  further  review of the Directive during the 
first  half  of  1995.  This  review will  assess  the  need  for  proposals  in 
relation to: 
extending  the  flexibility  of  Directive  90/220/EEC,  so  that  its 
acope  and  the  procedures  to  be  followed  are  always  appropriate  to 
the risks involved,  and are easily adaptable; 
atrengthening more  uniform decision-taking between Member  States in 
the case of research and  development  releases; 
introducing  further  opportunities  for  notifiers  (industry  and 
researchers),  so that they can benefit more  from  the existence of a 
uniform  Community  system; 
facilitating  the  link  between  this  Directive  and  product 
legislation. 
Other legislation 
The  Commission  has  noted that,  to date,  one  specifi~ piece of  product 
legislation,  namely  for  medicinal  products  of  biotechnology,  is  in 
force.  As  from  1  January  1995,  this  will  be  replaced  by  a  centralised 
procedure  which  will  result  in  a  COmmunity-wide  marketing 
authorisation.  This  new  piece  of  legislation  is  the  reault  of  a 
streamlining  of  existing  marketing  authorisation  procedures  so  that 
patients  can  benefit  from  new  innovative  medicinal  product& 
simultaneously  in  all  Member  States,  while  at  the  same  time 
safeguarding maximum  standards of public health. 
In  respect  of  other  product-baaed  regulations  which  contain  or  will 
contain  an  environmental  risk  assessment  similar to that  in  Directive 
90/220/EEC,  one  other  such  piece  of  legislation  (namely,  additive&  in 
feeding atuffs)  has been adopted  - which will enter into effect aa  from 
1  October  1994  - and  a  further two  (on  novel  foods  and  seeds)  are under 
discussion  before  the  other  institutions.  The  rapid  adoption  by  the 
Council  of  this  legislation,  as  an  essential  part  of  the  overall 
framework,  is seen as a  matter of urgency.  The  Commission will continue 
to  make  efforts  to  arrive  at  this  and  to  ensure  ita  proper 
implementation,  by  drawing  upon  experience  and  knowledge  already 
available. 
6 It will,  as  a  matter  of  urgency,  make  a  proposal  for  an  amendment  to 
Council  Directive  91/414/EEC  on  the  placing  of  plant  protection 
products  on  the  market  in  order  to  complete  the  environmental  risk 
assessment,  already  provided  for  in the  Directive,  with  the  technical 
complements  which  are  necessary  to  cover  adequately  plant  protection 
products  containing  or  consisting  of  GMMs.  A  fast  track  procedure  for 
certain  low  risk plant protection products,  including  biological  plant 
protection  products,  whether  derived  from  GMMs  or  not,  will  also  be 
proposed. 
In  relation  to  the  legislation  to  protect  workers  from  the  risks 
related to  exposure  to  biological  agents  at  work,  the  Commission  will 
press Kember  States for  a  more  rapid transposition. 
The  review  again  demonstrated  the  need  for  adequate  patent  protection 
for  inventions,  as an  important condition.for attracting investments in 
biotechnology.  The  Commission  re-emphasises  therefore  that  Community 
legislation,  which  has  been  under  discussion  since  1988  and  1990 
respectively,  in  the  area  of  intellectual  property  (patents  for 
biotechnology inventions  and plant variety rights)  should be  adopted as 
a  matter  of  urgency.  By  doing  so,  an  important  gap  in  the  regulatory 
framework will be closed. 
The  same  applies  to  the  draft  modification  of  the  seed  marketing 
directives  aiming  at  integrating  the  environmental  risk  assessment  in 
the established variety acceptance procedure. 
The  Commission will seize opportunities - as is foreseen,  at the end of 
1997,  for  example,  in  the  legislation  for  medicinal  products  - as 
regards further simplification and/or streamlining of procedures of the 
biotechnology  regulatory  framework  as  part  of  its  general  policy  in 
this  area  as  stated  in  the  White  Paper.  An  ongoing  review  of  the 
biotechnological  regulatory  framework  shall  be  carried  out  as  new 
scientific  knowledge  and  the  emerging  regulatory  practice  of  major 
international  competitors  indicates  that  this  is  necessary  or 
desirable. 
STRENGTHENING OF SCIENTIFIC ADVICE 
The  White  Paper  recognised  the  importance  of  scientific  advice 
available  to  the  Commission,  which  is  particularly  relevant  in  the 
field of biotechnology with applications  in  a  broad  range of  areas.  At 
present,  it  is  therefore  assessing  whether  there  is  a  need  for 
reinforced scientific input to regulations,  for  example,  in view of  an 
appropriate implementation of product legislation containing a  specific 
environmental  risk  assessment  for  products  consisting  of  or  derived 
from  CMOs.  This  assessment  will  also  take  account  of  the  work  of 
exiating  advisory  acientific  coaaittees  at  Comriaunity  level  and  that 
carried out by  a  number of national adviaory COmmittees  on bioaafety or 
genetic modification proyiding advice at national level.  A meeting will 
be  organised  between  the  Commission  and  the  chairpersons  of  theae 
acientific  committees  to  ahara  experiences  and  to  identify  whether 
there are further needs in the area.  A  European Science and Technology 
Aasembly ia being aet up to assist the COmmiasion  in the conception and 
implementation  of all Community  research  and  technological  development 
policies,  including  those relating to biotechnology.  This will  further 
strengthen the links between the Commission and the research world. 
7 RESEARCH AND DEVELOPMENT 
One  of  the  greatest  resources  for  the  European  biotechnology  industry 
is ready  access to a  well-established science base  and  a  highly-skilled 
workforce.  A'  recent  survey  of  some  400  new  biotechnology  companies 
indicated that,  generally  speaking,  they  have  grown  up  around  areas of 
academic excellence.  This vital resource of  innovation  and skills,  much 
of  it  funded  by  governments,  is  also  readily  available  to  Europe's 
large  pharmaceutical  and  chemical  companies,  either  via  strategic 
partnerships  or  directly-funded  research.  Experience,  however,  has 
shown  that,  despite  this,  Member  States  need  to  give  greater 
recognition to the importance of the science base for biotechnology,  as 
has  been  done  elsewhere.  Furthermore,  increased  coordination  is needed 
between  and  within  Member  States'  research  programmes  to  minimise 
wasteful  duplication  and  to  maximise  collaboration,  with  the  aim  of 
improving the efficiency of  R&D  expenditure. 
Ca..uni~T initia~ives 
To  these  ends,  the  Commission  has  recently  proposed  considerably 
expanded  research  programmes  activity within  the area  of  Life Sciences 
and  Technologies:  biotechnology  (552  MECU),  biomedecine  and  health  (336 
MECU)  and  agriculture  and  fisheries  (684  MECU)  under  the  Fourth 
Framework  Programme.  This  total  proposed  expenditure  of  1572  MECU 
signifies  an  increase  in  budget  of  741  MECU  in  comparison  to  the 
relevant programmes  as included in the third Framework Programme. 
The  Cormnission  realises  that  the  European  Union  as  a  whole  is  not 
matching  research  and  development  expenditure  made  elsewhere.  However, 
it is compensating  for this by  focusing  on the most  vigorous  R&D  areas 
and  on  increasing  coordination  between  the  Member  States'  and  the 
Community's research programmes. 
To  improve  these  aspects,  the  three  Specific  Programmes  in  the  Life 
Sciences and Technologies area propose three mechanisms: 
Areas offering the highest potential returns on  R&D  in the abort to 
medium term will receive special priority for  funding  (concentrated 
financial  support).  This  will  often  involve  a  multi-diaciplinary 
and  integrated approach. 
Areas  which  are  strategically  important,  but  where  limited 
financial  support  is  available,  will  be  supported  by  the 
establishment  of  networks  aimed  at  coordinating  and  building  upon 
Member  States•  research programmes. 
Areas which are essential to the exploitation of the life sciences, 
but which may  require apecial attention in reapect of other factora 
such  as  socio-economic  or  ethical  issues,  will  be  addressed  by 
horizontal activities.  These will involve the key players and usera 
in  dialogue  aimed  at  socially  acceptable  solutions  and  a  well-
informed public. 
By  the rapid adoption of the three specific programmes  and  through the 
implementation  of  the  above  mentioned  mechanisms,  the  Commission 
expects  to  achieve  a  fuller  realisation  of  the  Coamunity' a  inherent 
potential in biotechnology R&D. 
8 BIOTECHNOLOGY AND SMES 
As  shown  by  previous  major  technological  advances,  small  and  medium 
sized  enterprises  play  a  vital  role  in  the  early  stages  of 
technological  innovation  and  diffusion.  This  sector  is  growing,  and  a 
number  of  important  firms  have  been established.  In terms  of  numerical 
importance,  SMEs  specialising  in  modern  biotechnology  are  located  in 
the  UK,  France,  the  Netherlands,  Denmark  and  Germany,  and  focus 
primarily  on  the  therapeutic  and  diagnostic  fields  of  research  and 
production.  · 
Coaaunity  suppo~ 
A  recognition  of  the  important  role  of  small  and  medium  sized 
enterprises  has  led many  Member  States to encourage the  development of 
the  SME  sector.  Building  on  this,  the  White  Paper  has  set  out 
guidelines  for  an  integrated  programme,  whose  focus  is  on  three  major 
themes:  improving  access to finance  and credit facilities,  support  for 
cooperation  between  firms  and  support  for  improvements  in  management 
quality. 
These  objectives  respond  in  large  measure  to  the  needs  of  the  small 
and  medium  sized  biotechnology  enterprises.  Like  other  SMEs,  these 
firms  face  difficulties  in  accessing  private  sector  sources  of  funds, 
whether  from  financial  intermediaries,  equity  market  or  venture 
capital.  Small  and  medium  sized  biotechnology  firms  have  a  particular 
need  for industrial and financial partners when  starting up. 
Other specific characteristics of  biotechnology SMEs  are  the need  for 
and availability of high-tech scientific input and the need to overcome 
hurdles quickly in bringing inventions and  innovations onto the market. 
In  view  of  this,  the  Fourth  Framework  R&D  Programme  opens  up 
opportunities: 
for  facilitating  the participation of  SMEs,  irrespective of their 
RTD  capability,  in Community  R&D  programmes,  via the implementation 
of  a  special procedure based on the experience of CRAFT  activities; 
for  encouraging  the  establishment  of  industrial  platforms.  These 
consist  of  groups  of  European  companies  associated  with  s~cific 
projects under the Community  research programmes,  with preferential 
access to their results; 
for  demonstrations.  The  application  of  the  innovative  results  of 
research  in  the  life sciences  area will  be  addressed  through  well 
targeted  and  pre-competitive  demonstration  activities.  This  will 
enhance the attractiveness of new biotechnology applications; 
for  helping  SHEa  to  find  suitable  partners  to  carry  forward 
innovative  applications  of  biotechnology  and  to  establish  trans-
national networks  for technology transfer. 
Science paries 
The  characteristics that  biotechnology  SHEs  share  with  other  science-
based  SHEs  underlie  the  emergence  of  science  parks  at  the  combined 
initiative  of  the  SHEs  themselves  and  universities,  in  collaboration 
with  local  and  regional  authorities.  Up  to one-third  of  biotechnology 
SHEs  in  the  Community  are  located  in  science  parks.  With  the  steady 
entry  of  new  biotechnology  firms,  some  59  of  the  250  science parks  in 
the Community  now  contain an  important biotechnology component. 
9 Science  parks  facilitate  the  process  of  technology  innovation  and 
diffusion and  offer  a  number  of advantages  for  SMEa.  For example,  they 
provide  easy  and  close access  to science  facilities,  which  enables the 
SME  to have  a  •window on the technology•  and to be  informed  on the most 
up-to-date  developments.  The  costa  involved  in  seeking  venture  or 
investment  capital  partners  are  considerably  reduced  for  firms  and 
investors alike;  sourcing of  intermediates and  laboratory materials is 
facilitated;  and  labour  mobility  can  be  encouraged  between  academic 
work  and research applications. 
This evident trend of  growth,  in the Community,  of science parks with 
a  biotechnology  component,  mirrors  a  development  already  witnessed  in 
the  USA  in  the  past  decade,  where,  by  1992,  there  were  81  dedicated 
biotechnology  centres,  with  some  730  firms,  specialising primarily  in 
applied research. 
Under  the  Programme  for  Innovation  and  Technology  Transfer,  SPRINT 
1989/93  (Council  decision  89/286/EEC),  modest  Community  funding  waa 
envisaged  to  support  feasibility  studies  and  expert  assistance  in 
creating  science  parks  that  serve  a  market  need  and  that  are  able  to 
attract  firms.  Presently  the  Commission  is,  following  the 
recommendations  of  the  Communication  on  Cohesion  and  RTD  Policy 
undertaking  a  study  to evaluate  the  need  to create  networks,  the  type 
of  network  most  conducive  to the  opttmal  functioning  of  science  parks 
and  collaboration  between  Technology  Parks  within  the  European  Union. 
This  would  allow  a  fuller  exploitation of  opportunities  for  increased 
cooperation between  firms  operating on  the  internal market,  and  hence 
would  contribute  to  realising  the  objectives  of  the  integrated 
programme  for  SMEs. 
THE INVESTMENT CLIMATE 
The  importance  of  the  investment  climate  to  the  transfer  of  applied 
research  and  product  development  to  the  commercialisation  stage  is 
fully  recognised.  In  general,  the  allocative  mechanism  in  market 
economies is efficient in shifting investment  flows  and  factors towards 
sectors  experiencing,  or  likely  to  experience,  high  growth,  as  with 
certain areas  of application of biotechnology. 
While,  in  a  number  of  products  derived  from  modern  biotechnology, 
market-driven  growth  is  evident,  there  are  others  of  major  long-term 
potential such as bioremediation products and  new  ranges of bioaensors, 
where  growth  is  variable  or  modest.  The  result  is  that  medicinal 
products  of  biotechnology  is  the  target  domain  of  over  60'  of  the 
current  modern  biotechnology  firms,  while  bioremediation  product 
development  occupies  leas  than  5'  of  the  existing  firma.  Investment 
incentives  in  particular  by  Member  States,  within  the  existing 
Community  framework,  to  improve  the  investment  climate  in these  areas 
are  recommended.  This  would  cover  support  for  R&D  activities,  or  the 
start-up  or  expansion  of  business  activities,  together  with  the 
establishment  of  sound  technological  clusters  and  a  business-friendly 
tax  climate.  In  doing  so,  Member  'tates  would  strengthen  Burope•a 
competitiveness  in  high-value  added  future  growth  markets.  Por  ita 
part,  the  Community  will,  through  the  implementation  of  a  newly-
proposed  specific  programme  on  the  diffusion  and  exploitation  of  HD 
results  (involving expenditure of 293  MECUs),  help to overcome barriers 
preventing  the  conversion  of  scientific  achievements  into  commercial 
successes. 
10 PUBLIC UNDERSTANDING 
The  introduction  of  any  new  technology,  whether  in  the  past  or  at 
present,  has  raised critical reactions  from  the general public.  This is 
especially  true  of  biotechnology,  as  it  raises  value-laden  issues. 
Surveys  indicate  that  understanding  of  biotechnology  varies  widely 
within the Community,  as does.the perception of  the risks  and  benefits 
of different applications. 
The  Commission  has  helped  to  bring  about  a  number  of  initiatives  to 
raise  public  awareness,  although  it recognises  that  other  public  and 
private bodies  have  primary  responsibility  in this area.  The  focus  for 
the  Community's  activities has  been  the Life  Sciences  and  Technologies 
Research  Prog~ammes. The  following actions will be reinforced: 
analytical  work  concerning  public  attitudes,  including  the 
Eurobarometer surveys.  This is necessary in order to understand the 
scale of the problem and the factors which lie behind it. Such  work 
will  guide  future  awareness  activities  to  be  undertaken  by  the 
Commission,  Member  State  governments  and  other  interested  parties 
from the public and private sectors. 
raising  awareness  among  the  main  players.  Building  upon  the 
experience  of  analytical  work,  increased  information  will  be 
provided  in  a  balanced  and  impartial  way  to  raise  awareness  in 
industries  where  the  commercial  potential  of  the  emerging 
technology  may  not  be  well  understood;  in  the  public  sector, 
including  government  institutions,  where  policies  and  strategies 
are  developed;  among  the  media  communicating  biotechnology  to the 
public;  among  scientists  increasing  public  understanding  of 
science;  and public interest groups  and educators. 
raising  awareness  and  providing  information to the  general  public. 
A  European  Initiative in Biotechnology Education  has  been  launched 
and  will  be  reinforced to provide teaching materials  and  expertise 
to school teachers throughout the European Union.  other specialised 
materials will  be  prepared  and  workshops,  conferences  and  meetings 
will be held to encourage dialogue and to aid openness. 
The  Commission  recognises  that  modern  biotechnology  comprises  many 
varying applications.  In view of this,  it is important that all parties 
concerned  develop  reliable  information  on  all  aspects  of  these 
applications,  especially as regards their potential benefits and  risks. 
This  involves  illustrating innovative  advantages  as  well  as  addressing 
issues  such  as  safety,  ethics  and  environmental  protection.  It would, 
however,  like to stress that,  ultimately,  it is the market  place which 
decides the successful commercialisation of individual biotechnological 
applications. 
ETHICS 
General 
Developments  in biotechnology may  raise questions of  an ethical nature 
in  certain  areas.  There  is  concern  about  tampering  with  nat·ure  and 
life,  and  the  White  Paper  stressed  the  need  to  ensure  that  these 
questions  are  addressed  and  identified properly.  In  response  to this, 
the  Commission  has  reinforced the profile of  the  Group  of  Advisers  on 
the  Ethical  Implications  of  Biotechnology,  thereby  building  on  the 
results achieved during the first two  year term of the Group. 
11 This group,  established in 1991,  is concerned with: 
the  identification  and  definition  of  ethical  issues  raised  by 
biotechnology; 
the appraisal of the ethical aspects of  Community  activities in the 
field  of  biotechnology,  and  their  potential  impact  on  society  and 
the individual; 
and  advising  the  Commission  as  regards  the  ethical  aspects  of 
biotechnology,  with  a  view to improving public understanding. 
So  far,  the  group  has  given  three  opinions  on  the  ethical 
implications  of  the  use  of  performance  enhancers  in  agriculture  and 
fisheries,  of medical  products derived  from  human  blood  and  plasma,  and 
of  legal protection of biotechnological  inventions.  These opinions  have 
greatly  assisted  the  Commission  in  formulating  its  policy  in  these 
areas. 
The Group's mandate  has  been  renewed  recently to increase the number of 
advisers,  and  hence  to  make  available  a  broader  range  of  advice.  It 
consists of  independent  leading experts  from  several different branches 
of  science.  It is  the  Group's  intention to  step  up  its contacts  with 
the  general  public  and  international  organisations.  At  the  same  time, 
it has also intensified its work  programme  and its Secretariat has  been 
reinforced.  At  present,  opinions  are  under  preparation  on  the  ethical 
aspects  related  to  transgenic  animals,  gene-therapy  and  pre-natal 
diagnosis,  all of which will  be  finalised before the end  of this year. 
Because of its terms  of reference,  the Group  has  a  unique place in the 
European  Union.  It is closely  involved,  in  a  consultative capacity,  in 
the  elaboration  of  relevant  Community  policy,  but  is  completely 
independent.  It  is  also  able,  at  its  own  initiative,  to  examine  any 
topic touching on biotechnology. 
Several  activities such  as workshops  and  seminars  on  legal  and  ethical 
aspects  related  to  biotechnological  and  biomedical  research  including 
their  application  in  the  agricultural  sector  are  proposed  under  the 
Fourth  Framework  Programme.  These  activities  are  related  to  more 
general  issues  concerning  biotechnology  (patents,  biodiversity,  an~al 
models)  and  the  application  of  classical  rules  of  medical  ethics 
(informed  consent,  confidentiality,  ethical  review  of  research 
protocols)  to  new  fields  of  biomedecine  like  brain  research,  gene 
therapy and  neurotransplantation. 
Bia.edical ethics 
In  the  past,  the  COIIIDission  has  taken  a  number  of  initiatives  to 
clarify ethical  issues  in relation to biomedical  and  health  research. 
For  example,  the  human  embryo  and  research  (HER)  working  group  baa 
monitored  the legal  and practical aspects of research on  human  embryos 
in the Member  States and  identified sectors where  a  consensus  could be 
reached.  TWo  reports,  on  embryos  before  and  after  implantation,  have 
been  published,  and  the  state  of  legislation  on  embryo  research  was 
reviewed.  Protection  of  embryos  and  specific  issues  like  pre-
implantation diagnosis will be the next tasks of this working group. 
Moreover,  the  ESLA  (Ethical,  Social  and  Legal  Aspects)  working  group 
under  the  human  genome  analysis  research  prograiiiDe,  has  encouraged 
public  discussion  and  made  recommendations  to  the  Commission  on  the 
legal or other initiatives to be taken in this field. 
12 Research  in all areas of biomedical ethics has  been initiated under the 
first Biomedical  and  Health research programme,  and the COmmission  bas 
proposed to continue this under  the  new  second  specific Biomedical  and 
Health  research  programme.  To  this end,  it intends to organise working 
groups  to prepare  reports  and  surveys  for  the  European  Parliament  and 
council  of  Ministers  on  relevant  biomedical  ethical  issues.  Targeted 
workshops  are  to  be  held  to  identify  and  debate  issues  requiring 
clarification and  debate at an  international level. 
Interuational 
An  increasing  number  of  international  organisations  have  undertaken 
initiatives to clarify the ethical issues related to the different kind 
of  applications  of  biotechnology.  In  this  respect  the  Commission 
attaches  importance  to  the  work  of  the  Council  of  Europe  towards  the 
preparation of a  Convention on  Bioethics.  The  Commission  is preparing a 
Communication to the Council  on its participation in this convention. 
CONCLUSIONS 
The  Commission  considers  that  the  application  of  modern  biotechnology 
will have  a  major  ~pact on the development of a  wide  range of sectors. 
Whilst naturally committed to guaranteeing  maximum  standards of safety 
for  man  and  the  environment,  it is  of  the  opinion  that,  by  taking  a 
number  of  specific  steps,  as  a  follow-up  to  the  White  Paper'a 
recommendations,  it  will  encourage  the  competitiveness  of  Burope'a 
bioindustries.  It count&  upon the other Inatitutions,  Member  Statea and 
interest  groups  to  give  force  to  tbeae  maaaures.  The  Commisaion 
recognises  the  important  interest  of  the  European  Parliament  in 
developments  in  biotechnology  and  is ready  to establiah the  neceaaary 
dialogue on biotechnological  issues,  in particular with the Parliament. 
It will also seek,  as. in the past,  to organise round-table discussion&. 
Taking  account  of  the  considerations  outlined  above,  it  has  decided 
upon the following: 
to  ~plement a  two-track approach as regards the future development 
of the biotechnological regulatory  framework i.e. to exploit fully, 
where  they exist,  the  inherent possibilities to adapt  to technical 
progress  (via regulatory Committee procedure).  At the same  time,  it 
will bring forward  amendments  in order to incorporate changes which 
cannot  be  achieved  by technical  adaptation while  leaving the baaic 
structure  of  the  framework  intact.  In  line  with  this  approach  it 
will,  as regards  : 
directive 90/219/EEC  on the contained use of  GMMa,  continue to 
review  Annexea  II  to  V  and  conduct  the  necesaary  broad 
conaultationa  with  operator&,  uaera,  Member  State  authoritiea 
and  intereat  groupe,  in  order  to  propose  amendment•  in  the 
indicated  areaa  before  the  Buropean  council  at  Bsaen  ao  that 
the  wide  ranging  available  knowledge  and  experience  ia 
incorporated  in  that  directive.  By  doing  ao,  ita  functioning 
will  be  improved  without  jeopardising  exiating  aafety 
atandarda. 
directive  90/220/EEC  on  the  deliberate  releaae  of  GMOa,  make 
full  use  of  the  poaaibilitiea  to  adapt  to  progress  and  in 
particular  to  aimplify  procedures.  on  the  basis  of  ongoing 
13 experience  and  scientific  and  technological  devalopnents,  in 
the first half  of  1995  an  evaluation will  take  place  following 
the  objectives  set  out,  whereby  an  assessment  will  be  made  of 
the need  for  bringing  forward  amendments. 
other parts of  the regulatory  framework,  continue  to press  for 
a  rapid  adoption  of  the  intellectual  property  protection 
legislation  as  well  as  of  product  legislation  containing  an 
environmental  risk  assessment  similar  to  that  of  directive 
90/220/EEC.  It  will  ensure  adequate  implementation  of  such 
legislation  by  preparing  guidelines  drawing  upon  already 
available  expertise.  The  Commission,  for  its part,  will,  as  a 
matter of  urgency,  make  a  proposal  for  an  amendment  to Council 
Directive  91/414/EEC,  in  order  to  complete  the  environmental 
risk  assessment  of  plant  protection  products  derived  from  or 
consisting of genetically modified microorganisms.  A fast track 
procedure  for  certain  low  risk  plant  protection  products, 
including biological plant protection products,  whether derived 
from  GMMs  or not,  will be proposed. 
The  rapid  transposition of  the  workers•  protection  legislation 
by the Member  States is a  matter of urgency. 
An  ongoing  review  of  the  biotechnological  regulatory  framework 
shall  be  carried  out  as  new  scientific  knowledge  and  the 
emerging regulatory practice of major international competitors 
indicates that this is necessary or desirable. 
to  identify  and  remedy  the  needs  for  strengthening  scientific 
advice at its disposal. 
to  enhance  the  rapid  adoption  of,  in  particular,  the  proposed 
specific  programmes  for  biotechnology,  biomedecine,  health  and 
agriculture and  fisheries within the Life Sciences and Technologies 
area.  The  concentrated  financial  support  for  areas  offering  the 
highest  potential returns  on  R&D  and the establishment of  networks 
to build upon  Member  States'  research programmes  are guarantees of 
further developing Europe's inherent strength in the area; 
to  facilitate  the  development  of  small  biotechnology  firma,  given 
their  inherent  advantages  for  developing  new  ideas  and  products. 
The  Fourth  Framework  R&D  Programme  opens  up  opportunities  for 
facilitating  the  participation  of  SHEs  and  for  helping  them  to 
carry forward  innovative applications of biotechnology,  both within 
and  outside science parks.  currently,  the Commission  is evaluating 
the  need  to  create  networks,  and  the  type  of  networks  moat 
conducive  to  the  optLmal  functioning  o~  science  parks.  The 
continued development of a  favourable  investment clLmate, ·following 
existing Community guidelines,  is also essential; 
to  facilitate  public  understanding  of  biotechnology  through  the 
reinforcement of  a  number of outlined initiatives; 
to  reinforce  the  profile of  the  Group  of  Advisers  on  the  Ethical 
Implications  of  Biotechnology  in  order  to  clarify  further  value-
laden  issues  related  to  biotechnology.  Biomedical  ethical  issues 
will be sLmilarly identified and debated. 
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STATB  OF  PLAY  OF  THE  BIOTECHNOLOGICAL  REGULATORY  FRAMEWORK 
The  Community's  regulatory  framework  is  composed  of  both  "horizontal" 
and  product  legislation  (medicinal  products,  additives  used  in  animal 
nutrition,  plant  protection products,  novel  foods,  seeds).  Legislation 
on  intellectual property protection also  forms  part of  this  framework, 
which is founded  upon the following  underlying principles: 
Necessity:  the  Commission  will  propose  legislation  in  this  area 
only  if it is shown  to be  necessary  by  a  thorough  examination,  on 
a  case-by-case basis,  of the characteristics inherent in  specific 
biotechnological applications. 
Efficient  interaction:  biotechnologically-derived products  will  be 
subject  to  only  one  authorisation  and  assessment. procedure  before 
being placed on the market. 
Evaluation  criteria:  product  evaluation  will  take  place  in 
accordance  with  the  three  established criteria of  safety,  quality 
and  efficacy.  The  Commission  will  normally  follow  scientific 
advice.  In  exceptional  cases,  however,  it reserves  the  right  to 
take  a  different  view  in  the  light  of  its general  obligation  to 
take into account other Community  policies and objectives. 
Adaptation to progress:  the regulatory framework will be kept up to 
date with scientific and technical  progress.  This  is of particular 
importance in a  rapidly developing field such as biotechnology. 
Standards:  the  development  and  existence  of  standards  may  be  used 
to  complement  legislation,  particularly  on  technical  details  of 
good practice and safety procedures. 
International  obligations:  the  Commission  will  ensure  that  all 
decisions  in the field of biotechnology will  be  in conformity with 
international  obligations,  in  particular  with  the  provisions 
resulting from the Uruguay Round  negotiations. 
The state of play regarding relevant legislation is as follows: 
A.  LBCISLA'l'IOR  ALRBADY  ADOPJ'BD 
•Hori&ontal•  legislation 
Council  Directive  90/219/EEC  of  23  April  19902)  which  covers  any 
contained  use  of  genetically~ified microorganiams  (GMMs),  both  for 
research and  commercial purposes; 
council  Directive  90/220/EEC  of  23  April  19903)  on  experimental  and 
marketing-related  aspects  of  genetically-modified  organisms  (GMOs), 
2)  OJ  No  L  117,  8.5.1990,  p.  1 
3)  OJ  No  L  117,  8.5.1990,  p.  15 
15 which  covers  any  R&D  release  of  these  organisms  into  the  environment 
and  contains  a  specific  environmental  risk  assessment  for  the  placing 
of  any  product  containing  or  consisting  of  such  organisms  onto  the 
market; 
council  Directives  90/679/EEC  of  31  December  19904)  and  93/88/EEC  of 
29  October  19935),  which  provide  a  minimum  requirement  designed  to 
guarantee  a  better  standard  of  safety  and  health  as  regards  the 
protection of workers  from the risks of exposure to biological agents. 
Member  States have transposed or are at the final stages of transposing 
Directives  90/219/EEC  and  90/220/EEC,  and  competent  authorities  have 
bean  appointed  in all Member  States.  Legislation has  yet to be  adopted 
in  Greece  and  Luxembourg,  and  has  nearly  been  completed  in  Spain.  In 
Ireland,  the  specific  regulations  putting  into  effect  the  framework 
enabling  legislation  have  still to  be  adopted.  over  250  research  and 
development  releases  have  been  notified  under  Directive  90/220/EEC  to 
the  Commission  and  have  taken  place,  the  vast  majority  of  which 
concerned  plants.  These  releases  were  in  Belgium  ( 60),  Denmark  ( 11), 
Germany  (10),  Spain  (8),  France  (78),  Italy  (18),  the Netherlands  (32), 
Portugal  (4)  and the United  Kingdom  (35). 
Three products have  so far been cleared under the 90/220/EEC  system. 
As  regards  Directives  90/679/EEC  and  93/88/EEC,  the  transposition  has 
yet to be widely realised. 
- Product legislation 
In  respect of the other main part of the regulatory  framework,  namely, 
specific product legislation,  the situation is as  follows: 
Council  Directive  93/114/EC,  amending  Directive  70/524/EEC  on 
additives  in  feeding  stuffs.  This  amendment  introduced  new  categories 
of  additives,  including,  among  others,  additives  containing  or 
consisting  of  GMOs  into  the  existing  legislation:  the  amendment  will 
enter into effect as of  1  October 19946); 
Council  Directive  93/41/EEC,  repealing  Directive  87/22/EEC  on  the the 
approximation  of  national  measures  relating  to  the  placing  on  the 
market  of  high-technology  medicinal  products,  particularly  those 
derived  from  biotechnology:  the  legislation will  enter  into effect  as 
of  1  January  19957).  Under  the  1987  procedure  about  SO  medicinal 
products of biotechnology have been approved  ; 
Proposal  for·  a  Directive  to  amend  Directive  91/414/BEcB)  on  the 
placing  on  the  market  of  plant  protection  products:  this  Directive 
provides for  a  apecific procedure for evaluating the environmental risk 
of  GMM  plant protection  product&  to be  included  in the Directive.  The 
Commiaaion is preparing a  Proposal to that end. 
The  COmmiasion  baa  propoaed to the Council to extend,  for the lifettma 
of the milk quotas,  the present moratorium on the  pl~cing on the market 
4)  OJ  No  L  374,  31.12.1990,  P·  1 
S)  OJ  No  L  268,  29.10.1993,  P•  71 
6)  OJ  No  L  334,  31.12.1993,  p.  24 
7)  OJ  No  L  214,  24.8.1993,  p.  40 
8)  OJ  No  L  230,  19.8.1991,  p.  1 
16 and  administration  of  bovine  somatotropin  (BST).  ·.1·ne  t...uuu~.  .... 
adopted  a  Decision extending the moratorium for  one  year,  to allow tLme 
for  a  detailed  examination  of  all  of  the  available  information  on 
BST9). 
B.  PROPOSALS  ROT  YET  ADOPTBD 
Proposal  for  a  Council  Regulation  concerning  novel  foods  and  novel 
foods  ingredientslO); 
Proposal  to  modify  existing  seed  marketing 
particular  Directives  70/457/EEC  and  70/458/EEC 
varietiesl1); 
directives,  and  in 
on  the  acceptance  of 
Draft  Council  Directive  on  Legal  Protection  of  Biotechnological 
Inventionsl2); 
Draft Council Regulation on  Community  Plant Variety Righta13). 
9)  OJ  No  L  332,  31.12.93,  p.  72 
10)  COM  (92)  295  and  COM  (93)  631  Final 
11)  COM  (93)  598 
12)  OJ  No  c  10,  13.1.1989,  p.3 and  COM(92)  589  final 
13)  COM(90)  347  and  COM(93)  104 
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4.  Commission Communication on Competitivity for 
Industry in Biotechnology - Extracts EUROPEAN CO:MMJSSION 
Secretariat General 
SG/C/1 
COMMISSION COMMUNICATION "PROMOTING THE COMPETITIVE ENVIRONMENT FOR 
THE INDUSTRIAL ACTIVITIES BASED ON BI01ECHNOLOGY WITIUN TilE COMMUNITY" 
SEC (91) 629 final 
D.  ETHICS AND OTHER  ISSUES 
Biotechnology,  through  its  wide  ranging  imrlication:  for  fvod.  health  and  the 
environment,  and  through  the  new  knov.:ledge  ~nd tecr.nologie5  it  offers,  will  have 
considerable  positive  impacts  on  our  \&:ay  oi  life.  It  also  offers  specific  new 
possibilities  for  information  and  in ten entions  2ffecting  human  life,  and  raising  or 
reinforcing basic ethical issues.  For both  the:;e  general  ~nd eth  i.:-al  reasons.  it  attracts 
considerable  public  interest and  debate.  som~ vf  it  contused.  This  is  important  for 
industry as  such  confusion  can  adverse)~  inlluence  the  whole  .:limare  for  industrial 
development of biotechnology. 
The questions  arising  in  public debate  ~elong to  distin.:t  categories  and  debate  will 
continue  to  be  ill-defined  (and for  public  policy  purpcr5es.  inefiectual) so  long  as  a 
clear differentiation is  not made between the:S-e  issues: 
(i)  ethical  consideralions  relating  to  human  life  and  identity,  which  may  arise 
(for example)  in  medical  practice  and  counselling,  or  in  research  on  human 
embryos and the human genome: 
(ii)  other value-laden issues  which mJy t'e  nised by biotechnology, including: 
• 
animal welfare issues con.:erning. inter alia,  no,el methods  to enhance 
the  productivity  of agricultunl  ~nimals :and  the  development  of  new 
animals by biotechnologinl  methods  for  medical  research. agricultural 
or other purposes; 
issues  relating  to  the  limits  of  int~lleclual  property  rights  (patents, 
plant  breeders·  rights)  and  concerning  a  mixture  of  economic  and 
ethical  aspects  - eg.  patenting  human  beings  might  be  universally 
rejected, patenting of modified microorganisms widely accepted. 
(iii)  environmental  issues  about  the  potential  impacts  of  release  of  living 
genetically modified organisms into the  environment.  There is  a  Community 
framework for  the  protection of the environment and  it  is  important that this 
is  implemented.  Issues  relating  to  prot~tion  of  health,  safety  and  the 
environment are to  be satisfied. 
(iv)  health  and  safety  related  issues.  either  concerning  worker  safety  vis-a-vis 
biological agents,  or consumer and public s.:Jfety  issues  such  as are addressed 
by  applying  the  usual  criteria of Quality,  safety and  efficacy  to  products of 
biotechnology; 
(·.·)  issues  related  to  transparency  and  informJtion  to  allow  for  well-informed 
consumer choice. 
(vi)  issues  relating  to  the  socio-econ9mic  impact  (eg. 
employment)  of  new  biotechnology-aid:?d  methods 
agriculture. 
on  production  and 
of  production  in It  is  essential  that  a  clear  distinction  be  made  between  ethical  questions,  related 
mainly to  the first and partly to  the  second of the above categories  and other issues 
raised  by the applications of biotech  no  log~.  A II  of  these concerns are important and 
both  national  and  Community  policy  makers  must  ensure  that  legislative  and  other 
measures (agricultural. environmental. consumer  protection.  research,  product safety, 
protection of human  rights)  respond  to  the  concerns  expressed.  The  Commission  is 
aware  that  its  responsibilities  in  this  area  exund  beyond  the  borders  of  the 
Community. 
On  bio-ethical  issues,  the  Community  has  been  seriously  involved  in  the  succession 
of international conferences, from  the first  at  Hakone,  Japan,  in  1985  to  that held  in 
Rome in  1988 (on ethical issues  in  human genome :Sequencing)  and that hosted by the 
Commission  in  1989  on- environmental  ethics.  Reference  has  been  made  to  ethical 
elements of research  programmes  in  biotechnology  and  human  genome analysis  (and 
to  the latter's working group on ethical. social  and  legal aspects): similarly the future 
programme  of environmental  research  will  inclode  ethical  aspects  of environmental 
policy and management. 
The  Commission  organised· in  1988,  in  conjunction  with  the  German  Ministry  of 
Research  and  Technology,  the  first  ·European  Bioethics  Conference·  on  human 
embryos  in  modern  medical  and  biological  research.  During  the  conference,  the 
scientific and  technical aspects relating to this  issue  were presented and discussed  by 
biologists,  physicians,  sociologists,  philosophers  and  theologians,  as  well  as  legal 
experts  and  legislative  authorities.  A  common  position  was  reached  on  basic 
considerations:  rejection  of  commercial  exploitation:  protection  of  genetic 
information; and establishment of multidisciplinary ethical committees. 
Following  a  meeting  of  Ministers  of  Research  at  Kronberg  in  March  19990,  the 
Commission  has  now  established  a  working  group on  human  embryos and  research, 
which  held  its  first  meeting  in  Brussels  in  March  1991.  In  this  field  it  is  seen  as 
particularly  important  to  maintain  close  contact  v.·ith  the  substantial  and  continuing 
work of the Council of Europe (as  it  has already done,  for  example.  in  the field  of 
animal welfare conventions). 
Regarding  the  other,  kss  dire~tly  eihical.  issues  listed  above.  the  Co~missior.  has 
been and  rem  a ins  acti' ely in'  C'lved.  Some are  treated elsewhere at  appropriate rvints 
in  this commun  •  .:ation. 
The  Commission  will  continue  to  .:arry  out  social.  economic  and  t~chnological 
assessment  studies  to  accompany  its  policy  initiatives  and  research  programm~s  in 
biotechnology.  as  it  hlS  dont  for  mJny  years  through  programmes  su.:h  as  FAST 
(Forecasting  and  Assessment  in  Scien~e and  Technology),  and  through  the  work  of 
the  European  Foundation  for  the  improvement  of  Living  and  Working  Conditions 
(who  ha"e  accorded  to  biote.:hnology  the  highest  priority  in  their  work  on  social 
assessment of tf\:hnology). 
Through  these  and  other  101t1at•'·es.  in  conjun.:tion  v.·ith  the  concertation .action  of 
the  BRIDGE programme. the Commissi0n  is  d~veloping an approach to  stimulate  the 
formation and growth of small Cc:'mpanses  in  bi0technology. £.ETHICS 
The  Commission  realizes  that  it  is  not  possible  to  find  general  solutions  for  ethical 
issues  which  can  be  applied  as  a  uni' ersal  rule  and  that  ethical  issues  need  to  be 
identified on  a  case  by case  basis.  Re.:ent  debate  has  focussed  on ethical and  other 
aspects  of  human  genome  analysis.  oi  hum2n  embryo  research,  of  environmental 
research. of animal  welfare, and of intellectual property law. 
It  is  desirable  that  the  Community  ha\·e  ~n  advisory  structure  on  ethics  and 
biotechnology which  is  capable of dealing  with ethical  issues where they arise  in  the 
course  of Community  activitie5.  Such  a  structure  should  permit  dialogue  to  take 
place  where  ethical  issues  which  ~1ember States  or other  interested  parties consider 
require resolution could be openly discussed.  It would also enable recognised experts 
from  relevant  groups  to  participate  in  guiding  the  legislative  process.  The 
Commission  consiaers  that  this  would  be  a  positive  step  towards  increasing 
acceptance  of  biotechnology  and  to\l·:!rds  ensuring  the  achievement  of  the  single 
market for its  products. 
The Commission is  profiting from.  and collaborating with,  t.he  important work of the 
Council of Europe in this area. 
The Commission considers that through addressing explicitly the ethical challenges.  it 
is  helping to  improve the climate of public understanding and opinion concerning the 
responsible  development  of  biotechnology;  htnce  facilitating  the  acceptance  of  its 
benefits, and ensuring a  single market for  its  products. BloETHICS AND THE EUROPEAN UNioN 
5.  European Commission activities EUROPEAN CO~SSION 
SECRETARIAT GENERAL 
SG/C/1 
ACTIVITIES  OF THE EUROPEAN COMMISSION IN THE FIELD OF BIOE11IICS 
In  recent years the European Commission  has taken a number of steps to gauge more 
accurately the impact of biotechnology on society.  The main steps have been to set up 
groups  of experts,  reorganize  internal  structures  and  introduce  the  ethical  aspect  into 
research programmes financed by the Commission.  The European Medicines Evaluation 
Agency, which will be operational from  1 January  1995, will also base itself on certain 
ethical principles laid down at European level. 
1.  Groups of experts 
1.1  Group of Advisers on the Ethics of Biotechnology (SG) 
The  Group  of Advisers  was  set  up  in  November 1991  following  the  Commission's 
communication entitled "Promoting the competitive environment for industrial activities 
based on biotechnology within the Community". 
The Group's terms of reference are as follows: 
to identify and define ethical issues raised by biotechnology; 
to  appraise  the  ethical  aspects  of  CommunitY  activities  in  the  field  of 
biotechnology and their potential impact on society and the individual; 
to advise the Commission in its legislative role as regards the ethical aspects of 
biotechnology with a view to improving public understanding and acceptance of 
it. 
The Group of Advisers issued three opinions during its first term (1991-93).  The first 
was on BST (bovine somatotropin), the second on the legal protection of  biotechnological 
inventions and the third on products derived from  human blood or human plasma.  The 
Group  is  currently  looking  at  the  ethical  implications  of gene  therapy,  the  use  of 
transgenic animals and prenatal diagnosis. 1.2  HER Working Party (Human Embryos and Research) 
In  response  to  a  recommendation  made  at  the  meeting  of Ministers  in  Kronberg  in 
March  1990,  the Council  and  the Commission  set  up  the HER Working Party,  whose 
objectives are to: 
monitor, analyse and  discuss legislation and current practice relating to research 
on embryos in the Member States; 
detennine common  ground and  scope for  cooperation between national  ethical 
bodies or committees and for the development of a common code. 
The HER Working Party has produced two reports: 
First Report: 
Second Report: 
The Embryo before Implantation,  1992 
The Embryo after Implantation,  1994. 
1.3  The ESLA  Working  Party (Ethical,  Social  and  Legal  Aspect  of Human 
Genome Analysis) 
In  June 1990  the  Council  adopted  the  "Human  Genome  Analysis  Programme"  and 
allocated  7%  of the  programme's  budget  for  the  study  of ethical,  social  and  legal 
implications.  The ESLA Working Party was set up within the programme for the purpose 
of: 
analysing the ethical, social and legal aspects of human genome analysis; 
encouraging public discussion; 
making recommendations to the Commission on the legal or other initiatives to 
be taken in this field. 
The ESLA Working Party's First Report was dated 31  December 1991;  the second will 
be finalized at the end of 1994. 
1.4  Advisory Committee on the protection of animals used for experimental and 
other scientific purposes 
This Committee was set up by Commission Decision of 9 February 1990 in connection 
with  the  implementation  of  Directive 86/609/EEC  on  the  approximation  of 
Member States' legislation on the protection of animals used for experimental and other 
scientific purposes. 
Its purpose is to help the Commission organize the exchange of  relevant information and 
to assist it in matters raised by application of the directive. 
1.5  Scientific Veterinary Committee (DG VI) 
This Committee was set up by Commission Decision of 30 July  1981.  It provides the 
Commission with information on all scientific and technical issues concerning the health 
and protection of animals and veterinary measures affecting public health. 
2 1.6  Committee for Proprietary Medicinal Products and Committee for Veterinary 
Medicinal Products 
These two committees were set up  in  1981  to  centralize requests for  authorization to 
market proprietary medicinal products and veterinary medicinal products.  They issue an 
opinion on each application submitted to them.  These two committees are incorporated 
in the European Medicines Evaluation Agency (see Section 4). 
2.  Internal structures and orgnaization 
2.1  The Bioethics Unit, DG Xll 
In  1992 the Commission set up  a unit (XII.E.S) concerned with the legal  and ethical 
aspects  of the  life  sciences,  which  acts  as  the  interface  between  research  activities 
undertaken by the EC in  this field  and all  t~e legal  and ethical implications of other 
Community and national policies.  Its brief is to study matters relating to the patentability 
of living matter, the human genome, the confidentiality of medical  data in general and 
genetic data in particular, with special reference to employers and insurance companies, 
and all  other questions relating to the protection of individual rights in applications of 
biology  and  medicine,  animal  welfare,  the  ecological  implications  of biotechnology, 
biodiversity, food legislation and consumer protection in agro-industrial technology. 
Unit E.S  will  be  organizing  workshops,  the  first  covering  sperm  donations,  genetic 
screening and euthanasia. 
2.2  Coordinating Committee on Biotechnology, SG 
This interdepartmental  committee,  set up  in  February 1991,  is made up  of high-level 
officials  from  Directorates-General  concerned  with  biotechnology.  Its  role  is  to 
coordinate Commission action in this field,  its main tasks being to: 
examine measures taken by Commission departments; 
check that new operations are consistent with Community policy; 
resolve  the  problems  of  overlapping  responsibilities  between  Commission 
departments; 
coordinate the Com~ission position in international forums; 
organize round table discussions with  special  interest groups and  Commission 
departments; 
evaluate the results of Community policy on biotechnology. 
3.  Research programmes (DG Xll) 
The ethics debate raises questions and identifies new situations to which responses cannot 
be found without specific research into the ethical issues themselves. 
3 The  research  programmes  financed  by  DG XII  which  have  ethical  aspects  are  listed 
below.  Some of them may be amended under the fourth programme.  This programme, 
which has been proposed by the Commission, is  currently being discussed by Parliament. 
3.1  Biomedicine and health 
Budget:  ECU 131.67 million 
Ref.:  Council Decision:  OJ L 267, 24.9.1991 
Objectives 
The objectives are to improve the effectiveness of medical  and  health research, 
in  particular  by  better  coordination  of Member States'  research  activities  and 
pooling of  resources to achieve better application of  results.  Research in bioethics 
is also included in this programme. 
Structure 
The programme covers four areas: 
1.  development  of coordinated  research  on  prevention,  care  and  health 
systems; 
2.  study  of major  health  problems  and  diseases  of great  socio-economic 
impact; 
3.  human genome analysis; 
4.  research on biomedical ethics. 
The studies selected in this latter field are listed at Annex 2. 
NB  Under the human genome analysis programme (1990-92) 18 international 
research  projects  into  the  ethical,  social  and  legal  aspects  of  this 
programme were selected by the ESLA Working Party for Commission 
support.  These are short (one year) projects covering genetic counselling, 
prenatal screening, patentability of the human genome, etc.  (See the full 
list at Annex  1  ). 
3.2  Biotechnology (1992-94) 
Budget:  162.36 million 
Ref.:  Council Decision:·  OJ C 174,  16.7.1990 
Objective 
This programme concerns new priorities to enhance basic biological knowledge 
for applications in agriculture, industry, health, food and the environment.  It has 
a specific sector devoted to study of  the ecological implications of  biotechnology. 
4 Structure 
The programme is in three parts: 
1.  molecular approaches; 
2.  cellular and organism approaches; 
3.  ecology and population biology. 
3.3  Environment 
Budget:  ECU 261.4 million 
Ref.:  Council Decision:  OJ L  192,  16.7.1991 
Objectives 
This programme is aimed at developing the scientific knowledge and technical 
know-how required for the Community environment policy:  understanding of 
fundamental mechanisms, identification of sources of pollution and evaluation of 
their  combined  effects  on  the  environment  and  prevention  of natural  and 
technological risks and restoration of the environment. 
Structure 
There are four research areas: 
1.  participation in global change programmes; 
2.  technologies and engineering for the environment; 
3.  research on economic and social aspects of environmental issues; 
4.  technological and natural risks. 
3.4  Agriculture and agro-industry 
Budget:  ECU 329.67 million 
Ref.:  Council Decision:  OJ L 265, 21.1.1991 
Objective 
The  purpose  of this  programme  is  to  improve  the  quality  and  diversity  of 
agricultural  products,  to  enhance  the  competitiveness  of the  agricultural  and 
agri-foodstuffs sectors and to improve management of  the rural and forestry area 
and to protect the environment. 
Structure 
The programme is in four parts: 
I.  primary  production  in  agriculture,  horticulture,  forestry,  fisheries  and 
aquaculture; 
5 2.  inputs to agriculture, horticulture, forestry,  fisheries and aquaculture; 
3.  processing  of biological  raw  materials  from  agriculture,  horticulture, 
forestry,  fisheries and aquaculture; 
4.  end use and products. 
3.5  Life sciences and technologies for developing countries 
Budget:  ECU 109.89 million 
Ref.:  Council Decision:  OJ  L 196,  19.7.1991 
Objectives 
The  purpose  of the  programme  is  to  promote  cooperation  between  European 
scientists and those in developing countries in the fields of agriculture, medicine, 
health and food. 
Structure 
The development programme is in two main parts: 
1.  improvement of living conditions; 
2.  improvement in health. 
3.6  Training programmes 
Education and training are key issues in the field of  biotechnology.  Training is a priority 
within various Community research programmes such as COMETT, ERASMUS, FORCE 
and TEI\WUS. 
4.  European Medicines Evaluation Aaency 
In June and July  1993  the Council adopted a regulation and three directives concerning 
the future marketing authorization system and the creation of the European Medicines 
Evaluation Agency (OJ L 214, 24.8.1993).  The Agency is to be based in London.  From 
1995  onwards, therefore, there should be three registration procedures for medicines in 
the European Community: 
a  centralized  Community  procedure  valid  for  the  twelve  Member States  and 
restricted to certain new medicines; 
a  decentralized  procedure,  applying  to  most  medicines,  based  on  mutual 
recognition of national authorizations; 
a  national  procedure for  certain medicines restricted to the market of a  single 
Member State. 
6 Use of the centralized procedure will be compulsory for biotechnological medicines and 
optional for other high technology medicines and new active substances.  Requests for 
authorization will be sent direct to the European Medicines Evaluation Agency, made up 
principally of the Committee for Proprietary Medicinal Products and the Committee for 
Veterinary Medicinal Products with additional resources,  the assistance of a permanent 
administrative and technical secretariat from the Member States and appropriate logistics. 
The opinions of these two committees will subsequently become Commission decisions 
valid for the entire Community. 
The objective of  the decentralized procedure is to enable a marketing authorization issued 
by one Member State to be extended to one or more other Member State as a result of 
the recognition of the initial authorization.  In the event of major objections and after 
exhaustion  of all  the  means  of bilateral  conciliation,  the  matter  will  be  put  to  the 
European Agency for arbitration. 
Upon completion of these procedures, the opinions of the Agency (expressed by one or 
other  of the  committees)  will  be  sent  to  the  applicant,  the  Commission  and  the 
Member States.  If there are no serious objections, the Commission will adopt a decision 
making this opinion enforceable.  In the event of a major objection the Commission will 
take a decision in consultation with a regulatory committee and with the possibility of 
appeal to the Council. 
The European Medicines Evaluation Agency will also be responsible for the coordination 
of national  pharmacovigilance activities, laboratory inspection and controls in order to 
guarantee the safety of medicinal products available in the Community. 
The  Management  Board  of  the  Agency  is  made  up  of  representatives  of  the 
Member States, the European Commission and the European Parliament.  The Agency's 
initial  budget  of ECU 23  million  in  1995  will  increase,  in  line  with  the  new  tasks 
assigned  to  the  Agency,  to  around  ECU 60 million  in  1999.  It  will  be  financed 
increasingly by fees paid by pharmaceutical companies. 
7 BIOETHICS AND THE EUROPEAN UNION 
6.  State of play of dossiers related to the 
biotechnological regulatory framework EUROPEAN COMMlSSION 
Secretariat General 
SG/C/1 
STATE  OF PLAY OF DOSSIERS  RELATED  TO TilE BIOTECHNOLOGICAL 
REGULATORY  FRAMEWORK 
A.  Implementation of Legislation 
1.  Council  Directive  90/219/EEC  on  the  Contained  Use  of  Genetically 
Modified  Micro-Organisms  I  Council  Directive  90/220/EEC  on  the 
Deliberate  Release  into  the  Environment  of  Genetically  Modified 
Organisms  (DG  XI) 
The  date  of  entry  into  force  of  these  directives  was  23  October 
1991.  Member  States  have  adopted  or  are  at  the  final  stages  of 
adopting  legislation  and  competent  authorities  have  been  appointed 
in all Member  States.  A Commission report on  implementation will  be 
published shortly. 
A  summary  notification  information  format  for  Directive  90/220/EEC 
(Article  9)  was  adopted  by  the  Council  on·4  November  1991  (O.J.  L 
322  23.11.1991).  A  further  summary  format  (Article  12)  was  adopted 
by the Commission  on  11  February  1992  (O.J.  L  60  5.3.1992). 
A  Commission  Decision  establishing  criteria  for  simplified 
procedures  concerning experimental  releases of genetically modified 
plants was  adopted  on  22  October  1993  (O.J.  L  279/42,  12.11.93). 
A  Commission  decision  adapting  to  technical  progress  and 
simplifying  the  summary  notification  format  taking  into  account 
specifically  the  requirements  for  releases  of  plants  is  currently 
in written procedure  for  Commission  adoption. 
Equally  a  Commission  Decision  adapting to technical  progress  Annex 
II  (notification  requirements  for  releases  and  streamlining  it for 
releases  of  plants)  is  currently  in  written  procedure  for 
commission  adoption. 
In  total  250  field  test  notifications 
products  containing  GMOs  have  now  been 
products  have  been  approved. 
and  4  notifications  of 
received.  Three  ·of  the 
2.  Council  Directive  90/679/EEC  on  the  Protection of  Workers  from  the 
Risks  Related to Exposure to Biological Agents at Work  (DG  V) 
Member  States  are  required  to  bring  into  force  the  laws, 
regulations  and  administrative  prov~s~ons necessary  to  comply  with 
the  directive  not  later  than  29  November  1993.  So  far, 
transposition  has  not  been realised  in any  of the  Member  States. 
3.  Future  system  for  the  free  movement  of  medicinal  products  in  the 
European  Community 
The  package  has  been  adopted  by  the  Co~ncil  on  22  July  1993  and 
most  parts  enter  into  force  by  1  January  1995  (O.J.  L  214  of 
24.8.1993,  p.1).  As  regards  the  authorisation  of  biotechnology 
derived  medicinal  products  for  human  use  and  veterinary  medicinal products  is  concerned,  one  integrated  notification  and  one 
assessment  procedure  has  been  fixed.  Work  has  started  on  the 
implementation of the provisions  concerned. 
B.  Discussion at Council Level 
1.  Draft  Council  Directive  on  Legal  Protection  of  Biotechnological 
Inventions  (see also point 8.2)  (DG  XV) 
The  proposal  was  put  forward to the Council  in  1988. 
At  the  EP  plenary  session  of  October  1992  the  first  reading 
procedure  was  completed  and  an  op~n~on  was  voted.  A  common 
position  on  the  proposal  has  been  reached  on  7  February  1994  (SEC 
(94)  275  Final  - COD  159).  The  period of three months  in which  the 
EP  has  to  vote  its opinion  in  second  reading  began  February  25th. 
During its plenary session the European  Parliament voted,  on  4  May, 
three amendments  with respect to the common  position. 
2.  Draft  Council  Regulation  on  Community  Plant  Variety  Rights 
(COM  (90)  347)  (DG  VI) 
The  proposal  based  on  Article  43  of  the  Treaty,  was  sent  to  the 
council  in  September  1990.  It  deals  with  industrial  property 
protection of plant varieties of all types  including those obtained 
by the use of biotechnology. 
The  Community  protection  provided  for  under  this  proposal  is  a 
system sui generis  ((UPOV-type)  UPOV  =Union pour  la Protection des 
Obtentions Vegetales).  However,  patenting of biotechnology-derived 
plant  material  other  than  plant varieties  is dealt  with  under  the 
proposal  on  patenting  referred  to  in  item  8.1.  Decisions  on  the 
appropriate  interface  between  the  two  types  of  protection  have 
still  to  be  taken  (cf.  relevant  recital  in  the  above  mentioned 
proposal). 
The  EP  voted  an  opinion  on  the  proposal  at  its plenary  meeting  of 
October  1992.  An  amendment  on  farmers'  privileges  was  adopted. 
Work  has  been  pursued  at Council  level  on  the  basis  of  an  amended 
proposal  (COM(93)104  final).  On  11  December  1993  a  political 
agreement  on  the agricultural part of the proposal  was  reached. 
3.  Council  Directive  on  the  Placing  on  the  Market  of  EEC  Accepted 
Plant  Protection  Products  (DG  VI) 
The Directive 91/414/EEC was  adopted by the Council of Ministers of 
Agriculture  of  26  June  1991.  A  draft proposal  on  the  assessment  of 
GMO  derived pesticides is under preparation. 
4.  Proposal  for  a  Council  Regulation  Concerning  Novel  Foods  and  Novel 
Food  Ingredients  (DG  III) 
The  proposal  provides  for  a  safety  assessment  of  all  novel  foods 
and  novel  food  ingredients  including  those  containing  GMOs  and 
those  produced  from  GMOs  except  if  they  have  not  undergone  any 
significant  change.  It  aims  to  ensure  that  foodstuffs  and  food 
ingredients  for  human  consumption  including  those  derived  from 
biotechnology are safe and  wholesome. 
2 The  proposal  was  adopted  by the Commission  on  7  July  1992  (COM  (92) 
295)  and  it  accomplished  its  first  reading  in  October  1993.  The 
Commission  has  adopted  an  amended  proposal  on  1  December  1993  (COM 
(93)  631  Final). 
An  orientation debate  on  the file took place at the  latest meeting 
of the Council  of Ministers  for the Internal Market. 
5.  Proposal  for  a  Council  Directive  on  the  approximation  of  the  laws 
of  Member  States with regard to the transport of  dangerous  goods  by 
road  (DG  VII)  (COM  93,  548  final) 
The  proposed  framework  directive extends  the  scope  of  the  European 
Agreement  concerning  the  International  Carriage  of  Dangerous  Goods 
by  Road  (ADR),  to national traffic in order to harmonise across the 
Community  conditions  under  which  dangerous  goods  are  carried  by 
road.  Under  this  directive  the  establishment  of  conditions  of 
safety is possible under which biological agents  and  GMOs  regulated 
under  Directives  90/219/EEC,  90/220/EEC  and  90/679/EEC  should  be 
transported. 
6.  Draft council Directive on Genetically Modified Varieties of Plants 
The  Commission  adopted  on  November  26  1993  a  Draft  Directive 
amending,  among  others,  the  Directives  70/457/EEC  and  70/458/EEC, 
which  lay  down  the  conditions  for  inclusions  in  the  Common 
Catalogue of Varieties of agricultural and vegetable plant species. 
The  legal basis is Article 43  of the Treaty. 
This  proposal  establishes  a  legal  basis  to  take  account  of 
developments  in the areas  of genetically modified  varieties,  novel 
food  and  novel  food  ingredients.  It integrates  in these Directives 
an  environmental  risk assessment  s~ilar to the  one  foreseen  under 
Directive  90/220/EEC  and  a  food  safety  assessment  similar  to  that 
envisaged  under  the  proposed  Novel  Food  and  Novel  Food  Ingredients 
Regulation. 
7.  The  Administration of  BST  (DG  VI) 
The  Counc  i 1  has  agreed  on  a  ban  for  another  year  as  regards  the 
administration of  BST  in the Union  (OJ  L  333,  31.12.93,  p •.  72).  The 
product  has  been marketed  in the US. 
3 A  N  N  E  X 
RELEVANT  LEGISLATION  ADOPTED 
council Directive 85/374/EEC  on  product liability; 
council  Regulation  1010/86/EEC  laying  down  general  rules  for  the 
production  refund  on  certain  sugar  products  used  in  the  chemical 
industry; 
council  Regulation  1009/86/EEC  establishing general  rules  applying 
to production refunds  in the cereals and rice sector; 
Council  Directive  87  /21/EEC  amending  Directive  65/65/EEC  on  the 
approximation  of  provisions  laid  down  by  law,  regulation  or 
administrative action relating to proprietary medical  products; 
Council  Directive  87/22/EEC  on  the  . approximation  of  national 
measures  relating to  the  placing  on  the  market  of  high-technology 
medicinal  products,  particularly those derived  from  biotechnology; 
Council  Decision  89/45/EEC  amended  by  Decision  90/352/EEC 
notification  of  dangerous  products  presenting  a  serious  and 
immediate  risk with the exception of  products  notified  under  other 
equivalent  Community  notification  procedure  pharmaceuticals 
(Directives  75/319/EEC  and  81/851/EEC);  animals  (Directive 
82/894/EEC);  products  of  animal  original  as  far  as  they  are 
concerned  by  Directive  89/662/EEC;  the  system  for  radiological 
emergencies  (Decision 87/600/Euratom); 
Council  Directive  89/381/EEC  extending  the  scope  of  Directives 
65/65/EEC  and  75/319/EEC  on  the  approximation  of  provisions  laid 
down  by  law,  regulations  or  administrative  action  relating  to 
proprietary  medicinal  products  derived  from  human  blood  or  human 
plasma; 
Council  Directive  89/342/EEC  extending  the  scope  of  Directives 
65/65/EEC  and  75/319/EEC  and  laying  down  additional  provisions  for 
immunological  medicinal  products  consisting of  vaccines,  toxins  or 
serums  and  allergens. 
Council  Directive  90/219/EEC  on  the  contained  use  of  genetically 
modified micro-organisms  (O.J.  no.  L  117  of 8  May  1991,  p.  1) 
Council  Directive  90/220/EEC  on  the  deliberate  release  into  the 
environment  of  genetically  modified  organisms  (O.J.  no.  L  117  of 
8  May  1990,  p.  15) 
Council  Directive  90/679/EEC  on  the  protection  of  workers  from 
risks  related to exposure to biological agents at  work  (O.J.  no.  L 
374  of  31  December  1990,  p.1) 
4 Commission  Decision  91/274/EEC  concerning  a  list  of  Community 
legislation referred to in Article  10  of Directive 90/220/EEC  (O.J. 
L135  of  30.5.1991) 
commission  Decision 91/448/EEC  on guidelines  for the classification 
as  laid down  in Article  4.3  of  Directive  90/219/EEC  (O.J.  no.  L239 
of  28.8.1991,  page  23) 
council  Decision  91/596/EEC  concerning  the  summary  notification 
information  format  referred to in Article 9  of Directive 90/220/EEC 
(L322  of 23.11.1991) 
Council  Directive  92/59/EEC  on  the  safety  of  products  (O.J.  no. 
L228  of  11  August,  1992,  p.  24) 
Commission  Decision  92/146/EEC  concerning  the  summary  notification 
format  referred  to  in  Article  12  of  Directive  90/220/EEC 
(11.2.1992)  (L60  of  5.3.1992) 
Council  Decision  92/218/EEC  of  26  March  1992  adopting  a  specific 
research  and  technological  development  programme  in  the  field  of 
biotechnology. 
Council  Regulation  (EEC)  N°  2309/93  of  22  July  1993  laying  down 
Community  procedures  for  the  authorization  and  superv~s~on  of 
medicinal  products  for  human  and  veterinary use  and  establishing  a 
European  Agency  for  the  Evaluation  of  Medicinal  Products.  (O.J. 
no  L214  of  24.8.1993,  p.  1) 
Council  Directive  93/39/EEC  of  14  June  1993  amending  Directive 
65/65/EEC,  75/318/EEC  and  75/319/EEC  in  respect  of  medicinal 
products  (O.J.  no  L214  of 24.8.1993,  p.  22) 
Council  Directive  93/40/EEC  of  14  June  1993  amending  Directives 
81/851/EEC  and  81/852/EEC  on  the  approx~ation of  the  laws  of  the 
Member  States  relating  to  veterinary  medicinal  products  (~.J.  no 
L214  of  24.8.1993,  p.  31) 
Council  Directive  93/41/EEC  of  14  June  1993  repealing  Directive 
87/22/EEC  on the approximation of national measures relating to the 
placing  on  the  market  of  high-technology  medicinal  products, 
particularly  those  derived  from  biotechnology  (O.J.  no  L214  of 
24.8.1993,  p.  40) 
Commission  Decision  93/584/EEC  of  22  October  ~993 establishing the 
criteria  for  simplified  procedures  concerning  the  deliberate 
release  into  the  environment  of  genetically  modified  plants 
pursuant to Article 6(5)  of Council Directive 90/220/EEC. 
Council  Directive 93/114/EEC of  14  December  1993  amending Directive 
70/524/EEC  concerning  additives  in  feedingstuffs  (O.J.  no  L  334  of 
31/12/12 
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EXTRACTS  FROM SPEECH BY PRESIDENT J. DELORS 
"The ethical  dimension is once again coming to the fore, 
and we must step  up the debate about these fundamental 
issues which concern the very  essence of human life and 
society.  On the basis of what scientists tell  us about the 
laws  of Nature,  we  must take responsibility  and  decide, 
according to a certain idea of life and human beings, what 
action we want to take.  For my  part I would like [  ... ] to 
see the debate conducted in philosophical and ethical terms 
so  that  our  understanding  advances  to  keep  pace  with 
scientific progress". 
Jacques Delors, Speech on human rights and the European 
Community  :  1992  and  beyond",  Strasbourg,  20-21 
November 1989. EUROPEAN COMMISSION 
Secretariat-General 
SG/C/1 
EX1RACfS FROM SPEECH BY PRESIDENT J. DELORS 
SIXIEME CONFERENCE DU SOMMET ECONOMIOUE SJJR LA BIOETiflOU£ 
"ETiflQUE DE L'ENVIRONNEMENT" 
DISCOURS D'OUVERTURE DU PRESIDENT DELORS(Extraits) 
Seul le texte prononce fait foi 
Embargo 10 mai  1989, 9 heures  Bruxelles, le 10 mai  1989 
Co Mesdames, Messieurs, 
L'environnement est aujourd'hui une question posee a l'echelle de Ia planete, les valeurs 
qu'elle invite a fonnuler doivent etre des  valeurs communes et partagees.  En  d'autres 
termes,  l'ethique  de  l'environnement  se  prete  aussi  a  Ia  reflexion  du  legislateur,  de 
l'economiste, ou bien encore du simple citoyen.  Reflexion en forme de questions surtout. 
A quels problemes devons-nous faire  face?  La plupart sont desormais bien  connus du 
grand public - meme si  parfois inexactement,  ou  sous Ia pression parfois alarmiste des 
medias.  Nous savons taus cependant que le rechauffement de !'atmosphere et les risques 
d'alteration  climatique,  l'appauvrissement  de  Ia  diversite.  biologique,  l'epuisement 
progressif des  ressources,  pour  ne  citer  que  celles-la,  sont  aujourd'hui  des  donnees 
irrefutables de l'evolution de Ia planete.  Aucun de ces problemes ne peut d'ailleurs faire 
l'objet d'une approche separee : ils se posent a nous de maniere globale, et transcendent 
nos cadres traditionnels de reflexion et d'action, celui des espaces strictement nationaux 
ou  des generations presentes. 
Ce que ces problemes soulignent d'abord, c'est Ia dependance mal formulee jusque-la de 
l'homme a  l'egard de son milieu.  lis mettent en valeur Ia fragilite soudaine de Ia relation 
traditionnellement maitrisee,  faite  d'usage et d'exploitation,  qui  unissent l'homme et Ia 
nature.  Ce sont  done,  au  sens  large,  les conditions  memes  de  notre  humanite  qu'ils 
invitent a  repenser, a  reconstruire, dans Ia mesure ou le maintien des modes traditionnels 
de notre presence au  monde entrainerait un nombre toujours plus grand de dommages, 
et, a  breve echeance, menacerait de nous detruire. 
D'ou Ia  validite de !'approche ethique : elle vise en  effet les valeurs qui  regissent  les 
comportements sociaux.  Elle est aussi au fondement du  droit ; elle determine done les 
differents codes au nom desquels nous agissons, ces codes consacres par Ia  tradition, et 
dont il faut aujourd'hui retablir les veritables enjeux.  La degradation continuelle du cadre 
de vie que l'homme a revu en heritage aura par necessite conduit l'homme a  s'exprimer, 
a  l'egard de cet heritage, en tennes de devoirs et de responsabilites. 
L'ETinQUE DE L'ENVIRONNEMENT 
( ... )  Nous en  semmes venus aujourd'hui a  delaisser les  biens collectifs,  et a  proposer 
comme carte des comportements Ia satisfaction des besoins ou des desirs de l'individu, 
a  n'importe quel  prix. Nous n'avons cesse d'etendre dans notre societe le domaine des 
droits de l'individu.  Ce_ sont aujoud'hui les biens collectifs, les ressources communes qu'il 
faut par un mouvement inverse, proteger et preserver.  C'est l'ensemble des rapports de 
l'homme au milieu naturel que nous devons, sinon reconstruire, du mains reorienter. 
II  s'agit bien d'ethique : a  des valeurs jusqu'alors acceptees par l'ensemble des societes 
industrielles, et qui faisaient du cadre de vie un simple bien marchand, il faut substituer 
d'autres valeurs, une autre approche de l'environnement. 
·Cette· autre approche,  elle passe,  par une redefinition de nos responsabilites et de nos 
devoirs.  Responsabilites a  l'egard de Ia nature mais aussi  des generations futures et de 
nos propres societes, developpees et en voie de developpement. 
2 (  ... ) Nous devons apprendre a  respecter le milieu naturel pour lui-meme, et non seulement 
pour Ia satisfaction de nos besoins.  II  existe une logique de la nature, qui  peut differer 
de Ia notre.  Et, serions-nous dans l'impossibilite de definir cette logique, de dire a  quelles 
fins Ia nature obeit, il demeure que rienne nous autorise, par exemple, a  reduire toujours 
plus  Ia  diversite  biologique,  en  favorisant  Ia  disparition  de  certaines  especes,  ou  en 
mettant  en  danger  les  possibilites  de  leur  reproduction.  La  valeur  du  patrimoine 
genetique de Ia nature est proprement incalculable et celui-ci suppose aujourd'hui, pour 
etre conserve, l'exercice de Ia responsabilite humaine.  Et celle-ci  passe parfois par une 
attitude de profonde humilite: dans !'absence d'une connaissance etablie des consequences 
d'une action humaine sur Ia nature, il est sage de nous abstenir. 
Mais cette responsabilite a egalement une dimension temporelle : ce que nous mettons 
en danger par notre comportement a  l'egard de notre habitat,  c'est aussi  !'existence des 
generations appelees a nous  succeder,  c'est !'existence de  notre  posterite.  Les  anglo-
saxons disent justement que nous n'avons pas herite Ia terre de  nos ancetres,  mais que 
nous l'avons empruntee a  nos enfants. ( ... ) 
En d'autres termes, l'usage que nous ferons desormais de Ia nature, de la biosphere, nous 
devons considerer que nous en sommes comptables au regard du futur.  Les dilapidations 
soot  irreversibles  : nous  nous  y  sommes  livres  par  egolsme  concerte,  et  en  fonction 
d'interets immediats.  L'apprentissage de Ia responsabilite s'impose aussi par consideration 
du  long  tenne,  et,  comme  tel,  il  doit  etre  aujourd'hui  place  au  premier  rang  des 
preoccupations collectives. 
Notre responsabilite doit s'exercer enfin a  l'egard de nos  socit~tes, dans Ia mesure ou il 
faut assurer a  celles-ci le cadre de vie auquel elles aspirent.  11  ne s'agit pas de condamner 
en bloc l'intervention de l'homme dans Ia nature : Ia nature est aussi par vocation son lieu 
d'habitation.  D'ou Ia necessite de prendre en compte !'interet commun dans une ethique 
de  l'environnement,  et  Ia  pluralite  souvent  discordante  des  opinions.  C'est  notre 
responsabilite envers autrui que nous engageons en effet des lors que nous recherchons 
le bien public, qui  est Ia destination meme de l'ethique : cette responsabilite est de celle 
aussi  que les problemes de l'environnement doivent nous aider a  reinventer. 
Et  cela  d'autant  plus  que  nos  societes  connaissent  aujourd'hui  des  stades  de 
developpement  tres  inegaux,  que  les  richesses  sont  inequitablement  distribuees. 
L'environnement  est  cependant  une  donnee  planetaire,  qui  ignore  les  decoupes 
geographiques : il suppose des decisions communes.  La responsabilite des pays les plus 
industrialises joue ici  a l'egard de  ceux  qui  ont a supporter les  courts tres lourds  du 
developpement et des ajustements structurels, et a  qui  nous ne pouvons pas imputer les 
maux - ainsi Ia pollution) dont nous avons ete les premiers instigateurs. 
(  ... ) 
Mais il fallait souligner des maintenant qu'a l'egard des pays en voie de developpement 
nous  avons,  dans  le  domaine  de  l'environnement,  "des  obligations  particulieres 
d'assistance"  (Conference  de  La  Haye,  mars  1989).  Des  politiques  communes 
d'environnement peuvent aider a  instaurer cettte pratique nouvelle de Ia  responsabilite 
· partagee.  A  probleme  de  dimension  mondiale,  il convient,  faute  de  gouvemement 
mondial, de repondre par !'adoption et le respect de regles universellement appliquees. 
3 Tels soot nos responsabilites et nos devoirs : devoir de proteger notre ecosysteme, devoir 
de preserver cet ecosysteme pour les generations futures,  devoir d'assurer a  l'homme un 
environnement viable,  devoir  d'assistance  enfin a l'egard  des  pays  en  developpement. 
Telles soot aussi  les valeurs au  nom  desquelles nous devons agir.  (  ... ) 
LE DROIT DE L'ENVIRONNEMENT 
(  ... )  L'ethique  de  l'environnement  rend  ainsi  compte  de  !'emergence  d'un  droit  de 
l'environnement,  qui  pourrait etre aussi,  au  sens  large,  un droit vivant.  Car l'une des 
fonctions premieres de l'ethique est d'eclairer et de faciliter Ia  prise de  decision.  Elle 
pennet, en d'autres tennes, de legiferer.  11 faut done que les responsabilites et les devoirs 
que  j'ai  cites  trouvent,  a bref  delai,  le  cadre  juridique  dans  lequel  ils  puissent 
effectivement se transfonner en obligations. 
(  ... ) 
A  breve echeance  ( ... ),  le droit de  l'environnement devra  se  rapprocher d'un  droit du 
vivant.  A cet egard,  Ia  conference qui  s'ouvre aujourd'hui  ne  peut pas etre separee de 
celles qui l'ont precedee et qui toucheraient Ia question specifique de Ia bio-ethique.  De 
l'environnement au  vivant, Ia transition nous est imposee par les faits  : l'homme,  apres 
s'etre approprie Ia  nature comme espace geophysique,  est en  passe  de  soumettre a Ia 
meme exploitation le  dynamisme biologique de Ia  nature,  et son  principe createur,  Ia 
reproduction. 
L'essor des biotechnologies, dans le domaine medical en particulier, a beau se reclamer 
de  l'imperatif therapeutique,  il n'est  aujourd'hui  comprehensible  qu'en  fonction  de  Ia 
logique commerciale et industrielle, et done du droit de propriete.  Le vivant peut-il etre 
entierement  appropriable.  C'est  une  des  question  qu'il  faut  poser a  nouveau  et  que 
rendent  possible  nos  interrogations  sur  l'ethique  environnementale.  ll  n'y  sera  pas 
repondu, en tout cas,  sans que soient clairement fixees les valeurs dont il  faut affecter 
auj ourd'hui Ia nature et son symbiote, l'homme. 
ETIDQUE DE L  'ENVIRONNE:MENT ET TECHNO LOGIE 
(  ... )La technique n'est pas seulement fauteuse de troubles, elle est aussi un instrument au 
service des politiques environnementales, et elle peut tres certainement agir dans le sens 
des  valeurs  ethiques et des  devoirs.  II  revient  au  politique d'orienter,  de guider les 
emplois de Ia technologie, non de renier, par decision de methode, ces apports specifiques 
a  Ia  cause qu'il  a  choisi  de defendre.  Mais il  incombe aussi  a  tous  les responsables 
politiques  et  scientifiques  d'associer  leurs  efforts  pour  rendre  chacun  sensible  a 
l'imperieuse necessite de gerer Ia nature "en bon pere de famille".  Et je crois pouvoir 
ajouter, sans trop m'avancer, que cette conception correspond aujourd'hui a  l'enseignement 
des religions occidentales. 
4 LES  IMPLICATIONS  POLITIQUES  ET  ECONOMlQUES  DE  ·L'ETHIQUE  DE 
L'ENVIRONNEI\ffiNT 
L'ethique  de  l'environnement,  Ia  reconnaissance  de  nos  responsabilites  ne  sont  pas 
separables non  plus  de leurs  implications  politiques  et economiques.  Non seulement 
parce qu'elles doivent s'accompagner du droit et qu'elles affectent ainsi Ia vie de Ia cite, 
mais aussi parce qu'elles sont susceptibles d'aboutir a Ia revision des traditionnels modes 
de faire des societes industrielles et de notre culture par trop empreinte de productivisme. 
Les implications economi'ques de ces valeurs surtout sont immediatement sensibles dans 
Ia  mesure  ou  Ia  depense  et  Ia  protection  du  milieu  naturel  constituent  un  secteur 
d'acitivites competitif, et qu'un tel  engagement peut avoir des consequences favorables 
sur  l'emploi.  II  y  a  une  economicite  veritable de  l'environnement,  surtout Iorsqu'on 
reconnait Ia necessite de privileier Ia prevention par rapport a Ia  preparation. 
(  ... ) 
Les politiques environnementales dans les pays en voie de developpement engagent done 
aussi  notre responsabilite : nous detenons les moyens de les rendre effectives, donnee 
globale, elle ici synonyme d'interdependance, phenomene egalement global.  Et c'est done 
aussi !'importance et le desequilibre des liens economiques au sein du dialogue Nord/Sud 
que  Ia  reconnaissance de  nos  responsabilites a  l'egard du  patrimoine naturel  de toute 
l'humanite invite en demiere analyse a  reconsiderer. 
Ainsi,  Ia  quete  d'une ethique de l'environnement ouvre bien  des  perspectives dans  le 
champ traditionnel de nos activites, de nos comportements, de nos·textes de loi.  (  ... ) 
Je souhaite que le sommet des pays industrialises ne se contente pas de prendre acte de 
ces  conclusions,  mais  qu'il  engage une reflexion  operationnelle  et digne  en effet  de 
l'economie politique, puisque ce concept unit le travail de l'homme et sa relation tant avec 
Ia  nature  qu'avec Ia  societe,  et qu'il  doit etre eclairer par Ia  connaissance ·et  par une 
ethique. 
Nul doute que vous ayez l'ambition et Ia capacite de contribuer ace qui deviendra un reel 
progres de l'homme sur lui-meme.  Que le savant puisse l'y aider, c'est en tout cas rna 
conviction profonde. 
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STATE OF PLAY OF WORK OF THE GROUP OF ADVISERS ON ETHICS OF 
BIOTECHNOLOGY 
1.  OPINIONS ADOPTED 
1.1  Ethical implications of the application of performance enhancers (BST) 
Rapporteur :  Lady Warnock and Prof.  Siniscalco 
Ref:  Second Commmission report on BST (SEC {91} 2521  final) 
Request of Opinion from the Commission, dated 27.02.1992 
Diffusion :  to the public on request 
1.2.  Directive concemina medicinal products derived from  human blood and plasma 
Rapporteur :  Mrs Mikkelsen 
Ref.  :  Directive 89/381/EEC,  14 June 1989 
Own initiative report, dated 03.1992. 
Diffusion :  to the public on  request 
1.3.  Legal protection of biotechnological inventions 
Rapporteur : 
Ref.  : 
Diffusion : 
Mrs Lenoir 
Proposed directive (COM {88} 496 final) 
Own initiative report, dated 03.1992 
European Parliament, Council of the European Union, Council of  Europe, 
World intellectual Property Organization, European Patent Office, public 
on request. 
2.  OPINIONS PENDING 
2.1.  Transgenic animals 
Rapporteur :  Prof. Schroten 
Ref.  :  Request from the Commission, dated 29.09.1992 
2.2.  Gene therapy 
Rapporteur :  Prof. Archer 
Ref.  :  Request from the Commission dated 23.09.1992 2.3.  Prenatal diagnosis 
Rapporteur :  Prof. Rodota 
Ref.  :  Own i  ni ti ati ve report 
3.  FUTURE THEMES WHICH COULD BE TREATED BY THE GROUP 
Bank of tissues and organs 
Biodiversity and North-South relations 
Risk Management and biotechnology 
Medical data protection 
Ethics, biotechnology and environment 
Ethics and new agriculture 
Biotechnology and Society - Employment 
2 EUROPEAN COMMISSION's GROuP OF ADVISERS 
ON ETHICAL IMPLICATIONS OF 
BIOTECHNOLOGY 
9.  Terms of reference 
C! EUROPEAN COMMISSION 
Secretariat-General 
SG/C/1 
TERMS  OF REFERENCE  OF TilE GROUP OF ADVISERS ON TilE ETHICAL  IMPLICATIONS 
OF BIOTECHNOLOGY 
The Commission has decided to set up a Group of Advisers on the Ethical Implications 
of Biotechnology. 
Terms of Reference 
Identification and definition of ethical issues raised by biotechnology. 
Appraisal  of  the  ethical  aspects  of  Community  activities  in  the  field  of 
biotechnology and their potential impact on society and the individual. 
Advising  the  Commission  in  the  exercice  of its  powers  as  regard  the  ethical 
aspects of biotechnology with a view to improving public understanding. 
Composition 
The Group will consist of not more than 9 members. 
Its members will be eminent figures. 
It will elect a chairman from amongst its members. 
Procedure 
In petfonning its tasks, the Group shall  : 
provide  the  Commission  with  appraisals  of the  potential  ethical  impact  of 
activities based on biotechnology; 
give  consideration  to  the work of Commission  working  parties  dealing  with 
specific problems linked to the ethics of  biotechnology such as the working parties 
on the human genome and the human embryo; 
submit reports to the Commission on its own initiative and deliver opinions on all 
general matters of an ethical nature. The Commission may also request the Group for an  opinion on  a particular issue. 
The term  of office of each  member of the Group  shall  run  for two years.  Members 
remain in office until they are replaced or their term is renewed. 
Members shall not be paid for their services.  Travel and subsistence expenses in respect 
of Group meetings shall be covered by the Commission in accordance with the current 
administrative rules. 
The Commission, acting in close collaboration withe the Chairman of the Group,  shall 
be responsible for organizing the work of the Group and its secretariat. 
The  Group  shall  meet at  least twice  a  year  at  the  headquarters  of the  Commission. 
Meetings shall be convened by the Chairman of the Group. 
Any person with particular knowledge of a subject entered on the agenda may be invited 
by the Group to attend a meeting to give an expert opinion.  Experts may only take part 
in the discussion of those items for which they are invited. 
The  Secretariat-General  or,  where  appropriate,  his  representative,  shall  represent  the 
Commission within the Group and shall take an  active part in its discussions. 
No vote will be taken following the Group's deliberations.  The positions expressed shall 
be  recorded in  a report drawn up under the responsibility of the Chairman. 
Where the Group is unanimously agreed on its opinion in response to a request, this shall 
be set out in a joint conclusion. 
In seeking the opinion of the Group, the Commission may set a deadline by which the 
opinion must be delivered. 
The group's deliberations shall be confidential.  No opinions may be published without 
the prior approval of the Commission. 
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COMPOSffiON OF 1HE GROUP OF ADVISERS ON ETHICAL IMPLICATIONS OF 
BI01ECHNOLOGY 
Madame Noelle LENOIR 
Nationalite  Fran~aise 
Titre  Membre du Conseil Constitutionnel fran~ais, presidente du Groupe de conseillers 
pour  l'ethique  de  Ia  biotechnologie,  presidente  du  Comite  International  de 
Bioethique de l'UNESCO, Maire de Valmondois. 
. Fonnation  Diplome de l'lnstitut d'Etudes Politiques de Paris, DES de Droit Public  . 
Experience  Administrateur au Senat (1972-77). Administrateur Principal au Senat (1977-82). 
Directeur de Ia Reglementation de la Commission Nationale de l'Infonnatique et 
des  Libertes  (1982-84).  Maitre  des  requetes  au  Conseil  d'Etat  (Oct.  1984). 
Affectee a la Section  du  Contentieux  du  Conseil  d'Etat  et a Ia  section  des 
Travaux publics (1984-88). Directeur du Cabinet du Garde des Sceaux, Ministre 
de la Justice (Nov.  1988-0ct. 1990). Chargee par le President de Ia Republique 
et  le  Premier Ministre  d'une  mission  sur  Ia  bioethique  (  depuis  oct.  1990). 
Assistante a  la Faculte de Droit de  Paris  (1972-82).  Maitre de conferences a 
l'Institut d'Etudes Politiques de Paris (1982-88). 
Rapporteur  Protectionjuridique des Inventions biotechnologiques (Avis adopte en sept 1993) Dr Anne Me LAREN 
Nationalite  English 
Titre  Reproduction biologist, Foreign Secretary of the Royal Society, Member of the 
Nuffield Bioethics Committee, London.  Member of the  Human Fertilization of 
Embryology  Authority, UK. 
Formation  Doctor in Biology. 
Experience  Member of scientific staff of Agricultural Research Council's Unit of Animal 
Genetics  in Edinburgh  (1959-74).  Director of Medical  Research  Council's at 
Univ.  College  London  (1974-92).  Pioneer  Award  of International  Embryo 
Transfer Society. Chairman of the European Dvpt. Biology Organisation and the 
WHO Scientific & Technical Advisory  Group on Human Reproduction. 
Dr Margareta MIKKELSEN 
Nationalite  Danish 
Titre  Former Head of the Department of Medical Genetics, John F. Kennedy Institute, 
Member of the Danish Ethics Council (1988-93). 
Formation  Professor in genetics, medical doctor. 
Experience  Teacher  at  WHO  courses  in  medical  genetics  for  university  teachers  from 
developing countries (1962, 64, 66, 68). Member of the Paris Conference (1971), 
of the EEC workinggroup on Down syndrome, of the EEC  Steering Committee 
on  "First  trimester prenatal  diagnosis",  of the  EEC  Study  Group  on Ethical, 
Social  and Legal  Aspects  of the  Human Genome  Analysis Programme  (since 
1988). President of the European Society of Human Genetics (1992-93). 
Rapporteur  Products derived from human blood or plasma (Opinion adopted in  March 1993) 
Prof. Luis ARCHER 
Nationalite  Portuguese 
Titre  Professor of  Molecular Genetics and Chairman of  the Department Biotechnology, 
Lisbon. Member of the National Council of Ethic, Lisbon. 
Formation  Licenciate  in Biology,  in  Philosophy  and  Theology.  Ph.  D.  in  molecular 
Biology, Doctor degree in Biology, "Agregado" in Botany. 
Experience  Chairman of the lab. of Molecular Genetics at the  Guibenkian Inst.  of Science 
(1971-91), of  the OECD "Group of  National Experts on Safety in Biotechnology" 
(1990-92).  Member  of the  CAHBI  (Council  of Europe)  (1983-87).  Elected 
member of several  Academies.  Member  of the  EC  Study  Group  on Ethical, 
Social and Legal  Aspects of the  Human Genome  Analysis Programme  (since 
1988). 
Rapporteur  Gene Therapy 
2 Prof Gilbert HOTTOIS 
Nationalite  Beige 
Titre  Professeur en Philosophie contemporaine. Co-directeur du Centre de Recherches 
Interdisciplinaires en Bioethique (CRIB) de  l'Universite de Bruxelles. 
Formation  Licence  en philologie  romane  et  en  philosophie.  Doctorat  en philosophie. 
Agregation de l'Enseignement secondaire. 
Experience  Auteur de 8 livres sur des questions de philosophie du langage, des sciences et 
de  Ia  technique  (1976-93).  Coordinateur et editeur scientifique  d'une  dizaine 
d'ouvrages  collectifs,  d'une  soixantaine  d'articles.  Co-directeur  d'un  ouvrage 
encyclopedique "Les Mots de Ia Bioethique" (1993). Co-directeurde Ia collection 
"Sciences- Ethiques- Societes". Membre de plusieurs Comites de Revues et de 
Societes scientifiques. 
Prof. Di etmar MIETH 
Nationalite  Gennan 
Titre  Professor of Theology Ethics.  Chainnan of  the Centre of  Ethics in the Scientific 
and Humanities of the University of Tiibingen. 
Formation  Studies in theology, gennanistics and philosophy. Doctorate in theology (1968). 
Habilitation in the Theological Ethics. 
Experience  Publication of a  number of works  on social-ethical  subjects  and editor of a 
collection on bioethics. Professor of Theological Ethics (1974-81, Fribourg/Ch, 
since  1981  at Tiibingen).  Chainnan of the Centre of Ethics (now). Member of 
different societies in ethics. Director of the section "ethics" of the international 
Journal "Coucilium" (now). 
Rapporteur  Biotechnology, Ethics and Environment 
M.  Octavi QUINTANA TRIAS 
Nationalite  Spanish 
Titre  Advisor  to  the  Vice-Minister  for  Public  Health,  President  of the  Bioethics 
Steering Committee (CDBI) of the Council of Europe. 
Formation  Graduate  on Medicine and  Surgety  (1976).  Specialist in Intensive Medicine 
(1980).  Master on Public Health & Health Administration (1986). 
Experience  Resident MD. Valencia Regional Hospital (1976-80). Staff M.D. (1980-84) then 
Medical  Director  (1986-89)  in  Malaga  Regional  Hospital.  Deputy  General 
Director of INSALUD  (health  care  institutions)  (1989-92).  Secretary  of the 
Spanish Society of Quality Assurance (1990). 
3 Prof.  Stefano RODOT  A 
Nationalite  I  tali en 
Titre  Professeur en droit civil, membre du Comitc d'ethique du Conseil National de  Ia 
recherche, Depute du Parlement italien. 
Formation  Professeur de Droit civil. 
Experience  Membre du Comite d'ethique du Conseil National de Ia Recherche. Directeur de 
Ia  recherche  "Identite  personnelle  et  nonnalite  genetique".  Travaux  dans  le 
domaine  des  effets juridiques et  sociaux  des  innovations  scientifiques  (1972-
92).Travaux majeurs dans le domaine  de Ia bioethique (1989-1993).  Auteur de 
livres et directeur de plusieurs revues. 
Rapporteur  Diagnostic prenatal 
Prof. Egbert SCHROTEN 
Nationalite  Dutch 
Titre  Professor of Christian Ethics  at Utrecht University, Director of the  University 
Centre for Bioethics and Health law. 
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the debate conducted in philosophical and ethical terms so 
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3 1.  INTRODUCTION 
The past few  years have seen an  explosion in the biological  and biomedical  sciences, 
which has triggered an ethical debate both among the general public and at the political 
level and has led to the emergence of a concept of bioethics. Ethics may be defined as 
"the collective norms adopted by a group or a society which wishes to preserve a sense 
of proportion" (Jean Bernard) and bioethics as "a collection of questions with an ethical 
dimension  (i.e. which raise the issue  of values  and  can  only  be resolved  by  making 
choices) prompted by the growing capacity for technical  and  scientific intervention in 
living matter" (Gilbert Hottois). 
The ethical debate has spawned numerous committees at local, regional, national and even 
international level with the establishment of  the UN's International Bioethics Committee 
1 
and the Council of  Europe's planned standing conference ofNational Ethics Committees. 
The European Union cannot remain isolated from the mainstream, not least because as 
a member of the international community it must respect the undertakings entered into 
by  its Member States and/or those which it has itself accepted, namely: 
1)  at  universal  level  :  in  particular  the  Universal  Declaration  of Human  Rights 
(ONU, 1948), the International Covenant on Economic and Social Rights and the 
International Convenant concerning Civil and Political Rights (ONU,  1966), the 
Rio Convention on Biodiversity (ONU,  1992); 
at Council of  Europe level, the European Convention on Human Rights of 1950 
2 
at European Union level, the Joint Declaration of April  1977, the Preamble to the 
Single European Act,  paragraph 3 and the Treaty of European Union,  common 
provisions and declaration. 
In  addition,  the  Community  has  already  adopted  many  instruments  concerned  with 
bioethics in the areas where it has traditionally exercised powers (agriculture, industry, 
the environment, etc  ... ), i.e. the directive on the deliberate release of  genetically modified 
micro-organisms  into  the  environment  and  the  directive  on  the  legal  protection  of 
biotechnology inventions which will be adopted soon. 
2 
This Committee was set up in September 1993 and has 50 members representing various 
disciplines and coming from 35 countries.  Its tenns of  reference include a study into the 
possibility of  drafting an international instrument on the protection of  the human genome, 
which would base bioethics on universal principles of  Human Rights. 
A  Bioethics  Convention  is  in  progress,  based  upon  the  principles  of the  European 
Convention on Human Rights. 
4 Several "ad-hoc" working parties have also been set up within the Commission services: 
the  human  embryo and  research group  (HER),  whose  purpose is  to  draw up  an 
inventory of legislation in the Member States and  develop a code of conduct in 
the field  of human embryo research; 
the ESLA group which  investigates the  ethical,  social  and  legal  aspects  of the 
Community's specific research programme on human genome analysis; 
the Advisory Committee for the protection of  animals used for scientific purposes, 
which insures the fow up of directive 86/609/EEC; 
the bioethics working group  which  monitors progress in  the  preparation of the 
Council  of Europe's bioethics convention. 
The Commission is also backing research projects in bioethics under the Human Genome 
Analysis Programme and BIOMED and has created a unit specifically concerned with the 
legal  and ethical aspects of Life Sciences and Technologies. 
The growing importance of ethical parameters in biotechnology has led the Commission 
towards making a new step by creating an original structure.  The Group of Advisers on 
Ethical Implications ofBiotechnology is indeed independent, multidisciplinary and cutting 
across the Commission  services.  Its area  of action is wide.  Its procedures are based 
upon the notion of  an indispensable dialogue between the various Community institutions 
as well  as with the relevant external bodies. 
This report gives an account of the Group's activities during its first term. 
It describs its role and working methods. 
It presents the results achieved so far. 
It  makes  proposals  for  the  future  which  will  integrate  the  Group  in  the 
Community process. 
5 2.  THE GROUP  OF ADVISERS  ON  THE ETIDCAL IMPLICATIONS OF 
BIOTECHNOLOGY 
2.1  Creation and role 
In its communication entitled "Promoting the competitive environment for the industrial 
activities  based  on  biotechnology  within  the  Community"  (SEC(91)629 final),  the 
Commission warns that the confusion  surrounding the ethical  debate  could  adversely 
affect  the  general  climate  for  industrial  development  of biotechnology.  It  considers 
biotechnology to be one of the keys to the industrial development of the Community, an 
objective which was reaffirmed in its recent White Paper on Growth, Competitiveness and 
Employment.  Besides,  progress towards a citizens'  Europe depends  on  informing the 
public better as to this objective and to the likely effects that the spread of biotechnology 
applications are likely to bring into play fundamental  issues concerning rights. 
In  the  light of these  considerations  and  on  the  basis  of a  proposal  by  the President, 
Jacques Delors, the Commission set up the Group of Advisers on the Ethical Implications 
of Biotechnology by  a decision of 20 November 1991.  Its terms of reference were as 
follows: 
to identify and define the ethical issues raised by biotechnology, 
to  evaluate  the  ethical  aspects  of  Community  activities  in  the  field  of 
biotechnology and their potential impact on society and the individual, 
to advise the Commission in  the exercise of its  powers  as  regards the  ethical 
aspects of biotechnology with a view to improving public understanding. 
2.2  Composition 
In view of the nature of the interests at stake a pluralist and multidisciplinary approach 
was called for.  The members of the Group of Advisers are accordingly drawn from the 
world of science, law, philosophy and politics. Each member serves a two-year term. 
The Group was intended to be a flexible structure which would encourage exchanges. The 
members during its first term were as follows: 
Lady Warnock, philosopher, Mistress of Girton College, Cambridge; 
Noelle Lenoir, lawyer, Member of the Constitutional Council in France; 
Margareta  Mikkelsen,  Head  of the  Department  of Medical  Genetics  of the 
J.F. Kennedy Institute, Glostrup; 
Marcelino Oreja, lawyer, Member of Parliament in Spain; 
Professor Marcello  Siniscalco,  Professor  of genetics  in  Italy,  Member of the 
Imperial Cancer Research Institute, London; 
Professor Hans Zacher, Professor of law, President of the Max Planck Institute, 
Munch  en. 
Marcelino Oreja was elected Chairman for the first term. 
6 2.3  Procedure and working methods 
The Commission may  request an  opinion from  the Group  on  a specific topic,  but the 
Group may also present an  opinion to the Commission on its own  initiative. 
One member is appointed rapporteur for each  topic selected,  depending on  his  or her 
expertise and interests.  Once the research is completed, the rapporteur drafts a report 
accompanied  by  a  draft opinion,  which  is  then  considered  by  the  Group.  Dissenting 
opinions may also be attached. 
The Group meets four or five times a year.  In  order to facilitate contacts with ethics 
committees  in  the  Member  States,  some  meetings  have  been  held  outside  Brussels 
(e.g. Madrid, March 1993). 
The Group's discussions are not public.  However, the Commission decides whether to 
publish the Group's opinions. 
The  Biotechnology  Coordination  Committee,  chaired  by  the  Commission  general 
Secretary  : Mr  Williamson,  set  up  to  improve  internal  coordination  in  the  field  of 
biotechnology,  provides  the  link  between  Directorates-General  and  the  Group.  The 
Committee also puts forward the work programme to be examined by the Group. 
2.4  A guarantee of independence 
The Group's opinions are purely advisory.  They are designed to guide the Commission 
in biotechnology-related activities to enable it to lay down ethically responsible rules. 
Because of its advisory role, the Group of Advisers has to be an independent body. The 
external,  non-partisan  outlook  of the  Group  means  that  its  opinions  strengthen  the 
Commission's hand in its dealings with the Council, Parliament and the Member States, 
and with external bodies such as the Council of Europe, UNESCO, OECD and GATT. 
The different fields covered by Directorates-General are taken into account in the work 
of  the Group of  Advisers: industry, science and research, agriculture, the environment and 
social  affairs.  The  expertise  of Directorates-General  is  the  basis  for  the  Group's 
deliberations.  The composition of the Group reflects the different cultural sensitivities 
of European society. 
The fact that the Group can submit opinions to the Commission on topics of its own 
choice  and  the  complete  freedom  enjoyed  by  the  individual  Advisers  underline  the 
Group's independence. 
7 3.  THE WORK OF THE GROUP 
3.1  Opinions adopted 
3.1.1  Opinion No I on the ethical implications of the use of performance-enhancers in 
agriculture and fisheries (Annex  I) 
Rapporteurs:  Lady Warnock and Professor Siniscalco 
Ref.:  Second Commission report on BST (SEC(91)2521  final) 
Referral:  Commission request for an  opinion, 27 February 1992. 
Background 
Bovine somatotropin (BST) is a hormonal protein produced by the pituitary gland which 
stimulates not only bone growth and protein anabolism, but also galactopoiesis (increase 
in milk secretion during lactation in cattle). 
Several  studies  have  shown  that  the  use  of BST  increases  the  incidence  of bovine 
mastitis, which is treated with antibiotics.  The concentration of antibiotics in milk and 
beef could pose a danger to consumer health.  In addition levels of somatic cells in the 
milk produced using BST could be excessive and hence harmful to consumers. 
The risk of bovine mastitis and frequent inflammation as a result of the administration 
of BST could be harmful to the health and well-being of the animals concerned. 
In a decision of 10 February 1992 the Council asked Member States not to authorize the 
use of  BST until 31  December 1993 and asked the Commission to report on the situation 
by July  1993. The Commission accordingly referred the matter to the Group of Advisers 
in order to determine the ethical implications of BST. 
The Group's opinion 
The Group  concluded  that the use of BST was  ethically  acceptable  provided  certain 
measures were adopted, particularly as regards: 
Consumer health and safety: administration of  BST should be stopped if mastitis 
or other inflammatory reactions occur.  Milk produced by  animals treated with. 
antibiotics  should  be withdrawn  from  sale  until  all ·traces of antibiotics  have 
disappeared. The level of somatic cells per millilitre should not exceed that found 
in milk produced by traditional methods. 
Animal  welfare:  animals  should  not suffer extreme  pain  or discomfort that is 
disproportionate to the human benefit expected from the use of BST. 
Biological diversity: the use of BST does not adversely affect biodiversity. 
Freedom of choice of the consumer: milk and milk products derived from BST-
treated cows should be labelled accordingly once it is possible to distinguish them 
from other milk and milk products. 
8 The Group appreciated that, in addition to the ethical implications, the distribution ofBST 
also raised important economic and political problems. However, it felt that these issues 
went beyond its terms of reference. 
Subseguent developments 
The Commission felt that the measures recommended by the Group would be difficult to 
implement at the present time. Backed by the Group's recommendations and on the basis 
of  the conclusions of  the Committee for Veterinary Medicinal Products, the Commission 
issued a recommendation to the Council  and Parliament, on  13  July  1993, that the sale 
of BST should be banned within the Community for a period of seven years. 
The Commission authorized the distribution of the Group of Advisers' Opinion No 1 to 
the public upon request. 
3  .1.2  Opinion No 2 on products derived from human blood or human plasma (Annex 2) 
Rapporteur:  Margareta Mikkelsen 
Ref:  Directive  89/381/EEC  extending  the  scope  of Directives  65/65/EEC 
and 75/319/EEC 
Referral:  Own-initiative opinion (March 1992) 
Backw-ound 
Directive 89/381/EEC entered into force on 1 January  1992. It aims 
to  encourage  Community  self-sufficiency  through  voluntary  unpaid  blood and 
plasma donation; 
to  introduce  strict  criteria  guaranteeing  the  quality  and  safety  of medicinal 
products  derived  from  human  blood  or  plasma,  notably  to  avoid  viral 
contamination; 
to harmonize conditions for authorizing the manufacture of blood-based products 
by 1993. 
The  publication  of the  French  National  Ethical  Committee's  Opinion  No 28  of 
2 December 1991  triggered a debate and protests in France about the application of the 
Directive. The Committee took the view that, by treating blood and plasma as "starting 
material" and blood derivatives as "medicinal products", the Directive appeared to make 
them tradeable goods, which conflicted with the principle that the human body was not 
a marketable commodity and offended against human dignity. 
This terminological  difficulty connected with the use of the term  "medicinal  product" 
would no longer appear to be an issue. 
The Group also examined the issue with reference to the cases oflllV infection following 
contaminated blood transfusions, particularly in France, Germany and Spain. 
9 The Group's qpinion 
In the light of its discussions the Group identified the following ethical considerations: 
respect for the donor, donor anonymity and the principle of voluntary donations; 
health of the recipient, availability and quality of blood supplies; 
the human body is not a marketable commodity: no-one should make additional 
profits from blood donations. 
As  regards the Directive, the Group concluded that it was appropriate to use the term 
"medicinal product" with reference to products derived from  blood because it provides 
a guarantee of quality and security. 
In the Group's view, measures relating to blood donations should be the responsibility of 
organizations under strict public control. 
Subseguent develo.pments 
The Commission authorized the distribution of the Opinion to the public on request. 
3  .1.3  Opinion N. 3 on the ethical questions arising from the Commission proposal for 
a Council Directive on legal protection for biotechnological inventions (Annex 3) 
Rapporteur: 
Ref.: 
Referral: 
Background 
Noelle Lenoir 
Proposal  for  a  Directive  (COM(88}496  final)  and  amended  proposal 
(COM(92)589 final), Common Position of 7 February  1994, 2nd Report 
of Mr Rothley (EP 156.257) 
Own-initiative, March 1992 
The  proposal  for  a  Directive,  published  in  October  1988  was  one  of the  measures 
connected with the establishment of  the Single Market. Its purpose was the harmonization 
of Member States's laws on the patenting of biotechnological inventions. 
The adoption process has been held up since 1988, largely because of the ethical debate 
about the patentability of  living matter, but also because of  the discussions about farmer's 
privilege.  The compatibility of the Directive with the Rio  Convention on Biological 
Diversity prompted Parliament to ask the Commission to review all the provisions. 
The Group's opinion 
The  Group's  verdict  was  that  the  patentability  of living  matter,  a  long-established 
principle,  did  not in itself raise  any  ethical  problems.  Concerning the ethical  issues 
related  to human  body  and  transgenesis,  the Group  suggested  that the Directive had 
become too complex and should be simplified to include in its substantive provisions only 
certain elements essential for the protection of human rights. 
10 It should therefore expressly prohibit the patenting of: 
the human body or parts of the human body per se; 
techniques  of human  genetic  engineering  (except  those  used  for  therapeutic 
purposes and then only if they do not undermine human dignity). 
It  also  urged  the  Community  to  work  towards  the  conclusion  of an  international 
agreement  on  patentability  tests  for  inventions  resulting  from  genetic  research 
programmes.  The discussions about the patentability of genes with no known function 
had highlighted certain ambiguities in the basic principles of patent law when applied to 
living matter. 
Subseguent developments 
On  16 December 1992 the Commission presented an  amended proposal  for a Directive 
to the Council,  incorporating the ethical  dimension.  The Council  agreed  to adopt the 
Commission's proposals. The Group's opinion served as  a catalyst in  this process.  The 
Council's common position was adopted on 7 February 1994. 
The Group of Advisers achieved its full  potential in this particular case: 
because its opinion was perfectly timed to coincide with the preparation of the 
Directive. Consequently, the rapporteur, Ms Lenoir, was able to meet Parliament's 
rapporteur and take part in the Council's expert meetings 
it  strengthened  the  Commission's  position  in  relation  to  the  Council  and 
Parliament; 
because  the  opinion  addressed  issues  of general  importance  the  Commission 
distributed it widely. It was sent to Parliament, Council, the Council of Europe, 
the World Intellectual Property Organization and the European Patent Office.  It 
is available to the public on request. 
3.2  Work in progress 
3  .2.1  Transgenic animals 
Rapporteur: 
Referral: 
Background 
Lady Warnock and Professor Siniscalco 
Commission request of 29 September 1992 
Developments in the field  of animal  transgenesis raise numerous ethical  issues which 
require clarification. It is also important to decide whether there is a case for Community 
guidelines in this area,  particularly ·as  regards research and technological  development 
programmes funded by the Commission. 
11 Report 
The Advisers have studied the effect of animal  transgenesis from  the  point of view of 
animal  welfare,  genetic  diversity,  commercialization  and  the  current  state  of the 
technique.  · 
They have left the task of finalizing this report to their successors. 
3  .2.2  Gene therapy 
Referral:  Commission request of 23  September 1993 
Progress  in  genetic  engineering  suggests  vast  possibilities  for  applications  of gene 
therapy. While this raises very high hopes it also entails risks which pose certain ethical 
questions. Germ-line therapy, for example, would transmit the genetic modification to all 
descendants of  the patient. With a view to defining certain criteria and formulating certain 
ethical principles, the Commission requested an opinion from the Group of Advisers on 
this issue. 
The councellors, at the time of their initial discussion, made a clear distinction between 
somatic and  genn-line therapies.  Only the former had  been  experimented upon.  The 
latter,  where  experiments  were  not  yet  envisaged,  already  raised  ethical  issues  of 
unprecedented magnitude. 
The  Advisers  have  left  the  task  of formulating  an  opinion  on  this  issue  to  their 
successors. 
3  .2.3  Ethics and science 
In this report, produced by the Group on its own initiative, Professor Zacher examines 
the fundamental ethical values which have to be preserved in the field of biotechnology. 
The report is intended to serve as a philosophical basis for the Group of Advisers. 
3.3  International conferences 
The Group of Advisers was represented at recent major events in the bioethics field by 
one of its members and/or its secretariat. 
These  include  the ·following  conferences:  BioEurope  •93  organized  by  the  Senior 
Advisory  Group Biotechnology, Brussels, May  1993;  the colloquium  on  international 
cooperation for the Human Genome Analysis Programme in Bilbao, May 1993, sponsored 
by  the Banco Bilbao Vizcaya Foundation; the inauguration of UNESCO's International 
Bioethics Committee in Paris, September 1993; the second Council of  Europe Symposium 
on Bioethics in Strasbourg, November 1993. 
12 4.  GROUP WORKING METHODS 
Discussions between advisers and  the experience they  have acquired  have  enabled the 
Group to develop guidelines on which to base its future work. 
4.1  Approach followed 
The Group: 
* 
* 
* 
* 
4.2 
studies ethical  aspects  on  a case-by-case basis in  an  attempt to  extract general 
principles  or  ethical  criteria.  Its  aim  is  not  to  halt  progress  in  the  field  of 
biotechnology but to control the applications which can  raise ethical  questions. 
Any  bioethical compromise will  continue to depend on the progress of science. 
analyses ethical aspects following a triple approach: 
a general approach investigating any conflict of values, 
a  subjective  approach  taking  into  account  the  predictable  or  less 
predictable reactions of the public, 
a forward-looking approach  aimed  at assessing the consequences of the 
potential use of a product or the possible application of a technique. 
discusses  whether  or not  there  is  a  need  for  legislation  for  each  topic  under 
consideration. 
monitors  work  carried  out  at  Community  level  (European  Parliament  STOA 
programme, ESLA and HER working parties at the Commission) and in other 
bodies such as the Council  of Europe and  UNESCO.  Its  aim  is to work with 
these  organizations in a  spirit of cooperation  and  coordination to promote the 
emergence of a common system of values. 
Guiding principles 
The Group: 
* 
* 
gives  priority  in  its  deliberations  to  the  concerns  of European  citizen  and 
emphasizes the need to promote public infonnation, education and training in this 
field.  The idea is to increase awareness of risk, in order to avoid any unjustified 
hostile reaction.  In  all  its debates it takes into account the aspirations of the 
public and the need to set ethical markers; 
sees its role, in its relationship with the Commission, as  a watchdog, alerting it 
to the risks accompanying advances in biotechnology.  It uses its right of  initiative 
when it considers that such  a risk is virtual  or,  on  the  contrary,  is overstated 
because of erroneous data; 
13 * 
* 
* 
* 
is aware of the scale of the economic and industrial challenge of biotechnology, 
maintaining that ethical  considerations are  an  integral  part of the dev'elopment 
strategies concerned and are at the very heart of the political debate.  However, 
it makes a clear distinction between ethical  and  other considerations relating to 
the development of biotechnology (e.g.  the BST issue); 
applies a proportionality criterion to ensure that the benefits of biotechnological 
progress come before the possible drawbacks or the risks that may be involved; 
takes as its basis the principle of freedom of research.  Ethical control should not 
compromise this principle, even though today it demands that thought be given 
to the purpose of the research. 
stressed  the  priority  given  to  safeguarding  human  rights  ahead  of promoting 
economic and social development, ideas which are at the foundation of European 
construction. 
14 5.  CONCLUSION 
Throughout the Twelve bioethics is at the heart of the debate on the choices of society, 
a society which now, more than ever before, is debating its future. 
What is more, bioethics involves a sector- biotechnology- which,  in economic terms, 
represents a major proportion of what are  among the most strategic  activities for the 
development of the Community. 
Finally  bioethics  affects  the  relations  and  hence  the understanding  which  must  exist 
between the citizens of  Europe and the decision-makers at both national and Community 
level. 
For these reasons the Commission must be able not only to take part in the discussions 
on  bioethics but also to take clear options.  In each instance observance of individual 
rights must be reconciled with the demands of economic and social development. 
To do this the Commission must anticipate.  It must make a choice between what is 
foreseeable and what is desirable. 
This is the reason for enhancing the role of the Group of Advisers. 
The Group will operate in the following way: 
* 
* 
* 
To begin with,  it will  listen,  so that its opinions are based on comprehensive, 
accurate and up-to-date information. 
It will be pragmatic, taking each case individually and without any prejudices. 
It will  be  open  and  dynamic,  bearing  in  mind  that  progress  is  part  of the 
adventure of mankind and stopping progress would be to lose hope. 
For any further information on the Group of Advisers, would you please contact in the 
European Commission: Mrs I. Arnal and Mr. A.  St Remy, Secretariat-General, BREY. 
7/232, 200 rue de Ia Loi,  1049 Brussels, Tel.  322-296.21.19. 
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1  Date:  12.03.93 
*  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
THE  ETHICAL  IMPLICATIONS  OF  THE  USE 
OF  PERFORMANCE-ENHANCERS  IN  AGRICULTURE  AND  FISHERIES 
Reference:  Commission  request  for  an  opinion  dated  27  February  1992. 
Rapporteurs:  Lady  Warnock  and  Ur  Siniscalco 
*  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
1.  Presentation of  the problem 
1.1  DEFINITION 
Performance-enhancers  manufactured  using  biotechnology  are 
administered  to animals  and  fish  in  their  feed  or  by  techniques  such 
as  injection or  implantation,  on  a  regular  basis or  over  a  period,  to 
stimulate  their  productivity  and/or  Improve  the  ratio of  meat  to  fat. 
Bovine  somatotropine  (BST)  or  bovine  growth  hormone  is one  of  these 
performance-enhancers.  This  involves  a  hormonal  protein produced  by 
the pituitary gland which  stimulates  not  only  bone  growth  and  protein 
anabolism,  but  also galactopoesis  (increase  in  milk  secretion during 
lactation shown  in  cattle).  BST  can  currently  be  produced  by  genetic 
engineering on  an  industrial  scale. 
In  the  second  Commission  Report  on  bovine  somatotropine of  21  January 
19921,  the  Commission  outlines  ~urrent data on  BST  assessment  and 
Invites  the  Advisory  Group  on  biotechnology ethics  to  form  an  opinion 
on  the ethical  conseQuences  which  may  result  from  the administration 
of  growth  promoters  in  agriculture and  fisheries. 
1  SEC(91)  2521  final -2-
1.2  CURRENT  GENERAL  SITUATION 
currently,  four  American  pharmaceutical  companies  (American  Cyanamid, 
Eli  Lilly,  Monsanto,  UpJohn}  are  in  a  position  to market  BST  and  have 
appl led  to  the  American  and  European  authorities  for  authorization. 
Some  countries have  authorized  its use  (Mexico,  the  former  USSR, 
Czechoslovakia,  Bulgaria,  South  Africa,  Namibia  and  Zimbabwe}. 
However,  no  authorization has  been  given  to date  in  the  Member  States, 
the  United States,  Canada,  New  Zealand,  Austria,  Switzerland or  the 
Scandinavian countries. 
1.3  REGULATORY  SITUATION  AT  THE  COMMUNITY  LEVEL 
Under  Directive 87/22/EEC,  applications  for  authorization  to place 
veterinary medicinal  products on  the market  manufactured  using 
biotechnology  must  be  submitted  for  opinion  to  the  Committee  on 
Veterinary Medicinal  Products  (CMVP),  before  a  final  decision  can  be 
adopted  at  national  level  on  the authorization of  the  product  in 
Question.  These  opinions are delivered on  the basis of  objective 
scientific criteria of  Quality,  safety and  the  efficacy of  the 
product,  and  not  any  economic  or  other  consideration1. 
So  far  the  CMVP  has  delivered  an  opinion on  two  applications:  in  March 
1991  on  the  application submitted  by  Monsanto  for  "Somatech";  in 
December  1991,  the  Committee  delivered a  public opinion  in  the  form  of 
a  statement  on  the application submitted  by  Eli  Lilly  for 
"Optiflex  640".  From  the  point  of  view  of  safety,  Quality  and  efficacy 
both  products  are  apparently  considered  to  be  satisfactory.  However, 
some  Member  States  think  no  satisfactory  answer  has  been  given  to 
Questions  concerning  the  possibi I ity of  an  increased  incidence of 
mastitis and  inflammatory  reactions  at  the  site of  injection among 
dairy  COWS  treated With  8ST2. 
At  present  the  CMVP  consultation procedure  has  been  suspended  as  the 
Counci I  has  intervened  to prohibit  the  use  of  BST  in  the  Community 
unti I  31  December  1993  pending  the  results of  the current  studies on 
the effects and  conseQuences  of  this product- in  particular  from  the 
point of  view  of  health and  animal  welfare3. 
1  Second  Commission  Report  on  bovine  somatotropine  - ibid  p.7 
2  Second  Commission  Report  on  bovine  somatotropine- ibid  p.7 
3  Time  I imit  extended  successively  by  Counci I  Decisions 90/218 of  25  April 
1990,  91/61  of  4  February  1991  and  92/98 of  10  February  1992. -3-
2.  Identification of  the  aspects  to be  taken  into account  by  the GrouP 
2.1  GENERAL  ASPECTS 
The  Group  is  aware  of  the  fact  that  among  the  various  aspects  to  be 
taken  Into consideration  in  deciding  for  or  against  the  use  of  BST, 
economic  and  political  arguments  play  a  major  role,  such  as  the 
advisabil lty  or  not  of  an  increase  in  milk  production  in  Europe  and 
the  possible exploitation of  the  European  market  by  American 
pharmaceutical  firms. 
The  Group  is  also aware  of  the  fact  that  European  needs  cannot  be  seen 
in  isolation  from  the  needs of  the  rest of  the  world  and  yet  that  the 
european market  must  be  considered  in  a  realistic  1 ight. 
However,  the  Group  considered  that  such  problems  go  beyond  its  terms 
of  reference,  since  they  are  not  ethical  problems  in  a  narrow  sense. 
2.2  ETHICAL  ASPECTS 
The  ethical  considerations  relevant  to  the  use  of  BST  fel 1  into  four 
categories: 
2.2.1 
2.2.2 
2.2.3 
Human  health  and  safety 
Two  kinds  of  fears  have  been  expressed: 
The  US  General  Accounting  Office  finds  that  the  use  of  BST  is 
associated with  the  freQuency  of  bovine mastitis,  against  which 
antibiotics are  administered.  The  antibiotic concentration  in  milk  and 
in  beef  or  veal  could  be  a  risk  factor  (indeterminate)  for  consumer's 
health. 
Somatic  eel Is  in  the  milk  produced  using  BST  could  be  excessive  and 
damaging  to  consumers. 
Animal  welfare 
The  use  of  BST  or  medication  subseQuently  administered on  animals 
could  lead  to pain or  discomfort  for  these  animals  which  is 
disproportionate  to  the  human  good  expected  from  the  use of  the 
product. 
Freedom  of  choice of  the  consumer 
Concern  has  been  expressed  about  the  freedom  of  consumers  to choose 
between  BST  treated milk  and  other  milk. 
2.2.4  Biological  diversity 
The  fear  has  been  expressed  that  the  use  of  BST  on  selected subgroups 
of  animals  could  be  harmful  to  the  biodiversity of  the  species 
involved. -4-
3.  Opinion 
The  following  optnton  was  expressed with  respect  to  the  above  I isted 
Ethical  Aspects: 
3.1  HUMAN  HEALTH  AND  SAFETY 
Mastitis and  other  inflammatory  reactions are caused  not  peculiarly  by 
BST  but  by  high  yield of  lactation wether  brought  about  by  BST  or  by 
selective breeding.  Ml  lk  derived  from  animals  treated with  antibiotics 
for  mastitis  and  other  inflammatory  reactions should  be  banned  from 
human  consumption  for  as  long  as  reQuired  for  the  drug  to be  totally 
absent.  such  a  reQuirement  would  favor  the  practice- which  is  by 
itself sufficient  to solve  the  problem- of  control I ing  animal 
infections  through  the mere  observance of  drug  free  hygienic measures. 
In  addition,  it  has  to  be  pointed out  that  a  high-yield  lactation can 
be  stopped at  wi  I I  by  removal  of  the  drug  in  SST-treated animals,  but 
It  Is  Irreversible  in  animals  which  are  the  result  of  selective 
breeding. 
The  problem  about  a  possible,  yet  unproven,  unhealthy effect  of  an 
excessive number  of  somatic  eel Is  in  milk  produced  by  high-yield 
lactation animals  {again  regardless of  the  techniQue  applied  for  their 
production,  i.e.  BST  treatment  or  selective breeding)  can  be  easily 
settled by  fixing  a  threshold  level  of  somatic  cells acceptable  per 
mi  I IiI itre of  milk  such  as  the one  already  observed  for  the  milk  of 
high-yield  lactation cows  obtained  through  selective breeding. 
3.2  ANIMAL  WELFARE 
The  Group  considers  that  though  it  is ethically acceptable  for  humans 
to use  animals  for  good  human  ends,  they  must  not  treat  them  with 
indifference,  and  thus  any  drug  or  procedure  I ikely  to  induce  severe 
or  enduring  pain  should  not  be  authorized. 
3.3  FREEDOM  OF  CHOICE  OF  THE  CONSUMER 
The  Group  thinks  that  the  freedom  of  choice of  the  consumer  wi  II  be 
guaranteed once  it  is  possible  to detect  BST  traces  in  milk  and  it  is 
labeled as SST-treated milk. 
3.4  BIOLOGICAL  DIVERSITY 
The  Group  concludes  that  the procedure  of  inducing  high-yield 
lactation  through  drug-induced  treatment  is expected  to safeguard  the 
preservation of  Biological  Diversity  if  applied  judiciously  i.e.  to 
improve  the  performance  of  al 1  domesticated breeds of  animals.  On  the 
contrary,  the  persistent  application of  intensive selective breeding 
in  favor  of  the  phenotypical  trait  in  Question  with or  without  BST, 
could  not  only  lead  to general  loss of  genetic  heterogeneity,  but  -in 
the  long  run- also to  the  deterioration of  the  desired  phenotypical 
feature  itself,  as  a  result  of  the  well  known  irreversible 
accumulation of  homozygosity  brought  about  by  protracted  inbreeding. 
Thus  the  Group  considers  that  on  the  basis of  the data  available  the 
use of  SST  as  such  wi  11  not  threaten Biological  Diversity. •  12:03  '93  10:51  F:\.X  32  2  2957850 
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•·  Recommendation 
The  Grouo  concludes  that  the use of BST  to  increase  lactation  rn  cows  ia 
ethicallY unobJectionable,  and  safe for  both  human  and  animals.  Drovided 
that the  following measures are adopted: 
4.1- assurance should  be Drovlded  that SST-treated animals  do  not  suffer 
extreme  pain or even  discomfort  that  is dlspropgrtlonate  to  the  human 
gOOd  expected  from  the use of  the Droduct; 
4.2- treatment should be  stopped when  Increased  lactation of milk  rs 
associated with mastftis or other  Inflammatory  reactions: 
4.3- these  reactions should be controlled through  the application of  simple 
hygienic measures or -lf cured with  antlbfotfcs- the milk  produced  by 
the animals so treated should be  banned  from  human  consumDtion  until 
the antfblotles are totally eliminated: 
4.4- the  level  of somatic cells Der  mil II litre of milk  should not  be  higher 
than  the  concentration  found  fn  the milK  thus  far  croduced  by  high-
yield  lactation cows  obtained through  selective breeding; 
4.5- if  ft becomes  possible  to distinguish milk  derived  from  BST-treated 
cows  from  other milk.  then  the  vendors should  be  required to  label  it 
and  Its derivatives to allow  free  choice  to the buyers. 
Besides  these ethical  as~ects,  the  ~uesticn of  marketing or  non-marketing 
BST  In  the  European  Community  is mainly a  political  Issue which  should be 
discussed as such.  In  this context.  the effects of SST  on  evolution of 
agricultural  structures,  as well  as consumers'  reactions should  be  taken 
into account  in  the appropriate forum  when  the  relevant data  Is available. 
In  accordance with  Its terms of  reference.  the  Grouo  of Advisers on  Ethical 
Aspects of Biotechnology  submits  this Recommendation  to the COmmission. 
The  Chairman  Signatures of  the members  of 
the Group  of Advisers: 
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1.  General  Introduction 
1.1  MEDICAL  ASPECTS 
Blood  Is  an  integral  component  of  the  human  organism  and  can,  as  such,  be 
donated  to patients.  Its uniQue  feature  Is  that  the  same  donor  can  give 
blood  repeatedly over  a  consiserable number  of  years.  Blood  carries 
cellular and  non-cellular  components  throughout  the  vascular  system.  It 
consists of  red  and  white  eel Is,  platelets and  plasma.  The  major  proteins 
are albumin,  lmmunoglobul Ins  and  coagulating  factors which,  in  conjunction 
with platelets,  repair  lesions  to  the  vascular  walls.  Blood  eel Is  and  a 
variety of  plasma  proteins are extensively used  in  modern  medical  therapy 
and  prophylaxis. 
1.2  LEGAL  ASPECTS 
Directive 89/381/EEC  extends  the  scope  of  Directives 65/65/EEC  and 
75/319/EEC on  the  approximation of  provisions  laid  down  by  law,  regulation 
or  administrative  action  relating  to proprietary medicinal  products  and  lays 
down  special  provisions  for  medicinal  products  derived  from  human  blood  or 
human  plasma.  It  entered  into force on  1  January  1992;  six  Member  States 
(Denmark,  Greece,  Ireland,  Italy,  Portugal  and  the United  Kingdom>  have 
notified national  measures  transposing  it. 
The  Directive  pursues  the  following objectives: 
•  to encourage  the self-sufficiency of  the Community  through  voluntary 
unpaid  blood  and  plasma  donation; 
•  to  Introduce strict criteria guaranteeing  the  Qual lty,  safety and 
efficacy of  medicinal  products derived  from  human  blood or  plasma, 
notably  to avoid  viral  contamination; 
•  to harmonize  conditions  for  authorizing  the manufacture  of  blood-based 
products. 
The  Directive does  not  apply  to whole  blood,  plasma  or  blood  eel Is  of  human 
origin,  or  to blood  donation and  transfusion activities,  except  where 
aspects of  the  production of  medicinal  products  from  blood  are concerned. It  should  be  noted  that  blood  donation  is  now  considered  an  old  fashioned 
methodology  and  significant  ameliorations  are  expected  in  the  future. 
Production of  factor  8  by  genetic engineering  is  already  avai table  and 
should  be  encouraged  further.  Other  developments  wi  I I make  products  from 
human  blood  less  necessary. 
1.3  THE  NATIONAL  ETHICAL  COMMITTEE'S  REACTION  TO  THE  DIRECTIVE 
Opinion  N.  28  (blood  transfusion),  issued on  2  December  1991  by  the  French 
National  Ethical  Committee,  considers  that  the  Directive  treats blood  and 
plasma  as  a  "starting material"  ("mati~re premi~re"  In  French  corresponds 
more  closely  to  "raw  material"  In  English)  and  blood  derivatives as 
medicinal  products,  thus making  them  seem  to  be  tradeable  goods,  contrary to 
the principle  that  the  human  body  is not  marketable and  contrary  to  human 
dignity. 
The  Commission  does  not  accept  this.  Since  1965  the  Community  definition of 
medicinal  products  given  in  Article  1 of  Directive 65/65/EEC  has  applied  to 
blood products.  It  reads:  "any  substance or  combination of  substances 
presented  for  treating or  preventing disease  in  human  beings  ...  ". 
The  problem  is  thus  purely  terminological. 
1.4  THE  CONTAMINATED  BLOOD  AFFAIR 
When  the  human  immunodeficiency  virus  (HIV)  was  detected  among  blood  donors 
In  1980  or  thereabouts,  hemophi I lacs were  faced.with  the  new  fatal  risk of 
AIDS.  The  finding  of  a  link  between  seropositive hemophi  1 lacs  and  blood 
plasma  donations  was  first  shown  in  1983.  At  the end  of  1985  most 
fractionation  laboratories had  introduced  a  system of  deactivating HIV  by 
heat  treatment.  By  then  a  large  number  of  hemophiliacs  had  been  infected. 
Unluckily  there was  a  brief  period around  1985  when  hemophi  1 facs  were  sti II 
being  infected as  business  interests dictated  the  further  use  of  old 
techniQues. 
2.  Identification of ethical  considerations 
2.1  PROTECTION  OF  THE  DONOR 
Blood  Is  an  organ of  the  human  body  and  should be  treated as  such.  This 
should  Include  the  concept  of  human  dignity.  The  donor  should  be  protected 
against  to him  or  her  unfavourable  results of  blood or  plasma  donation.  This 
can  be  more  easily achieved when  blood donation  is  volontary  and  unpaid. 
Those  who  give  blood  for  money  may  not  be  motivated  by  wholly  idealistic 
considerations;  poverty may  play  a  role,  for  one  thing.  Excessively 
freQuent  plasmapheresis can  render  the subject  vulnerable  to  infection and 
even  provoke  a  state of malnutrition. 2.2  PROTECTION  OF  THE  DONEE 
There  are  pathogenic  risks  in  human  blood.  Several  diseases can  be 
transmitted  by  blood:  AIDS,  hepatitis,  syphi I is,  malaria  and  toxoplasmosis 
are  among  them.  On  the safety  front,  Directive 89/381/EEC  lays  down 
stringent  rules  to guarantee  the  Quality,  safety and  efficacy of  products 
derived  from  blood,  through  the  proper  val ldation of  manufacturing  and 
purification processes and  examination of  donors.  The  Directive makes  the 
measures  adopted  by  the  Council  of  Europe  and  the  World  Health Organization 
on  the selection and  testing of  donors  mandatory  In  the  Community. 
2.3  THE  MARKETING  OF  BLOOD 
Respect  for  the  individual  (right  to  I ife,  to physical  integrity  and  to 
human  dignity),  whether  as  donor  or  as  donee,  is at  the  foundation  of  the 
ethical  principle  that  the  hum~n body  in  general  and  human  blood  in 
particular  are  not  marketable. 
Two  points  flow  from  this: 
* 
* 
blood  donations  should  be  voluntary,  unpaid  and  anonymous; 
nobody  should  be  allowed  to make  a  profit  from  a  donor's  blood.  If 
blood  is used  for  the manufacture of  derivatives,  neither  the  supplier 
nor  the  manufacturer  should be  allowed  to charge more  than  the  actual 
costs  incurred. 
2.4  AVAILABILITY  OF  SUPPLIES  AND  SELF-SUFFICIENCY 
In  general  terms,  a  shortage of  blood supplies  is ethically unacceptable. 
Blood  should  be  used  more  economically  in order  to arrive  to a  level  of 
self-sufficiency as  fast  as  possible. 
National  and  Community  self-sufficiency helps  to  reduce  the  risk of 
spreading non-endemic  diseases  such  as  malaria  in  the  Member  States and 
makes  quality controls easier.  Article 3 of  the  Directive  requires  the 
Member  States  to  take  the  necessary measures  to promote  Community  self-
sufficiency.  In  cases of  blood  Importation  from  third countries,  the 
authorization process  should  include  requirements  for  the  blood  importation 
for  products  derived  from  human  blood. 3.  Opfnion 
The  Groug  has  scrutinized Directive 89/381/EEC  on  products derived  from 
human  blood  and  human  plasma.  It  has  concluded  that  It  is sound. 
It  has  also discussed  recent  develo~ments  In  the field,  and  In  ~articular 
the 0Dinion  given  by  the French  National  Ethic~r Committee  on  the Directive 
and  on  the  contaminated blood affair. 
Following  Its discussion,  and  having  regard  to the suggestions made  by  the 
French  Committee,  the Group  of Advisers on  the Ethics or Biotechnology  is of 
the ODinlon  that: 
3.1  The  following ethical  crlnclpJes should be  stressed  In  the Directive: 
•  the donee's health  Cavallabllfty and  QUality of  blood  sup~lles); 
•  the donor's  human  dfgnfty  (anonymity.  voluntary donations); 
•  non-marketability of the  human  body  (donations to be  unDald). 
Acart  from  the obvious  DIYments  that are  acce~table for  admlnfst~ative 
curpoaes  and  industrial  developments,  no  one  should  have  additional  croffts 
from  blood donations  that contradict  the prlnelple of  non-ma~ketabl llty of 
human  body. 
3.2  The  expression  "medicinal  products•  as agplled  to croducts derived 
from  blood,  should  not  be  reJected as  these products are used  as 
therapeutfcals,  and  this term  gives a  guarantee of quality to  the  products 
through  the authorization process  related to medical  products. 
3.3  All  the guarantees as to  the safety,  Quality and  efficacy of medicinal 
Droducts should be  ap~lfed In  relation to products derived  from  blood. 
3.4  All  the proceedings related to blood  donation  should rest with 
organizations submitted to public control  which  are able to ensure a 
maximum  guarantee with  respect  to the Quality of  the products. 
The  grouD  intends to deal  separately with  the problem of an  adeauate 
compensation  to  the vfctfms  of medicinal  products derived  from  human  blood. 
In  accordance  with  Its terms of  reference.  the Group  of Advisers on  the 
Ethics of Biotechnology hereby  cresents thfs Opinion  to the  Commission. 
Signatures:  The  members 
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I.  BACKGROUND 
1.1  scope  of the Directive 
The  purpose  of  the  proposed  Directive,  the  first  version  of  which  was 
presented  by  the  commission  on  21  october  1988,  is to  harmonize  patent  law 
relating to living matter throughout the  community. 
As  a  single market  measure,  it seeks  to ensure  the  free  movement  of  goods 
and prevent abuses  of dominant positions. 
since  protecting  innovation  through  patent  law  is  an  important  part  of 
promoting  research  and  economic  growth,  the  Directive  is  also  intended  to 
help  European  companies  compete  with  their  American  and  Japanese 
counterparts in the very promising biotechnology industry. 
The  Directive  would  appear  to  be  the  first  international  text  to  deal 
specifically with biotechnological inventions. 
1.2  History of patent law as  a  way  of protecting inventions 
The  beginnings  of  patent  law  can  be  traced  back  to  the  Age  of 
Enlightenment.  originally,  patents  were  seen  as  a  form  of  social  contract 
between  the  inventor  and  society:  society  protected  the  inventor,  by 
ensuring that  he  was  rewarded  for  the  disclosure  of  his  invention  and,  in 
return,  the  inventor agreed to make  his  invention freely available. 
Through the patent,  the inventor shared the  knowledge  of his  invention with 
the rest of society  (see the report to the French National Assembly  for  the 
debate  on  the  Act  of  7  January  1791,  one  of  the  first to establish patent 
protection of inventions). 
The  first  three  to  pass  laws  on  patents  were  after  Venice.  (Statute  of 
Inventors,  1474),  England  (Statute of  Monopolies,  1623),  the  United states 
(in  1790)  and  France  in 1791. 
since  then,  all  of  the  industrialized  countries  and  many  developing 
countries  have  enacted patent legislation. 1.3  The  situation today 
Patent  law today is complex  in the  extreme. 
First,  in  addition  to  all  the  domestic  legislation,  there  is  a  myriad  of 
international  conventions,  covering  many  different  fields  and  geographical 
areas. 
The  basic  agreement  is  the  1883  Paris  convention  for  the  Protection  of 
Industrial  Property.  It  established  such  corner  stones  for  the 
international  protection  of  intellectual  property  rights  as  the  principle 
of  national  treatment,  the  right  of  priority  and  other  minimum  rights.  It 
also  led  to  the  setting  up  of  an  International  Bureau  in  Berne.  This  has 
since  developed  into  the  World  Intellectual  Property  Organization  (WIPO), 
with  its headquarters  in  Geneva.  The  convention  has  been  ratified by  over 
100  countries. 
Patent  law,  whether  domestic  or international,  generally applies  across  the 
board  to  inert  and  living  matter  alike.  The  Budapest  Treaty  (1977), 
ratified  by  some  thirty  countries,  would  appear  to  be  the  only  treaty  to 
deal  exclusively  with  patents  on  living  matter,  albeit  only  with  the 
procedure  for  filing  patents.  It  does  no  more  than  require  international 
recognition of  the  deposits  of  microorganisms  with  the  relevant  institutes 
and  offices  by  contracting states. 
However,  in  countries  which  are  member  states  of  the  International  union 
for  the Protection of  new Varieties of Plants  an obligation for  legislation 
has  been  established  to  distinguish  between  inventions  relating  to  plant 
varieties  on  the  one  hand  and  to  other  living matter  (microorganisms,  for 
instance)  on  the  other  hand.  Due  to  the  originally  established  ban  on 
double  protection  under  the  so-called  UPOV  convention,  member  states  were 
obliged  not  to  protect  plant  varieties  belonging  to  the  same  botanical 
species  or  genera  by  utility patents  and  plant variety certificates  along 
the  lines  of  the  UPOV  Convention.  This  ban  on  double  protection,  however, 
has  been  removed  from  the  UPOV  convention through  the  new  UPOV  Act  adopted 
in March  1991. 
1.4  European regulations 
While  there  is  not  as  yet  community  patent  law  as  such,  there  are  many 
European  conventions  covering  more  than  just  the  twelve  community  Member 
states. 
The  first  of  these  to  be  concluded  was  the  strasbourg  convention  on  the 
unification of  certain  Points  of  substantive  Law  on  Patents  of  Invention, 
signed  by  the  Member  states  of  the  council  of  Europe  in  1963.  The 
strasbourg convention  has  established  an  obligation of  contracting parties 
to  protect microbiological  processes  and  the  resulting  products,  but  left 
open  to  the  contracting  states  to protect plant or  animals  and  essentialy 
biological  processes  for  the  protection  of  plants  or  animals.  This 
Convention  laid  down  the  criteria  for  the  patentability of  inventions.  It 
also  specified  the  circumstances  under  which  an  invention  was  not 
patentable. 
2 However,  the  main  convention  at  European  level  is  the  European  Patent 
convention  (EPC),  which  was  concluded  1n  Munich  in  1973  and  entered  into 
force  in  1978.  It was  signed  by  seventeen  states,  all the  community  Member 
states,  Austria,  sweden,  switzerland,  Lichtenstein and  Monaco. 
The  EPC  also  included  specific  provisions  on  biotechnology.  Although  it 
essentially  followed  the  basic  lines  of  the  Strasbourg  convention,  it 
introduced  an  essential  change  in  so  far  as  plant  or  animal  varieties  and 
essential biological processes  for the production of plants or animals  have 
been  declared unpatentable.  It also laid the  foundation  for  the  setting  up 
of the European Patents Office  (EPO),  which is  known  for the very  important 
part it has  played in developing European patent law. 
The  European  Community is about to adopt its own  rules  in two areas. 
First,  the  Directive  under  consideration  here  lays  down  rules  concerning 
biotechnology  in general. 
The  second set of rules is concerned,  in particular,  with the protection of 
new varieties of plants.  Special protection for  new varieties of plants,  as 
distinct  from  general  patent protection,  is already  afforded  by  the  "UPOV" 
Convention,  a  major  international convention  adopted in Paris  in  1961.  The 
new  community  legislation would take the  form of  a  Regulation  (currently at 
the  drafting  stage)  establishing  a  Community  system  for  the  protection  of 
new  plant varieties. 
A  comparison  of  European  legislation  (existing  and  draft)  with  us  laws 
reveals that: 
(a)  as  regards  the  tests  of  patentability  apart  from  novelty,  a 
universal  condition,  us  law  requires  also  "non-obviousness"  which 
equals  our  prerequisite  of  an  inventive  step.  us  requires  that  the 
invention  be  useful,  whereas,  under  European  law,  it must  be  capable 
of  industrial application  ("if it can  be  made  or used  in  any  kind  of 
industry,  including agriculture",  art.  57  EPC); 
(b)  us  law  makes  no  provision  for  the  many  exceptions  to  be  found  in 
European  law  (particularly  the  EPC)  which  make  certain  products  and 
processes  involving  living  matter  unpatentable.  Those  exclusion 
clauses  (art.  53  b  EPC)  have  been the main obstacles  for  EPO's  work. 
The  Directive  under  consideration  in  this  opinion  does  not  set  out  to 
revise  these  exceptions.  Its  stated  aim  is  merely  to  harmonize  the 
interpretation  of  existing  international  conventions  throughout  the 
Community.  The  Directive  even  includes  certain  provisions  taken  over 
verbatim from existing European conventions  (in particular the EPC). 
The  Group  notes  that,  in  spite  of  this,  the  drafting  process  has  taken 
longer  than  expected,  mainly  as  a  result of  the  ethical  objections  raised 
by  Parliament. 
several  new  provisions,  mostly  on  ethical  questions  relating  to  the 
patentability  of  living  matter,  were  added  to  the  Directive  at  the 
committee  stage  in  Parliament  (particularly  in  the  committee  on  Legal 
Affairs  and Citizens•  Rights,  acting on the Rothley Report). 
3 Most  recently,  Parliament  adopted  a  resolution  at  the  beginning  of  19 9 3 
condemning  the  pr~duction of  transgenic  animals  outright  and  calling  for  a 
moratorium. 
This  shows  that,  in  the  discussions  on  the  Directive,  ethical 
considerations  now  outweigh the purely legal and economic  concerns. 
II.  ISSUES  TO  BE  TAKER  INTO  CONSIDERATION 
2.1  General questions 
The  Group  is  aware  how  important  it  is  for  Europe  to  step  up 
biotechnological  research  and  develop  the  industry  as  a  whole.  It  feels, 
therefore,  that the  Community  should  have  its own  legislation on  the  legal 
protection of biotechnological innovation. 
The  Group  welcomes  the  fact  that,  during  discussion  on  the  Directive  in 
question,  the  Community  institutions,  particularly Parliament,  have  had the 
opportunity  to  express  their  concern  about  the  ethics  of  advances  in 
biology  and  genetics.  Lastly,  the  Group  sees it as  a  democratic  imperative 
that  the  public  be  provided  with  clear  up-to-date  information  on  the 
science  and the related ethical issues. 
2.2  Ethical questions 
2.2.1  Patentability of living matter 
since its birth in the  1970s,  genetic engineering  has  given  man  tremendous 
power  - power  to manipulate  living matter.  The  apprehension  about  this  is 
reflected in the debate  on the Directive. 
Some  people  are  so  concerned  as  to  question  the  legitimacy  of  patenting 
living matter.  "You  cannot invent nature",  was  how  one  French  lawyer put it 
in  a  highly critical commentary  on  the  judgment  given  by  the  supreme  Court 
of the united states on  16  June  1980  in Diamond  v  Chakrabarty,  which  upheld 
the  patentability  of  a  microorganism  per  se  (Ananda  M.  Chakrabarty,  a 
researcher  of  general  Electric,  had  discovered  plasmids  which,  when 
incorporated into bacteria,  were  capable of breaking down  the components  of 
petroleum,  and  had  patented  their  invention  as  a  useful  anti-pollution 
agent). 
The  Group is of course unable to subscribe to such  a  utopian and simplistic 
view of nature,  described as being never modified by  humankind. 
Its view on this is set out in greater detail below. 
1.  The  practice  of  granting  patents  on  living  matter  goes  back  a  long 
way.  It certainly  predates  the  emergence  of  gel'l:etic  engineering  and 
was  explicitly  endorsed  in  the  early  1960s,  first  by  the 
UPOV  convention  (1961)  and  subsequently  by  the  strasbourg  convention 
(1963). 
one  should  but  note  that  the  first  known  patent  of  a  living organism 
was  granted  in  Finland  in  1843  and  Louis  Pasteur  received  a  patent 
from  us  Patent  Office  for  a  yeast  free  from  organic  germs  of  desease 
as early as  in 1873. 
4 of  course,  the  opening  up  of  so  many  new  possibilities  for  altering 
living  organisms  does  justify  changing  patent  law,  which  is  what  the 
Directive rightly sets out to do. 
2.  The  Group  sees  no  ethical  grounds  for  opposing  the  patentability  of 
inventions  relating  to  living  matter  in  principle,  even  though  there 
are  certain  types  of  genetic  manipulation  which  should,  in  its  view, 
be  strictly prohibited. 
2.2.2 
This  should  be  mainly  a  matter  to  be  dealt  with  under  the  competent 
branches  of  public  law  dealing  with  the  use  and  commercialization  of 
research results  in respect to public  safety,  health,  environment  and 
animal  welfare.  Nevertheless  if patent  law  cannot  substitute  laws  in 
the  respective  fields,  it is  useful  to  mention  in  the  directive  the 
ethical concerns  raised by  genetic engineering. 
The  Group  is mindful  of  the reservations  some  people  have  had  for  some 
time  now  about biological inventions.  But it is also worth  considering 
that,  originally,  chemical  and  pharmaceutical  inventions  were  also 
denied all protection under patent  law.  The  value of biotechnology  for 
industry,  agriculture,  the  environment  and medicine  cannot  be  denied. 
The  Group  is  of  the  opinion  that,  in  order  not  to  hinder  its 
development,  the principle of the patentability of  inventions relating 
to living matter must  be  upheld wherever ethically possible. 
Non-patentability  of  inventions  whose  publication  or  exploitation 
would offend against public policy or morality 
The  Directive reproduces Article  53(a)  of the  EPC  prohibiting the patenting 
of  any  invention the  publication or application of  which  would  be  contrary 
to public policy or morality. 
when  the  Directive  was  going  through  the  Parliamentary 
provisions  were  added  prohibiting  the  granting  of  patents 
products  and  processes  involving humans  and  animals. 
committees, 
for  certain 
The  group  shares  the ethical considerations  behind  the  prov~s1ons  added  as 
reaction  to  the  debate  in  the  european  Parliament.  Yet,  it is  wondering 
wether the  amendments  are to be  considered as  part of the directive's body. 
The  appropriate  place  to  address  and  resolve  some  of  those  considerations 
seems  to be  the recitals of  the directive.  Moreover,  attention is  drawn  to 
the  fact  that  a  patent  does  not  confer  on  the  patent  owner  the  right  to 
make  use  of  the  patented invention but only to prohibit its use  by  others. 
There  is no positive right to make  use  linked with  a  patent. 
2.2.3  Protection of human  dignity 
The  concept of  human  dignity appears  for the first time  in community  law  in 
Article 2(3)(b)  of  the  amended  proposal  for  a  Directive,  which  states that 
"processes  for  modifying  the  genetic  identity of  the  human  body  for  a  non-
therapeutic  purpose  which  is  contrary  to  the  dignity  of  man"  are 
unpatentable  (implicit reference to cloning and chimera-production,  etc.) 
5 Human  dignity was  already expressly protected by  a  variety of international 
conven1:.ions  ( e • g.  the  European  convention  on  Human  Rights )  and  certain 
domestic  legal  instruments  (e.g.  the  Basic  Law  of  the  Federal  Republic  of 
Germany,  adopted  in  19  4 9 )  but  not,  it  would  appear,  by  conununi  ty  law. 
Hitherto,  the concept has  figured only in the  two  following declarations of 
principle: 
( i)  the  Parliament  resolution  of  16  March  19 89  on  the  ethical  and  legal 
problems  of  genetic engineering;  and 
(ii)  council  Decision  90/395/EEC  of  29  June  1990  adopting  a 
research  and  technological  development  programme  in  the 
health:  human  genome  analysis. 
specific 
field  of 
While it may  seem strange that the first-ever reference to the principle of 
respect  for  human  dignity  should  be  made  in  a  directive  on  patents,  it is 
an  indication of the  concern  aroused  by  certain developments  in the  fields 
of  human  genetics  and medicine.  That is not to say that the attention given 
to  ethical  considerations  in  the  Directive  does  not  constitute  a  new 
departure in patent law. 
(a)  Article 2(3)(a)  prohibiting  the  patenting  of  the  human  body  or  parts 
of the  human  body  per se. 
It is  necessary  that the  question  of  the  patentability of  human  genes  and 
partial  gene  sequences  should  be  dealt  with  in  the  recitals  to  the 
Directive.  The  controversy  over  this  issue  started  with  the  American 
National Research Institutes•  decision to file patent applications with the 
us  Patent  Office.  It must  be  made  clear that  identifying  genes  or partial 
gene  sequences  without  discovering  their  function  does  not  constitute  an 
"inventive step"  and is not patentable.  Any  ambiguity on this point must  be 
cleared  up  in  order  to  uphold  the  freedom  of  research  and  the  freedom  of 
researchers to exchange  information. 
Furthermore,  the  acknowledgement at a  community  level of  t~e principle that 
parts  and products of the  human  body may  notbe  commercially exploited  (e.g. 
in the case of organ transplants)  should be  studied. 
(b)  Article 2(3)(b)  on  human  genetic engineering 
The  Group  acknowledges  the  need to reaffirm the  ban  on  genetic  engineering 
for  non-therapeutic  purposes,  contrary  to  the  dignity  of  man,  but  feels 
that  the  Directive  is  not  the  right  place  to  deal  with  the  very  complex 
issue of the  legitimacy of germinal therapy. 
On  a  different  note,  it  is  questionable  whether  Article 2(3)(b),  which 
seemingly  endorses  the  patenting  of  genetic  therapy  techniques,  is 
compatible  with  the  other  provisions  of  the  Directive  prohibiting  the 
granting  of  patents  for  surgical  and  therapeutic  methods  of  treatment  and 
diagnostic methods  practised on the human  (or animal)  body. 
6 The  same  methods  are  also unpatentable  under Article  52(4)  of  the  EPC,  the 
original  ourpose  of  which  was  to  protect  medical  practitioners  from 
prosecution  for  infringement  in  the  exercise  of  their  profession.  Today, 
however,  the medical  profession would  appear  to  be  adequately  protected by 
the  laws  on the use  of  inventions  for private purposes. 
Nevertheless,  the 
medicine  should  be 
consistency. 
remaining 
removed 
restrictive  provisions 
from  the  Directive  in 
concerning  human 
the  interests  of 
2.2.4  Transgenic  animals 
By  making  it  possible  to  mix  genetic  material  from  separate  species, 
genetic  engineering  has  given man  the  power  to produce  an  endless  range  of 
plant and  animal varieties,  all tailor-made to suit his  own  needs. 
In  recent  years,  a  number  of  transgenic  animals  have  been  created  by 
micro-injection  and  embryo-fusion  (in the  United States,  four  patents  have 
been  issued for  Onco-mice,  including the  Harvard mouse,  and  in May  1992  the 
EPC  agreed  to  grant  a  patent  to  the  mouse's  inventor).  Transgenic  animals 
open  up  a  number  of possibilities: 
( i)  they  can  be  used  in  medical  research  to  study  human  disease 
patterns; 
(ii) 
(iii) 
they can be  used to synthesize chemical  substances  needed for  human 
medicines,  which  can  easily  be  obtained  from  their  physiological 
fluids; 
in  agriculture,  there  is  scope  for  rearing  fast-growing, 
high-weight  animals  yielding  predetermined  nutritional  values  or 
with in-built resistance to disease. 
Despite  the  fact  that  animals  have  always  been  used  by  man  as  a  resource 
(at one  time,  they constituted his  main  source  of  food),  the  production of 
transgenic  animals  arouses  strong feelings  among  the public. 
Parliament's resolution calling for  a  moratorium,  adopted at the beginning 
of  1993,  relayed  the  feelings  expressed  by  various  groupings  (e.g. 
associations opposing  animal experimentation). 
The  Group  cannot  ignore this reaction or the  people expressing it. 
At  the  same  time,  it  does  not  feel  it  would  be  advisable  to  ban 
transgenesis  on  animals  as  this  would  bring  medical  progress  to  a 
standstill  or,  worse  still,  result  in  experiments  being  carried  out  on 
humans  before essential preliminary tests had proved them safe. 
Thus,  there is a  strong case  for  making  transgenic  animals  patentable  (the 
animals rather than  just the process of transgenesis because of the  need to 
protect the inventor for  successive generations). 
The  Group  does,  however,  feel  that  the  legal  and  ethical  questions 
surrounding transgenic  animals  do  require  some  clarification. 
1.  The  Directive  should  make  clear  that  it is  possible 
production of  a  transgenic  animal if it is at the  end, 
particularly  in  the  field  of  scientific  research, 
agriculture. 
7 
to  patent  the 
useful to man, 
medicine  and 2.  A  more  detailed  study  should  be  carried  out  at  community  level  into 
the  uses  ot  transgenic  animals,  with  reference  to  the  objectives 
pursued in the various  areas  in question. 
3.  Effective  inspection  arrangements  should  be  devised  to  ensure  that 
animals  are  not  subjected  to  unnecessary  or  excessive  suffering  in 
laboratories. 
4.  It  is  essential  to  address  the  question  what  constitutes  an  animal 
species,  a  stock  or  a  "breed"  and  what  exactly  should  remain  non-
patentable. 
It  is  to  this  end  that  the  commission  has  just  officially  requested  an 
opinion  from the Group. 
2.2.5  Biological diversity 
Biodiversity  has  come  to  be  seen  as  ethically desirable.  some  people  fear 
that  it is  threatened  by  advances  in  biology  and  genetic  engineering.  As 
the  Group  sees  it,  however,  there is no  direct link  between  patent  law  and 
biodiversity. 
8 :III  OP:INI:ON 
The  Group's  opinion is set out below. 
After examination of  the ethical questions relating to: 
the  legitimacy of  patenting living matter; 
the need to protect human  dignity; 
the production of  transgenic animals;  and 
the preservation of biodiversity, 
the Group  of Advisers  on the Ethics of Biotechnology: 
is  of  the  opinion  that  there  are  no  ethical  objections  to  the 
patenting  of  biotechnological  inventions  per  se;  and  that, 
furthermore,  in  pursuit  of  its  economic  and  social  objectives,  it is 
essential  for  the  community  to  harmonize  patent  law  relating  to 
biotechnology; 
acknowledges  the  ethical  questions  raised  by  biological  and  genetic 
research and the applications thereof,  and considers it right that,  at 
the  initiative  of  Parliament,  in  touch  with  people's  concerns,  these 
questions  should be  addressed mostly in the recitals of the Directive; 
considers that,  since these  issues  have  never previously arisen in the 
field  of  patent  law,  some  clarifications  are  urgently  needed  on 
certain  concepts  and  on  the  scope  of  certain  provisions  in  the 
Directive. 
Human  genetics 
Genes  and partial gene  sequences  whose  functions  are  unknown  should be 
made  expressly  unpatentable  to  end  the  international  debate  on  the 
matter.  :rn  due  course,  the  community  should  try  to  arrange  an 
international  agreement  on  the  patentability  tests  for  inventions 
resulting from  genetic research programmes. 
Furthermore,  the  community  should take  a  stand against the  commercial 
exploitation of the  human  body. 
Transgenic  animals 
There  is  no  need  to  impose  a  complete  ban  on  the  production  of 
transgenic  animals.  Extreme care must be taken to ensure that they are 
used  for  adequate purposes,  not suffer inadequate pain or cause  damage 
for the general public. 
Biodiversity 
The  Directive  itself  poses  no  threat  to  biodiversity.  However,  with 
ratification  of  the  UN  Convention  on  Biological  Diversity,  the 
community  would  be  well  advised  to start considering  the  matter  with 
view  to  clarifying  what  it  understands  the  concept  to  mean  in 
practical terms. 
********** 
9 None  of  the  other  themes  dealt  with  in  the  Directive  (e.g.  farmer's 
privilege)  raises ethical  ~uestions which  fall within the Group's  remit. 
The  Group  wishes  to  draw  the  commission's  attention  to  the  need  for 
measures  to  familiarize  the  public  not  only  with  the  scientific  and 
economic  side of  biotechnology  but  also with  the  social,  legal  and  ethical 
implications.  This  is  a  democratic  imperative. 
In  accordance  with  its  remit,  the  Group  submits  this  opinion  to  the 
commission. 
one  member  of  the  group  is  of  the  opinion  that  the  demands  worded  in 
section II,  par.  2.2.4.,  points  n•  2  and  3  should  be  addressed  to  general 
public  law,  not to patent  law. 
concerning  Section  III,  3rd  par.,  second  dash,  one  member  of  the  group 
emphasizes  that  respective  provisions  must,  as  a  matter  of  principle,  be 
made  in general public  law,  not,  however,  in patent  law. 
[signed] 
chairman  ~ ~ 
y-o~~ 
(Signatures  of  the 
members  of  the  Group 
of Advisers) 
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12.  BST EUROPEAN COMMISSION 
Secretariat-General 
SG/C/1 
BST - OPINIONS ADOPTED  AND REPERCUSSIONS 
Opinion  No 1  on  the  ethical  implications  of the  use  of performance-enhancers  in 
agriculture and fisheries. 
Rapporteurs:  Lady Warnock and Professor Siniscalco 
Ref.:  Second Commission report on BST (SEC(91)2521 final) 
Referral:  Commission request for an opinion, 27 February 1992. 
Background 
Bovine somatotropin (BST) is a hormonal protein produced by the pituitary gland which 
stimulates not only bone growth and protein anabolism, but also galactopoiesis (increase 
in milk secretion during lactation in cattle). 
Several  studies  have  shown  that  the  use  of BST  increases  the  incidence  of bovine 
mastitis, which is treated with antibiotics.  The concentration of antibiotics in milk and 
beef could pose a danger to consumer health.  In addition levels of somatic cells in the 
milk produced using BST could be excessive and hence harmful to consumers. 
The risk of bovine mastitis and frequent inflammation as a result of the administration 
of BST could be harmful to the health and well-being of the animals concerned. 
In a decision of 10 February 1992 the Council asked Member States not to authorize the 
use ofBST until 31  December 1993 and asked the Commission to report on the situation 
by July  1993. The Commission accordingly referred the matter to the Group of  Advisers 
in order to determine the ethical implications of BST. 
The Group's o.pinion 
The Group  concluded  that the use  of BST was  ethically  acceptable  provided  certain 
measures were adopted, particularly as regards: 
Consumer health and safety: administration of BST should be stopped if mastitis 
or other inflammatory reactions occur.  Milk produced by  animals treated with 
antibiotics  should  be withdrawn  from  sale  until  all  traces  of antibiotics  have 
disappeared. The level of somatic cells per millilitre should not exceed that found 
in milk produced by traditional methods. 
Animal  welfare:  animals  should not suffer extreme pain or discomfort that is 
disproportionate to the human benefit expected from the use of BST. Biological diversity: the use of BST does not adversely affect biodiversity. 
Freedom of choice of the consumer:  milk and milk products derived from BST-
treated cows should be labelled accordingly once it is possible to distinguish them 
from  other milk and milk products. 
The Group appreciated that, in addition to the ethical implications, the distribution ofBST 
also raised important economic and political problems. However, it felt that these issues 
went beyond its terms of reference. 
Subseguent deyelgpments 
The Commission felt that the measures recommended by the Group would be difficult to 
implement at the present time. Backed by the Group's recommendations and on the basis 
of the conclusions of the Committee for Veterinary Medicinal Products, the Commission 
issued a recommendation to the Council  and Parliament, on  13 July  1993, that the sale 
of BST should be banned within the Community for a period of seven years. 
The Commission authorized the distribution of the Group of Advisers' Opinion No  1 to 
the public upon request. 
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BOVINE SOMATOTROPIN (BST) 
STATE OF PLAY 
Bovine somatotropin (BST) is a biotechnological product which stimulates lactation in cows.  The 
state of play as regards the marketing and administration  o~  BST in the Community and in the 
United States is as follows. 
Euro.pean Community 
In December 1993 the Council decided to extend the moratorium on BST until  31  December 1994. 
Discussions in the Council  can therefore be expected to resume in the autumn. 
The Commission had initially proposed a ban on BST until the year 2000 when the milk quota 
system is due to expire, since the effects of the substance conflict with the aims of the common 
agricultural policy. 
The Commission's Group of Advisers on the Ethics of Biotechnology has recommended specific 
safeguards (a veterinary certificate in each case) for the administration of BST. 
United States 
Marketing and administration of BST had been allowed in the United States since 
15 February  1994. 
Consumer groups are now campaigning for the introduction of a labelling system to identify milk 
from  cows treated with BST. Opinions adopted - Repercussions - State of play 
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PRODUCTS DERIVED FROM HUMAN BLOOD OR PLASMA 
OPINIONS ADOP'IED  AND REPERCUSSIONS 
Opinion No 2 on products derived from  human blood or human plasma. 
Rapporteur:  Margareta Mikkelsen 
Ref:  Directive  89/381/EEC  extending  the  scope  of Directives  65/65/EEC 
and 75/319/EEC 
Referral:  Own-initiative opinion (March  1992) 
Background 
Directive 89/381/EEC entered into force on  1 January  1992. It aims 
to  encourage  Community  self-sufficiency  through  voluntary  unpaid  blood  and 
plasma donation; 
to  introduce  strict  criteria  guaranteeing  the  quality  and  safety  of medicinal 
products  derived  from  human  blood  or  plasma,  notably  to  avoid  viral 
contamination; 
to harmonize conditions for authorizing the manufacture of blood-based products 
by  1993. 
The  publication  of the  French  National  Ethical  Committee's  Opinion  No 28  of 
2 December 1991 triggered a debate and protests in France about the application of the 
Directive. The Committee took the view that, by treating blood and plasma as "starting 
material" and blood derivatives as "medicinal products", the Directive appeared to make 
them tradeable goods, which conflicted with the principle that the human body was not 
a marketable commodity and offended against human dignity. 
This terminological  difficulty  connected with  the use  of the term  "medicinal  product" 
would no longer appear to be an issue. 
The Group also examined the issue with reference to the cases of  mv  infection following 
contaminated blood transfusions, particularly in France, Germany and  Spain. 
The Group's opinion 
In the light of its discussions the Group identified the following ethical considerations: 
respect for the donor, donor anonymity and the principle of voluntary donations; 
health of the recipient, availability and quality of blood supplies; 
the human body is not a marketable commodity:  no-one should make additional 
profits from blood donations. As  regards the Directive, the Group concluded that it was appropriate to use the term 
"medicinal product" with reference to products derived from  blood because it provides 
a guarantee of quality and security. 
In the Group's view, measures relating to blood donations should be the responsibility of 
organizations under strict public control. 
Subseguent developments 
The Commission authorized the distribution of the Opinion to the public on request. 
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STA1E OF PLAY 
Directive 89/381/EEC on medicinal products derived from human blood or human plasma 
Purpose of tbe Directive 
The purpose of the Directive is to protect human health by extending Community rules 
designed to guarantee the quality, safety and efficacy of medicinal products to products 
derived  from  human blood  or human  plasma (manufacturing authorization,  marketing 
authorization).  Application  of these  rules  also  guarantees  free  movement  of these 
products. 
The Directive also addresses the ethical aspects and advocates the promotion of  voluntary 
unpaid donations to achieve self-sufficiency in the supply of blood and blood products. 
Implementation of tbe directive 
1. Technical provisions 
Eleven  Member  States  have  transposed  Directive  89/381/EEC  and  the  twelfth  (the 
Netherlands) is in the process of doing so. National legislation is now being checked by 
Commission departments for conformity with the Directive. 
2.  Voluntary unpaid donations 
When  the  directive  was  adopted  in  1989 the  Council  left it to  the Member  States to 
determine,  in  the  light  of their  own  situation,  the  best way  of achieving  the goal  of 
Community self-sufficiency by means of voluntary unpaid donations without depriving 
patients of essential treatment. 
The Council of Europe, which is referred to in the Directive, has produced a definition 
of  voluntary unpaid donations. This specifies that donations of  blood, plasma and cellular 
components must be freely  made and that no benefits in cash or kind should be offered 
to the donor.  Gestures  such as  refreshments and  reimbursement of travel expenses are 
consistent with the notion of voluntary unpaid donations. The Council of Europe, which is referred to in the Directive, has produced a definition 
of  voluntary unpaid donations. This specifies that donations of  blood, plasma and cellular 
components must be freely made and that no benefits in cash or kind should be offered 
to the donor.  Gestures such as refreshments and  reimbursement of travel  expenses are 
consistent with the notion of voluntary unpaid donations. 
Three Member  States (France,  Belgium  and  the Netherlands)  have  opted to  promote 
voluntary  unpaid  donations  by  confining authorization to blood  and  plasma products 
derived  from  this  source.  Their degree  of self-sufficiency  made this  option  possible. 
Other Member States are not in a position to do the same without depriving patients of 
essential treatment. As a general rule
1
, they do not allow payment for blood donations on 
their  national  territory  but  they  do  import  plasma  or  products  derived  from  paid 
donations, notably from the United States, to make good the shortfall in supplies. 
In any event, provided they satisfy the requirements of Community legislation, products 
manufactured in any  Member State must be given access to the territory of the other 
Member States on the same terms as products manufactured locally. 
Follow-up to the Directive 
Directive 89/381/EEC was challenged, notably in France, by blood donor associations on 
the grounds that it classified blood derivatives as "medicinal products". 
The matter was referred to the Group of Advisers on the Ethics of  Biotechnology, which 
endorsed the Directive and its public health objectives in March 1993. 
In December 1993 the Council confirmed the importance of achieving self-sufficiency in 
blood and blood derivatives by means of voluntary unpaid donations, promoting blood 
donations  with  Community  support,  guaranteeing  the  quality  and  safety  of blood 
collection and ensuring optimum use of blood and blood products.  · 
The Commission will update its studies on blood donations and the utilization of blood 
and blood products at regular intervals and decide whether any action is needed. 
With the exception of Germany, which does allow a fixed payment for ttavel expenses and loss 
of earnings occasioned by absence from worlc. 
2 opinions adopted - Repercussions - State of play 
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LEGAL PROTECTION OF BIOTECHNOLOGY INVENTIONS 
OPINIONS ADOPTED  AND REPERCUSSIONS 
Opinion N. 3  on  the  ethical  questions  arising  from  the  Commission  proposal  for  a 
Council Directive on legal protection for biotechnological inventions. 
Rapporteur: 
Ref.: 
Referral: 
Background 
Noelle Lenoir 
Proposal  for  a  Directive  (COM(88}496  final)  and  amended  proposal 
(COM(92}589 final),  Common Position of 7 February  1994, 2nd Report 
of Mr Rothley (EP 156.257) 
Own-initiative, March 1992 
The  proposal  for  a  Directive,  published  in  October  1988  was  one  of the  measures 
connected with the establishment of  the Single Market. Its purpose was the harmonization 
of Member States's laws on the patenting of biotechnological inventions. 
The adoption process has been held up since 1988, largely because of the ethical debate 
about the patentability of  living matter, but also because of  the discussions about farmer's 
privilege.  The compatibility of the Directive with the Rio Convention  on Biological 
Diversity prompted Parliament to ask the Commission to review all the provisions. 
The Group's qpinion 
The  Group's  verdict  was  that  the  patentability  of living  matter,  a  long-established 
principle,  did  not in  itself raise  any  ethical  problems.  Concerning the ethical  issues 
related  to  human  body  and  transgenesis,  the  Group  suggested  that the Directive had 
become too complex and should be simplified to include in its substantive provisions only 
certain elements essential for the protection of human rights. 
It should therefore expressly prohibit the patenting of: 
the human body or parts of the human body ~; 
techniques  of human  genetic  engineering  (except  those  used  for  therapeutic 
purposes and then only if they do not undermine human dignity). 
It  also  urged  the  Community  to  work  towards  the  conclusion  of an  international. 
agreement  on  patentability  tests  for  inventions  resulting  from  genetic  research· 
programmes.  The discussions about the patentability of genes with no known function 
had highlighted certain ambiguities in the basic principles of patent law when applied to 
living matter. Subsequent developments 
On  16 December 1992 the Commission presented an  amended proposal  for a Directive 
to  the  Council,  incorporating the  ethical  dimension.  The Council  agreed  to adopt the 
Commission's proposals.  The Group's opinion served as  a catalyst in  this process.  The 
Council's common position was adopted on 7 February 1994. 
The Group of Advisers achieved its full  potential in this particular case: 
because its opinion was perfectly timed to coincide with the preparation of the 
Directive. Consequently, the rapporteur, Ms Lenoir, was able to meet Parliament's 
rapporteur and take part in the Council's expert meetings 
it  strengthened  the  Commission's  position  in  relation  to  the  Council  and 
Parliament; 
because  the  opinion  addressed  issues  of general  importance  the  Commission 
distributed it widely. It was sent to Parliament, Council, the Council of Europe, 
the World Intellectual Property Organization and the European Patent Office. It 
is available to the public on request. 
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LEGAL PROTECTION OF BIOTECHNOLOGICAL  INVENTIONS 
STATE OF PLAY ON mE CO-DECISION PROCEDURE 
PURPOSE OF THE PROPOSAL 
The purpose of  the proposal is to offer biotechnological inventions the same level of  legal 
protection in all  Member States, to require national  patent offices to follow a uniform 
patenting procedure and generate a uniform body of case law in national courts, and to 
define  the  scope  of patent  protection.  This  extension  of patent  law  has  been  made 
necessary by the growing market in biotechnological products. 
BACKGROUND 
1.  The Commission published its proposal for a directive on 20 October 1988. 
2.  On 29 October 1992 Parliament delivered a favourable opinion on first reading 
incorporating 46 amendments. 
3.  On 16 December 1992 the Commission adopted an amended proposal taking over 
27 of  Parliament's amendments in whole or in part. These related in essence to the 
ethical dimension and incorporation into patent law of  what is known as "farmer's 
privilege". 
4.  The Council  adopted  its common position on  7 February 1994.  On the ethical 
dimension  of biotechnological  inventions,  hotly  debated  at  Council  level,  the 
opinion of  the Group of Advisers on the Ethics of  Biotechnology (Opinion No 3, 
30 September 1993) did much to clarify the issues. 
5.  The Commission accepted the Council's common position on  17 February 1994. 
6.  On 4 May 1994 Parliament voted three amendments to the common position on 
second reading. 
OUTLOOK 
It must be said that Parliament's second reading did not go as planned. It could only vote 
three amendments because of  a quorum problem. Nevertheless, the co-decision procedure 
provided  for  in  Article 189b  of the  Treaty  will  continue to  apply  when these  three 
amendments are officially notified to the Council and the Commission.  The Conciliation 
Committee will  meet if necessary.  In line with the conclusions of the White Paper on 
growth, competitiveness and employment, the Commission will do everything in its power 
to facilitate  agreement between the Council  and Parliament on a joint text creating a 
legislative  environment  for  the  protection  of biotechnological  inventions  and  will 
contribute  in  an  appropriate  manner  to  the  necessary  political  compromise.  A  final 
Council decision can be expected before the end of the year. Relations with the European J>arliament and 
Council of Europe Relations with the European Parliament and 
Council of Europe 
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RELATIONS  WITI-11HE EUROPEAN PARLIAMENT 
The Group of Advisers would like to increase its exchanges with the other European 
Union Institutions and in particular with the European Parliament.  In this context it is 
foccusing  its  attention  on  dossiers  presently  submitted  to  the  European  Parliament, 
namely: 
The  Proposed  Directive  on  Legal  Protection  of Biotechnological  Inventions, 
examined in second reading (rapporteur : Mr Rothley); 
The Parliament report undertaken  at its  own  initiative on  competitivity  which 
follows the 1991  Commission Communication with respect to the promotion of 
the competitivity of bioindustries in  the Community (rapporteur : Ms Breyer); 
The new specific research programe in  biotechnology in the fourth framework 
programe which has been debated at the level of  the Energy Commission (CERT) 
The draft report on prenatal diagnosis, elaborated by Mr Pompidou. 
Finally,  the report "Bioethics in Europe",  edited in  September  1992  in  the context of 
STOA programe (Scientific and  Technological  Options Assessment)  of the European 
Parliament,  which  presents  analogies  and  differences between Member States'  ethical 
approaches, is used a great deal by the Group in its work.  · Relations with the European Parliament and 
Council of Europe 
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THE EUROPEAN COMMISSION AND THE COUNCIL OF EUROPE'S 
DRAFT BIOETIIICS  CONVENTION 
The  draft  bioethics  convention  was  produced  by  the  Council  of Europe's  Steering 
Committee on Bioethics (CDBI). 
It  sets  out  to  protect  human  dignity  and  to  guarantee  to  every  individual,  without 
discrimination, that the applications of biology and medicine respect  his identity and his 
rights and fundamental freedoms. 
Protocols on organ transplantation,  on medical  research and the human foetus,  and on 
genetic engineering  will be annexed to the Convention. 
The pace of work on the draft convention has slowed down because of the difficulty of 
reaching a consensus.  It now looks as if  the convention will not be finalized as expected 
in July  1994. 
The  draft  convention  is  being  monitored  by  Commission  departments  through  the 
working party on bioethics. 
This was set up to promote interdepartmental coordination and ensure that departments 
adopt a coherent position on bioethical issues. 
The working party is therefore taking a keen interest in work on the draft convention and 
is preparing a request for negotiating directives. 
The Legal Services of  the Commission and the  ~ouncil of  Europe are due to begin talks 
on the matter. 
The draft convention is also being monitored by the Group of Advisers on the Ethics of 
Biotechnology,  which includes Mr Quintana-Trias, chairman of the Council of  Europe's 
Steering Committee on Bioethics (CDBI). EUROPEAN COlvflvflSSION 
Secretariat General 
SGIC/1 
TEXTS  OF TilE COUNCIL OF EUROPE ON BIOETIIICAL MA TIERS 
CDBI!INF (93) 2 
TEXTS OF THE COUNCIL OF EUROPE 
ON BIOETHICAL MATTERS 
Directorate of Legal  Affairs 
Strasbourg  1993 
Th1s  document  w11/  not be d1stnbuted at the meetmg  Please brmg th1s  copy 
Ce  document ne  sera  plus distribue en  reumon  Pnere de  vous  mumr de cet exemplalfe A.  Parliamentary Assembly of the Council of Europe 
Resolution 613 (1976)  on the rights of the sick and dying 
Recomm~ndation 779 (1976)  on the rights of the sick and dying 
Recommendation 818 (1977)  on the situation of the mentally ill 
Recommendation 934 (1982)  on genetic engineering 
Recommendation I 046 (  1986)  on  the  use  of human  embryos  and  foetuses  for 
diagnostic,  therapeutic,  scientific,  industrial  and 
commercial purposes 
Recommendation 1100 (1989)  on  the  use  of human  embryos  and  foetuses  in 
scientific research 
Recommendation 1159 (1991)  on the hannonisation of autopsy rules 
Recommendation 1160 (1991)  on the preparation of a convention on bioethics 
Recommendation 1213 (1993)  on  developments  in  biotechnology  and  the 
consequences for agriculture B.  Committee of Ministers of the Council of Europe 
Resolution (78) 29 
Recommendations R (79) 5 
Recommendation R (83) 2 
Recommendation R (84)  16 
Recommendation R (90)  3 
Recommendation (90)  13 
Recommendation F (92)  1 
Recommendation R (92) 3 
on  harmonisation  of  legislation  of  member  States 
relating  to  removal.  grafting  and  transplantation  of 
human substances 
of  the  Committee  of  Ministers  to  member  States 
concerning international exchange and transportation of 
human substances 
of  the  Committee  of  Ministers  to  member  States 
concerning  the  legal  protection  of  persons  suffering 
from mental disorder placed as involuntary patients 
of  the  Committee  of  Ministers  to  member  States 
concerning notification of work involving recombinant 
deoxyribonucleic acid (DNA) 
of  the  Committee  of  Ministers  to  member  States 
concerning medical research on human beings 
of the  Committee  of Ministers  to  member  States  on 
prenatal  genetic  screening,  prenatal  genetic  diagnosis 
and associated genetic counselling 
of the Committee of Ministers to member States on the 
use of analysis of deoxyribonucleic acid (DNA) within 
the framework of the criminal justice system 
of the  Committee  of Ministers  to  member  States  on 
genetic testing and screening for health care purposes C.  Ministerial Conference 
European Ministerial Conference on  Human Rights (Vienna,  19 -20 March 1985): 
- Resolution No.  3 on  human rights and  scientific progress in  the fields of biology, 
medicine and biochemistry 
17th Conference of European Ministers of Justice (Istanbul, 5 - 7 June 1990): 
- Resolution No. 3 on bioethics 
D.  Report on human artificial procreation 
Principles set out in the report of the ad hoc Committee of experts on progress in the 
biomedical sciences (CAHBI, published in  1989) ',; EUROPEAN COMMISSION 
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PRODUCTS DERIVED FROM HUMAN BLOOD OR PLASMA 
STATE OF PLAY 
Directive 89/381/EEC on medicinal products derived from human blood or human plasma 
Purpose of the Directive 
The purpose of the Directive is to protect human health by extending Community rules 
designed to guarantee the quality, safety and efficacy of medicinal products to products 
derived from  human blood or human  plasma (manufacturing authorization,  marketing 
authorization).  Application  of these  rules  also  guarantees  free  movement  of these 
products. 
The Directive also addresses the ethical aspects and advocates the promotion of  voluntary 
unpaid donations to achieve self-sufficiency in the supply of blood and blood products. 
Implementation of the directive 
I. Technical provisions 
Eleven  Member  States  have  transposed  Directive  89/381/EEC  and  the  twelfth  (the 
Netherlands) is in the process of doing so. National legislation is now being checked by 
Commission departments for conformity with the Directive. 
2.  Voluntary unpaid donations 
When the directive was adopted in  1989 the Council  left it to the Member States to 
determine,  in the light of their own  situation,  the best way of achieving the goal  of 
Community self-sufficiency by means of voluntary unpaid donations without depriving 
patients of essential treatment. 
The Council of Europe, which is referred to in the Directive, has produced a definition 
of  voluntary unpaid donations. This specifies that donations of  blood, plasma and cellular 
components must be freely made and that no benefits in cash or kind should be offered 
to the donor.  Gestures such as refreshments and reimbursement of travel expenses are 
consistent with the notion of voluntary unpaid donations. The Council of Europe, which is referred to in the Directive, has produced a definition 
of  voluntary unpaid donations. This specifies that donations of  blood, plasma and cellular 
components must be freely made and that no benefits in cash or kind should be offered 
to the donor.  Gestures such as refreshments and  reimbursement of travel  expenses are 
consistent with the notion of voluntary unpaid donations. 
Three Member  States (France,  Belgium  and  the Netherlands)  have  opted to promote 
voluntary  unpaid  donations  by  confining authorization to blood and  plasma products 
derived  from  this  source.  Their degree of self-sufficiency  made this option  possible. 
Other Member States are not in a position to do the same without depriving patients of 
essential treatment. As a general rule
1
, they do not allow payment for blood donations on 
their  national  territory  but  they  do  import  plasma  or  products  derived  from  paid 
donations, notably from the United States, to make good the shortfall in supplies. 
In any event, provided they satisfy the requirements of Community legislation, products 
manufactured in any  Member State must be given access to the territory of the other 
Member States on the same terms as products manufactured locally. 
F  ollow-qp to the Directive 
Directive 89/381/EEC was challenged, notably in France, by blood donor associations on 
the grounds that it classified blood derivatives as "medicinal products". 
The matter was referred to the Group of Advisers on the Ethics of  Biotechnology, which 
endorsed the Directive and its public health objectives in March 1993. 
In December 1993 the Council confirmed the importance of achieving self-sufficiency in 
blood and blood derivatives by means of voluntary unpaid donations, promoting blood 
donations  with  Community  support,  guaranteeing  the  quality  and  safety  of blood 
collection and ensuring optimum use of blood and blood products.  · 
The Commission will update its studies on blood donations and the utilization of blood 
and blood products at regular intervals and decide whether any action is needed. 
With the exception of Germany, which does allow a fixed payment for travel expenses and loss 
of earnings occasioned by absence from work. 
2 opinions adopted - Repercussions - State of play 
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